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Although iron is required for essential biological processes, excess iron is detrimental due 
to oxidative damage induced by iron-mediated Fenton reactions, which promote tissue 
injury. Cellular iron uptake, transport and storage must therefore be tightly regulated. This 
task is accomplished mainly through hepcidin, the key iron-regulatory hormone. Hepcidin 
is synthesized primarily in hepatocytes as a circulatory antimicrobial peptide. It controls 
iron metabolism by inhibiting iron absorption from the duodenum and iron release from 
reticuloendothelial macrophages. Besides synthesizing hepcidin, the liver plays an 
important role in maintaining iron homeostasis by serving as the main storage organ for 
excess iron. Patients with liver diseases frequently display disturbances of iron metabolism 
but the underlying mechanisms are unclear. Due to obesity epidemic worldwide, the 
incidence of nonalcoholic fatty liver disease (NAFLD) is on the rise. This study therefore 
focuses on the regulation of hepcidin in NAFLD. NAFLD is the hepatic manifestation of 
metabolic syndrome, which is characterized by visceral adiposity, dyslipidemia and insulin 
resistance. Both the level and distribution of iron in the livers of NAFLD patients have 
been shown to correlate with disease severity. NAFLD patients have also been reported to 
display changes in hepcidin expression. The significance and relevance of these alterations 
regarding NAFLD pathogenesis are unclear. Although impaired fatty acid metabolism and 
  
lipid accumulation in the liver are major contributors to the pathogenesis of NAFLD, the 
role of lipids or lipid derivatives in hepcidin regulation have not been investigated. The 
studies presented in this dissertation identified new and unique mechanisms of hepcidin 
gene regulation by saturated fatty acids and the biologically active lipid derivative, 
ceramide in human hepatoma cells. The post-transcriptional regulation of hepcidin 
expression by palmitic acid was mediated through AU-rich element binding protein, 
Human Antigen R (HuR) and novel class of protein kinase C isoforms. Ceramide, on the 
other hand, induced hepcidin transcription via inflammatory JAK/STAT3 signaling. 
Furthermore, by using high fat-fed hepcidin knockout mice as an in vivo model, I have 
implicated a role for hepcidin in the regulation of hepatic lipid metabolism, and 
characterized these mice as a potential experimental model to study liver injury in NAFLD.  
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GENERAL HYPOTHESIS AND OBJECTIVES 
Obesity and metabolic syndrome are increasing worldwide in epidemic proportions 
affecting both adult and adolescent populations. Nonalcoholic fatty liver disease (NAFLD) 
is the hepatic manifestation of metabolic syndrome. The more severe form, nonalcoholic 
steatohepatitis (NASH) is characterized by inflammation, apoptosis, hepatocyte ballooning, 
fibrosis and cirrhosis. NAFLD/NASH patients also exhibit elevated serum and hepatic iron 
content. Iron acts as a secondary risk factor in liver diseases but the molecular mechanisms 
by which iron contributes to NAFLD/NASH pathogenesis are unclear.  
Hepcidin is the key iron regulatory hormone, which is primarily synthesized in the liver. 
Hepcidin inhibits iron transport in the duodenum and iron release from macrophages by 
blocking the transport function of the iron exporter, ferroportin. Various factors such as, 
iron, inflammation and endoplasmic reticulum (ER) stress have been reported to activate 
the transcription of hepcidin gene, HAMP. Some studies, but not all, have also shown 
elevated levels of hepcidin in the liver and sera of obese and/or NAFLD patients. The 
potential mechanisms underlying this increase are unclear but a role for elevated 
inflammatory cytokines or liver iron content in NAFLD patients have been proposed.  
Lipid accumulation in the liver (steatosis) is one of the initial pathological changes 
observed in NAFLD. Fat accumulates in the liver when the lipid uptake and lipogenesis 
outweigh the rate of lipid oxidation and secretion. Besides serving as energy storage 
molecules and structural components, lipids and lipid intermediates (e.g. ceramide) also 
act as intracellular signaling molecules. Lipid-induced signaling participates in the 
pathogenesis of NAFLD but its role in the regulation of hepcidin and iron metabolism has 
not been investigated.  
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We hypothesized that fatty acids and ceramide regulate hepatic HAMP mRNA levels 
through distinct cell signaling mechanisms. Both fatty acids and ceramide are potent 
inducers of apoptosis in hepatocytes. However, the direct effect of apoptosis on human and 
mouse hepcidin gene expression is unknown. We therefore addressed this question by 
using both in vitro and in vivo models of apoptosis induced by Fas signaling (see Chapter 
III). The role of fatty acid- (Chapter IV) or ceramide- (Chapter V) induced cellular 
signaling pathways in HAMP regulation was investigated in HepG2 human hepatoma cells. 
We further hypothesized that hepcidin (i.e. iron)-mediated changes in liver lipid 
metabolism contributes to NAFLD/NASH pathogenesis. To test this hypothesis, we 
employed hepcidin knockout mice with iron overload phenotype that were fed either a 
high-fat and high-sucrose or regular (control) diets. We also characterized these mice as 
potential experimental models to study the mechanisms of liver injury in NASH.  
The following specific aims have been proposed.  
AIM 1. To identify the post-transcriptional mechanisms by which saturated fatty acids 
stabilize hepcidin mRNA in human hepatoma cells.  
AIM 2. To investigate the regulation of hepatic hepcidin transcription by ceramide-
mediated cell signaling in hepatoma cells.  
AIM 3. To characterize hepcidin knockout mice with high-fat and high-sucrose intake as a 
novel experimental model to study liver injury and to confirm the role of hepcidin-induced 
iron overload in NAFLD/NASH pathology.  
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1 GENERAL SUMMARY 
Due to changes both in dietary and life style habits, the global rate of obesity has been increasing 
dramatically in the past two decades (1). According to the studies conducted in 2010, over one 
billion of the world’s population, including developing countries, has been estimated to be 
overweight, with 475 million out of these classified as obese (1). In U.S.A., the prevalence of 
obesity in both men and women has been estimated to be above 35% (approximately 73.3million 
in total number) in the year of 2010 (2). These numbers are expected to increase further in the near 
future (3). Most dramatically, the rate of obesity in the adolescent population is increasing at an 
alarming rate (1).  
Once considered as an advantage in ancient times when food resources were limited (4), obesity in 
our modern era is unfortunately recognized as a morbid state. Besides imposing a direct negative 
impact on the quality of life, obesity is also closely associated with metabolic syndrome (5). 
Metabolic syndrome is defined as a series of health conditions including excess body fat (in 
particular visceral adiposity), dyslipidemia and abnormal cholesterol levels, high blood sugar, 
insulin resistance, and hypertension, which acting in concert increase the risk for type 2 diabetes 
mellitus and cardiovascular disease.  
Insulin resistance, a key feature of metabolic syndrome, is associated with changes in the secretion 
and signaling of the hormone, insulin (6). The β cells of pancreas are the major site of insulin 
production. Under normal physiological conditions, the increases in the level of blood sugar (often 
post-prandial) stimulate the secretion of insulin. Insulin released into the circulation modulates 
glucose and lipid metabolism in a wide range of metabolic tissues to maintain blood glucose at a 
normal level. The action of insulin is accomplished through its binding to insulin receptors, which 
are members of the receptor tyrosine kinase family and expressed on the plasma membrane of target 
cells. The formation of the insulin and insulin receptor dimer complex induces the auto-
phosphorylation of tyrosine residues on the cytoplasmic receptor domains. This subsequently 
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results in phosphorylation of the insulin receptor substrates (IRS), IRS1 and IRS2, on tyrosine 
residues (7). IRS, in association with the activated lipid kinase, phosphoinositide 3-kinase (PI3K), 
further induces the phosphorylation and activation of the downstream protein kinase, PKB (a.k.a 
Akt). Insulin regulates glucose metabolism by inducing the translocation of insulin signaling-
sensitive glucose transporters, such as GLUT4 in muscle and adipose tissue from the storage sites 
to the plasma membrane, and thereby stimulating the uptake and utilization of glucose by these 
metabolic tissues (8). In order to control and limit glucose output by the liver, insulin 
simultaneously stimulates the synthesis of glycogen and suppresses gluconeogenesis (9). In 
addition to glucose metabolism, insulin regulates lipid metabolism in the liver by inducing the 
expression of enzymes involved in de novo lipogenesis through the transcription factor, sterol 
regulatory element-binding protein-1c (SREBP-1c). On the other hand, insulin regulates lipid 
metabolism in the adipose tissue by both decreasing lipolysis via the inhibition of the hormone 
sensitive lipase (HSL) and stimulating lipogenesis (10). Taken together, these actions of insulin 
exert a total effect of maintaining a normal postprandial level of blood glucose in healthy 
individuals. However, in the condition of insulin resistance, as observed with obesity and metabolic 
syndrome, the effect of insulin is blunted. As a result, glucose uptake by the muscle and glycogen 
storage, but not gluconeogenesis, in the liver are inhibited. This in turn leads to a significant 
elevation of blood glucose levels and thereby contributes to hyperglycemia. Similarly, in an insulin-
resistant state, the inhibition of HSL and lipolysis, and the increase in lipogenesis by insulin are 
compromised. These changes then trigger the increased breakdown of triglycerides and release of 
fatty acids into the circulation.  
Liver is one of the first organs assaulted by the metabolic changes induced by insulin resistance 
and metabolic syndrome. The excess fat in the circulation due to insulin resistance, are taken up 
the by the liver resulting in fat accumulation (i.e. steatosis). The changes in liver insulin signaling 
also contribute to the elevated levels of de novo lipid synthesis in the liver.  
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The diagnosis of nonalcoholic fatty liver disease (NAFLD) is established when the level of steatosis 
exceeds 5% of the liver tissue (11) in patients with little or no alcohol consumption (12). NAFLD 
is therefore the hepatic manifestation of metabolic syndrome (13, 14). Analytical studies with 
NAFLD patients have shown that the major source of fat in the liver is the uptake of surplus fat 
from the circulation, due to adipose tissue lysis or excess dietary fat, accompanied by the increase 
in de novo lipogenesis (15). Liver disposes of its excess lipid content in the form of VLDL secretion 
(16) and fatty acid oxidation (17). Fatty acid oxidation also fulfills the energy requirements of this 
metabolically active organ. The imbalance between lipid input and output in the liver plays an 
important role in steatosis. The detailed molecular mechanisms of hepatic lipid accumulation in 
NAFLD are discussed in later sections (see sections 2.6 of this chapter).  
NAFLD encompasses a spectrum of pathological conditions including steatosis, steatohepatitis, 
fibrosis, cirrhosis and hepatocellular carcinoma (12, 14, 18). Majority of NAFLD patients exhibit 
simple steatosis, which is currently considered to be a benign condition. However, if untreated, 
some of these patients can develop severe forms of nonalcoholic steatohepatitis (NASH), which is 
characterized by inflammation (steatohepatitis) and fibrotic changes due to the activation of stellate 
cells (12). A small percentage of NASH patients also present advanced stages of fibrosis and 
cirrhosis, which may ultimately lead to hepatocellular carcinoma and death (19).  
The mechanisms of NAFLD/NASH disease progression has been under intense investigation in 
recent decades. The so-called “two-hit hypothesis” was quickly adopted from the pathogenesis of 
alcoholic liver disease (ALD) as a popular theory to explain NAFLD/NASH pathogenesis (20). As 
the name suggests, it describes the process in two consecutive steps. Namely, the “first-hit”, which 
is widely accepted to be insulin resistance (21), promotes the development of simple steatosis. In 
the absence of a second-hit, steatosis remains to be benign and does not progress to severe forms 
of disease. However, the presence of a further hit (i.e. second-hit), such as abnormalities in 
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mitochondrial function, oxidative stress, lipid peroxidation, or inflammatory cytokines and 
adipokines, then exacerbates hepatocellular injury and triggers NASH pathology (20–22). 
In recent years, the “two-hit hypothesis” model of NAFLD/NASH pathogenesis has been 
challenged. First, it has been recognized that steatosis is the consequence of the interplay between 
multiple factors (i.e. insulin resistance, adipose tissue inflammation, and altered adipokine 
secretion) rather than a simple phenomenon which was previously defined as the “first hit” (23). 
As a result, a “multiple parallel-hits hypothesis” has been coined proposing that many progressive 
hits collectively contribute to the pathogenesis of NAFLD/NASH (24). Secondly, clinical 
observations have indicated that NASH is not always preceded by steatosis (23, 25). They 
questioned the initial notion that steatosis and NASH represent the early and advanced stages of  
NAFLD, respectively (23). It is feasible that the absence of typical NAFLD/NASH pathological 
features, especially in patients with advanced cirrhosis, might be due to the portosystemic shunting 
(26). Nevertheless, there is not enough direct evidence to support the sequential progression of 
NASH from simple steatosis (27). 
Although the mechanisms of NASH has not been clearly understood, iron has been proposed to 
contribute to NASH pathogenesis. Being a transition metal, iron participates in the Fenton reaction 
resulting in the production of highly toxic hydroxyl radicals (see section 3 of this chapter below for 
detailed overview) (28). NAFLD patients frequently display elevated iron levels (29, 30), which 
have been shown to correlate with the severity of disease and fibrosis (31–33). Despite these 
observations, the regulation of iron homeostasis and how it contributes to the NAFLD/NASH 
pathogenesis are not well understood.  
2 REGULATION OF LIPID METABOLISM IN HEALTH AND NAFLD 
Lipids are a class of hydrophobic molecules with both structural and bioenergetics functions. Free 
fatty acids (FFA) are molecules consisting of a carbon chain with hydrogen atoms along the length, 
and a carboxyl group and a hydrogen atom at either ends of the chain (Figure 1.1A). Based on the 
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presence of single or double bonds in the carbon backbone, they can be classified as saturated (e.g. 
palmitic, stearic acid) or unsaturated (e.g. oleic acid) (Figure 1.1A). Triacylglycerols (TAG), which 
are present both in plant oils and animal fats in our diet, are comprised of three fatty acids joined 
by a glycerol molecule (Figure 1.1A).  
Fatty acids serve as major energy storage molecules. Namely, the oxidation of fatty acid yields 
more ATP than any other biological substrate. Furthermore, fatty acids are important substrates for 
the production of other lipid intermediates such as sphingolipids, which are essential for membrane 
biogenesis and for the mediation of important intracellular signaling pathways.  
As an endocrine organ, liver is important for the regulation of fatty acid metabolism. Under normal 
conditions, healthy humans store fatty acids mainly in the adipose tissue in the form of non-toxic 
triglycerides. In pathological conditions, liver takes over the burden of eliminating excess fatty 
acids from the circulation. Unesterified free fatty acids in turn induces apoptosis and lipotoxicity 
further activating certain cell signaling pathways, which lead to liver injury, as observed with 
NAFLD patients. Here we provide a brief review of hepatic lipid metabolism and signaling 
focusing on both physiological and NAFLD conditions. 
2.1 Extrahepatic sources of fatty acids in the liver 
Dietary fatty acids are one of the sources of fatty acids contributing to steatosis in the livers of 
NAFLD patients (15). In the postprandial state, TAG obtained as dietary fats are hydrolyzed by 
various lipases, which are present in the lumen of the intestine, to release free fatty acids (FFA). 
FFAs are taken up by the absorptive enterocytes (34) to be re-synthesized into TAG in the 
endoplasmic reticulum (ER) and packaged into chylomicrons (Figure 1.1B). Chylomicrons are 
subsequently secreted into the blood stream through the lymphatic circulation. Lipoprotein lipases 
(LPL) present in the peripheral vascular beds can lyse TAG within the chylomicrons to release fatty 
acids to both the local tissues and blood (35). After losing part of their TAG content, chylomicrons 
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are converted to remnant particles, which are smaller in size. These remnants are then readily taken 
up by the liver (36) (Figure 1.1B).  
The specific mechanisms of fatty acid uptake into hepatocytes are not well understood. Passive 
diffusion (37), and fatty acid transporters such as fatty acid transport proteins (FATPs) and fatty 
acid translocase (FAT/CD36) (38, 39), are believed to play a role in this process. Under 
physiological conditions, hepatocytes also store limited amount of triglycerides in the form of small 
lipid droplets for immediate energy requirements (40). Lipid droplets are decorated with families 
of lipid-droplet surface proteins on the phospholipid monolayer, including perilipin and cell-death-
inducing DFFA-like effector (Cide). It is believed, that the presence of perilipins restrict lipolysis 
under basal conditions whereas their phosphorylation by protein kinase A stimulates lipolysis (41, 
42). Among the three isoforms of Cide proteins (Cidea, Cideb and Cidec), Cidec, also known as 
FSP27, is highly expressed in the white adipose tissue (43). The important role of DICEC/FSP27 
in lipid storage was underlined by the observations that overexpression of FSP27 resulted in 
triglyceride accumulation whereas FSP27 knockdown decreased the size of lipid droplets (44). 
In cases of energy deprivation, such as fasting, the lipolysis activity of the adipose tissue is elevated 
to supply fatty acids as an energy source for relevant tissues (41). The enzyme, adipose triglyceride 
lipase (ATGL) specifically catalyzes the hydrolysis of TAG to produce diacylglycerol (DAG) and 
fatty acids. The enzyme, hormone-sensitive lipase (HSL) can then release additional fatty acids 
from DAG (Figure 1.1B). Releasing of the first fatty acid is the rate-limiting step in this reaction, 
and free fatty acids released into the circulation are bound by albumin for the uptake into 
hepatocytes.  
2.2 Hepatic lipogenesis 
In NAFLD patients, de novo lipogenesis (i.e. freshly synthesized lipids within the liver) also 
contributes to steatosis (15, 45). Under non-pathological conditions, such as dietary carbohydrate 
supply exceeding the capacity of the liver for glycogen storage, substrates are diverted to pathways 
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of free fatty acid synthesis within the liver (Figure 1.1B) (46). The de novo lipogenesis (DNL) 
pathway has been extensively studied (36, 47) and will be described here briefly . The catabolism 
of glucose through the tricarboxylic acid cycle yields citrate, which is subsequently transported to 
the cytosol and converted to acetyl-CoA. The enzymes, acetyl-CoA carboxylase (ACC) catalyze 
the conversion of acetyl-CoA to malonyl-CoA. Malonyl-CoA, which serves as a two-carbon donor, 
is added to the acetyl-CoA primer by the enzyme, fatty acid synthase (FAS). Palmitic acid (PA) is 
the primary product of FAS. Palmitic acid precursor can be elongated by two carbon atoms to 
produce the saturated FA, stearic acid. The desaturation of saturated FA, which is catalyzed by 
stearoyl-CoA desaturase-1(SCD-1), yields unsaturated FA, such as oleic acid. (48).  
Insulin regulates mRNA expression of lipogenic genes through the activation of the transcription 
factor, sterol regulatory element binding protein-1c (SREBP-1c). SREBPs are considered to be the 
master transcriptional regulators of genes involved in lipid metabolism (49). This family consists 
of three members, SREBP-1a, SREBP-1c and SREBP-2. SREBP-1c is the predominant isoform 
responsible for the regulation of lipogenic genes in the liver (49). Insulin signaling regulates 
SREBP-1c both at the transcriptional and post-translational levels. The newly synthesized SREBP 
precursor is anchored at ER membrane (50) in association with both the SREBP cleavage activating 
protein, SCAP and the ER-retention protein, Insig (51). The activation of SREBP requires its 
dissociation from Insig and subsequent translocation to the Golgi apparatus. In Golgi, SREBP-1c 
protein is cleaved and its active N-terminal fraction released to be imported into the nucleus (52). 
The suppression of Insig-2a (53) and SREBP-1c phosphorylation by Akt are important steps in 
insulin-signaling-mediated processing of SREBP-1c. Furthermore, insulin up-regulates the nuclear 
translocation of SREBP-1c through the activation of mammalian target of rapamycin complex 1 
(mTORC1), a nutrient- and growth factor-responsive kinase (54). Activation of transcription 
factors, such as liver X receptors (LXRs) (55) and SREBP-1c itself (56) are also believed to be 
mechanisms by which insulin can up-regulate SREBP-1c at the transcriptional level. Most of 
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SREBP-1c targets genes, such as acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS), 
participate in de novo fatty acid synthesis pathway and harbor sterol regulatory element (SRE) 
DNA-binding sequences in their promoters (49).  
Glucose modulates the expression of genes involved in lipogenesis through the activation of the 
transcription factor, carbohydrate response element binding protein (ChREBP). The 
phosphorylation of ChREBP and its physical interaction with other molecules allows it to sense the 
level of intracellular glucose (49). Under basal conditions, when intracellular glucose levels are 
normal, ChREBP is phosphorylated by both by the cAMP-dependent protein kinase (a.k.a. protein 
kinase A, PKA) and the AMP-activated protein kinase (AMPK) (57, 58). When glucose levels are 
elevated, this leads to the stimulation of the pentose phosphate pathway and thereby the production 
of xylulose 5-phosphate (X5P). X5P subsequently activates protein phosphatase 2A (PP2A). 
Following dephosphorylation by PP2A, ChREBP is activated and translocates to the nucleus (59). 
Besides the post-translational modifications, the activity of ChREBP as a glucose sensor is 
mediated by intramolecular interaction between the low glucose inhibitory domain (LID) and a 
glucose response activation conserved element (GRACE) of ChREBP. When the glucose level is 
low, the interaction between LID and GRACE inhibits the DNA-binding activity of ChREBP. 
However, with high levels of glucose , this inhibition is eliminated resulting in ChREBP activation 
(58, 60). Activated ChREBP then binds to the promoters of genes, which are involved in glycolysis 
and lipogenesis, and activates their transcription (49). 
2.3 Hepatic fatty acid secretion 
Very low density lipoproteins (VLDL) are a class of lipoproteins important for lipid transport in 
the liver. Triglycerides accumulated in the liver are primarily exported via VLDL secretion to 
prevent steatosis (Figure 1.1B). Similar to chylomicrons in the intestine (see section 2.1 above), 
the assembly of VLDL requires apolipoprotein B (apoB) as the scaffold protein. Following its 
synthesis, the liver-specific form of apolipoprotein B, apoB-100, is translocated across the ER 
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membrane into the lumen and subsequently lipidated by microsomal triglyceride transfer protein 
(MTP) to form the primordial VLDL particles (61). Through the physical interaction, MTP 
stabilizes the newly synthesized apoB-100 (62, 63). Accordingly, in the absence of MTP, apoB-
100 is not optimally lipidated and becomes prone to proteasomal degradation (64). Furthermore, 
liver-specific deletion of MTP in mice has been reported to cause a significant decrease in VLDL 
synthesis accompanied by an increase in cytosolic fat droplets (65). The primordial VLDL particles 
subsequently fuse with the triglyceride-rich particles to form the mature VLDL particles (61).  
The expression of MTP is directly associated with VLDL secretion and is therefore frequently 
employed as marker for the study of hepatic lipid secretion (66). The promoter of MTP gene harbors 
multiple DNA-binding sites including hepatic nuclear factor-1 and 4 (HNF-1 and 4) response 
element, direct repeat (DR) 1, forkhead box (FOX), and sterol and insulin response elements 
(SRE/IRE). The binding of transcription factors, HNF-1α and 4α are important for the basal 
transcriptional expression of MTP (67–69). The agonists of PPARα are believed to stimulate MTP 
expression through the DR1 sequence in its promoter (70). Both the FOX and SRE/IRE response 
element sites have been suggested to mediate the inhibitory effect of insulin on MTP transcription 
(71, 72), It should however be noted that it is unclear whether insulin plays a significant role in the 
regulation of MTP expression and VLDL secretion because various experimental models of 
hyperinsulinemia display strong MTP promoter activity (73–75). Furthermore, excess dietary 
sucrose, fructose or fat supply induce MTP expression through yet unidentified mechanisms (75, 
76). 
2.4 Hepatic fatty acid oxidation 
Besides the synthesis or transport, oxidation of fatty acids is also an important component of hepatic 
lipid metabolism (Figure 1.1B). Liver is the central organ for fatty acids oxidation, which is the 
major pathway for fatty acid disposal and energy production. Of the three organelles, namely 
mitochondria, peroxisomes and ER, which participate in the oxidation of fatty acids, mitochondrial 
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β-oxidation pathway plays the most prominent role (36). When lipolysis is stimulated under non-
pathological (e.g. fasting) or pathological (e.g. insulin resistance) conditions, fatty acids are 
activated to acyl-CoA esters and shuttled into the mitochondrial matrix. The carnitine-palmitoyl-
transferase (CPT) system facilitates the transport of acyl-CoA into mitochondria in a two-step 
reaction (36). The enzyme, CPT1, which is located at the outer membrane of mitochondria, 
converts acyl-CoA to acylcarnitines. CPT1 catalyzes the rate-limiting step of β-oxidation (77) and 
its activity is inhibited by malonyl-CoA, a metabolic intermediate in the lipogenesis pathway (see 
section 2.2 above). Acylcarnitines are then transported across the mitochondrial inner membrane 
via the enzyme, carnitine acylcarnitine translocase. The enzyme, CPT2, which is localized in the 
mitochondrial inner membrane, then catalyzes the reverse reaction to restore CoA group to 
acylcarnitines. The released carnitines are subsequently used for the next round of shuttling 
reactions. Once inside the mitochondrial matrix, acyl-CoA carbon chain is shortened by 2 carbons 
at a time through a four-step β-oxidation reaction to produce acetyl-CoA. 
Peroxisome proliferator-activated receptor α (PPARα) is the major transcription factor participating 
in the regulation of genes related to fatty acid uptake and oxidation. Peroxisome proliferator-
activated receptors (PPARs) are a group of nuclear receptors and transcription factors belonging to 
the steroid receptor superfamily (78). PPAR family contains three isoforms, PPARα, PPARβ/δ, and 
PPARγ. The liver and other organs with high FA oxidation capacity mainly express the isoforms, 
PPARα and PPARβ/δ (79). PPARα is activated by lipid intermediates, which arise from the 
lipogenesis and lipolysis pathways, and fatty acid catabolism pathways (80). Upon activation, 
PPARα forms heterodimers with another nuclear receptor, retinoid X receptor (RXR) (80). 
Together with other co-activators (80), the PPARα/RXR heterodimer complex activates the 
transcription of the target genes involved in the regulation of FA transport and β-oxidation by 
binding to PPAR response element (PPRE) in their promoters (81). PPARα promotes fatty acid 
uptake by up-regulating the expression of FA transporters, such as FATP1 and FAT/CD36 (82, 83). 
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Moreover, PPARα activates mitochondrial β-oxidation by controlling the transcription of rate-
limiting enzymes, CPT1 and CPT2 (84, 85). In addition, PPARα regulates the transcription of 
SREBP-1c , thereby controlling lipogenesis (86). Although PPARβ/δ are not highly expressed in 
the liver, their levels have been suggested to be elevated in steatotic livers (87). They might act in 
concert with PPARα in the transcriptional regulation of genes responsible for hepatic lipid 
metabolism (87). In addition, PPARγ is highly expressed in fat tissues and plays a major role in the 
maintenance of lipid homeostasis by controlling lipogenesis in the white adipose tissue (88). The 
participation of PPARβ/δ and PPARγ in the pathogenesis of steatosis is currently being investigated. 
2.5 Lipid derivatives in the liver 
Besides fatty acids, fat accumulation in the liver gives rise to other lipid derivatives such as 
lysophosphatidic acid and ceramide (Figure 1.1B). However, the involvement of these 
intermediates in NAFLD pathogenesis is not well understood. We were particularly interested in 
ceramide because of its connection to saturated fatty acids. Ceramide belongs to the sphingolipid 
family of lipids. This family is unique in that besides their traditional role as structural molecules 
for membrane biogenesis, they have recently been recognized as intracellular second messengers. 
One of the pathways for ceramide (and other sphingolipid) synthesis, is so-called “de novo 
synthesis pathway”, which utilizes saturated fatty acid, especially palmitic acid, as the starting 
substrate (Figure 1.2). Ceramide is synthesized through a four-step reaction catalyzed by enzymes 
localized in the ER (89). Serine palmitoyltransferase (SPT), which transfers a serine residue to 
palmitoyl-CoA to produce 3-keto-sphinganine is the rate-limiting enzyme of de novo ceramide 
synthesis pathway. Ceramide can further be modified to produce other species of the sphingolipid 
family (Figure 1.2). In addition to the de novo pathway, two other alternative pathways exist for 
ceramide biosynthesis. One of them is the “sphingomyelinase (SMase) pathway”, which hydrolyses 
sphingomyelin located in the cell membrane for the rapid production of ceramide. The other 
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pathway known as the “salvage pathway” recycles ceramide from the catabolism of sphingolipids 
(Figure 1.2) (90).  
The rate of de novo ceramide synthesis is correlated with the availability of its substrate. The 
activity of SPT, which catalyzes the rate-limiting first step of the de novo ceramide synthesis 
pathway, is stimulated by serine and palmitoyl-CoA (91). Both endotoxin (i.e. lipopolysaccharide, 
LPS) and inflammation have been shown to be involved in the pathogenesis of NAFLD. The family 
of toll-like receptors (TLR) are important for the regulation of innate immune responses and each 
member is activated by different ligands (92). TLR4 is activated by the binding of LPS but besides 
LPS, saturated fatty acids also serve as natural ligands for TLR4 (93). Moreover, the activation of 
TLR4 by saturated fatty acids and LPS up-regulates the expression SPT, the enzyme required for 
de novo ceramide synthesis (94). This up-regulation is dependent on the activation of pro-
inflammatory kinase, IKKβ, which is part of the TLR-specific signaling cascade (94). 
Inflammatory cytokines, in particular TNF-α, have been shown to stimulate the activity of 
sphingomyelinase (SMase) for the rapid production of ceramide (95, 96). Ceramide production in 
NAFLD and diabetes patients is elevated, and the increase in ceramide production has been shown 
to contribute to the pathogenesis of metabolic diseases. Patients with type 2 diabetes exhibit 
elevated ceramide content in the serum (97, 98) and skeletal muscle (99) . Hepatic steatosis 
correlates with over-production of ceramide in the adipose tissue (100). High-fat diet-intake has 
been shown to increase hepatic ceramide content in animal models (101, 102). Weight loss in 
NASH patients has also been reported to lead to the suppression of genes, which are related to 
ceramide production (103).  
2.6 Mechanisms of hepatic lipid accumulation in NAFLD 
Steatosis, as observed in the livers of NAFLD patients, develops as a result of both hepatic and 
systemic dysregulation of lipid metabolism, which cannot be compensated by the lipid oxidation 
and export capacity of the liver (12). Although obesity and insulin resistance cause changes in lipid 
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metabolism, there are other factors, which make the liver conducive to excessive accumulation of 
hepatic triglycerides. Here, we briefly review the changes which contribute to hepatic steatosis by 
focusing on major players relevant to this process. 
In obese individuals, the adipose tissue is significantly expanded by increases in both adipocyte 
mass and synthesis. Visceral adiposity induces an inflammatory state and macrophages are 
infiltrated into the adipose tissue. This results in an increase in both the local and systemic 
expression of inflammatory cytokines and adipokines (104). Inflammatory cytokines inhibit insulin 
signaling and are therefore considered to be one of the major contributors of insulin resistance in 
obesity (105). Insulin resistance in adipose tissue impairs the inhibitory effect of insulin on the 
enzyme activity of hormone-sensitive lipase (HSL) (10). As a result of this, the rate of lipolysis is 
elevated despite the presence of high levels of insulin in the circulation (Figure 1.3). In agreement, 
NAFLD patients have been shown to exhibit an increase in the lipolysis activity of their 
subcutaneous adipose tissues (106). By using stable-isotope labeling method, Donnelly et al. have 
analytically demonstrated that in NAFLD patients, about 60% of hepatic triglyceride content 
originates from the uptake of fatty acids originating from the adipose tissue. This study further 
emphasizes the importance of adipocyte lipolysis in the development of hepatic steatosis (107). 
Dietary fat is another prominent source of hepatic triglycerides (Figure 1.3). Based on the species 
and structure, the dietary fats are usually categorized as polyunsaturated, monounsaturated, and 
saturated fatty acids, and trans-fats (12). In animal models fed with different compositions of high-
fat diets, it has been demonstrated that saturated and monounsaturated, but not polyunsaturated 
fatty acids, are capable of inducing hepatic steatosis (108). The effect of saturated fats was further 
confirmed by a number of other studies using both animal models and tissue culture cells (109, 
110). In a retrospective study comparing the dietary composition of NASH patients with age and 
BMI-matched controls, NASH patients consumed significantly higher amounts of saturated fats 
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from their diet (111). Trans-fats, which commonly exist in modern diets, have also been shown to 
cause NASH in rodent models (112).  
Both adipose tissue lipolysis and dietary fat absorption elevate the level of circulating fatty acids, 
which are taken up by the liver. The differential expression of the fatty acid transporter, FAT/CD36, 
in the livers (i.e. elevated) and adipose tissues (i.e. decreased) of NAFLD patients, compared to 
controls (113, 114), strongly points out a role for hepatocyte transporters in elevated fatty acid 
uptake.  
The increased rate of freshly synthesized lipids within the liver (i.e. de novo lipogenesis) also adds 
to the burden of hepatic triglyceride accumulation (Figure 1.3). Isotope studies with NAFLD 
patients pointed out that 26% of the liver triglycerides derive from de novo lipogenesis, compared 
to 5% in normal control individuals (15, 115). De novo lipogenesis is regulated by both blood 
glucose and insulin levels through the transcription factors, ChREBP and SREBP-1c, respectively 
(see section 2.2 above). Peripheral insulin resistance hampers the uptake and utilization of glucose 
in metabolic tissues (e.g. muscle), and consequently causes hyperglycemia. In addition, the hepatic 
insulin-resistance further increases the levels of blood glucose by both activating gluconeogenesis 
and suppressing glycogenesis (9). Increased glucose levels activate ChREBP, which subsequently 
actives the expression of the enzymes participating in lipogenesis. Accordingly, the deletion of 
ChREBP in mice significantly decreased the expression of a variety of genes involved in 
lipogenesis (116). Overexpression of ChREBP, on the other hand, stimulated the expression of 
lipogenic genes resulting in steatosis (117). Furthermore, steatosis level in NASH patients has been 
shown to correlate with elevated hepatic ChREBP expression (117). Taken together, these studies 
highlight the significance of ChREBP in lipogenesis and thereby steatosis, as observed in NAFLD 
patient livers. In addition to glucose, insulin stimulates lipogenesis by activating the transcription 
factor, SREBP-1c. However, the studies with both the experimental rodent models and NAFLD 
patients have shown, that despite the presence of insulin resistance, hepatic up-regulation of 
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SREBP-1c was not affected (118, 119). In a mouse model of steatosis, the absence of SREBP-1c 
ameliorated fatty liver phenotype (120) further supporting the importance of SREBP1-c in steatosis.  
Oxidation of fatty acids is essential to satisfy the energy requirements for metabolic functions and 
to maintain lipid homeostasis in the liver (121). In agreement, mice with disrupted expression of β-
oxidation genes developed hepatic steatosis (122, 123). As mentioned earlier, PPARα is a central 
player in the regulation of β-oxidation. In a genetic rat model of NAFLD, agonists of PPARα 
significantly alleviated steatosis (124). This improvement was associated with the up-regulation of 
a spectrum of genes involved in β-oxidation. In NAFLD patients, CPT1, the rate-limiting enzyme 
of mitochondrial β-oxidation, was down-regulated (113). In addition, the livers of NAFLD patients 
displayed abnormalities in mitochondrial structure and function, suggesting disturbances in the 
mitochondrial β-oxidation pathway in these livers (125–128).  
VLDL secretion is responsible for the export of extra triglycerides from the liver. Inhibition of 
MTP, the key enzyme of VLDL assembly and secretion, results in hepatic lipid accumulation (129). 
As supported by multiple studies, the level of VLDL secretion is elevated in NAFLD patients 
compared to control individuals (121, 130, 131). It should however be noted, that the initial linear 
increase in VLDL secretion in correlation with hepatic lipid content has been shown to reach a 
plateau without further increase in VLDL secretion despite elevated hepatic triglyceride loading 
(121). This saturation phenomenon might be due to the limited capability of the liver to secrete 
large VLDL particles (121). 
In summary, the development of hepatic steatosis occurs as a net result of the overwhelmed capacity 
of the liver for lipid oxidation and secretion in concert with an increase in the overall rate of hepatic 
lipid uptake and de novo synthesis (Figure 1.3).  
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2.7 Lipid-mediated signaling pathways in NAFLD 
Hepatic steatosis compromises the metabolic processes in the liver and sensitizes hepatocytes to 
secondary insults, such as mitochondrial dysfunction, oxidative stress, ER stress, apoptosis and 
inflammation (12). The accumulation of triglycerides in the form of lipid droplets is not detrimental 
per se but rather considered to be both a protective response and a measure of the lipid burden in 
hepatocytes (132). Indeed, the inhibition of triglyceride production alleviates steatosis but 
exacerbates the level of fibrosis and injury in the liver (133). Free fatty acids and other lipid 
intermediates are considered to be the most harmful lipid species in hepatocytes (132, 134). In this 
section, a brief summary of the signaling events induced by fatty acids and the lipid derivative, 
ceramide will be discussed.  
2.7.1 Fatty acid-induced signaling 
i- Fatty acid-induced apoptosis 
The word apoptosis, derived from a Greek word meaning “leaves falling from a tree” (135), 
describes a specific type of programmed cell death process characterized by membrane blebbing, 
shrinkage of the cell, chromatin condensation, nuclear fragmentation and the formation apoptotic 
bodies (136). Apoptosis can be induced either through the binding of a death ligand to a specific 
cell surface receptor (i.e. extrinsic pathway) or the leakage of cytochrome c through the 
mitochondrial outer membrane (i.e. intrinsic pathway) (137). Death receptors, including tumor 
necrosis factor (TNF)-α receptor, TNF-related apoptosis-inducing ligand (TRAIL), and Fas are 
highly expressed at a basal level in healthy hepatocytes (137). Binding of the corresponding ligand 
to the receptor stimulates the cleavage and activation of cysteine-aspartic proteases called initiator 
caspases, which include caspase 8 and 10. These caspases then activate the downstream caspases, 
caspases 3, 7 and 6 for the execution of the apoptotic process (136). The intrinsic apoptotic pathway, 
which is initiated when the pro-apoptotic Bcl-2 family proteins, such as Bax and Bak, permeabilize 
the mitochondrial outer membrane and release cytochrome c. Cytochrome c subsequently activates 
18 
 
caspase-9, which then activates the executioner caspases (i.e. caspase 3, 7 and 6). The activation of 
apoptosis in hepatocytes requires the cross-talks between the extrinsic and the intrinsic pathways 
through the cleavage of BH-3 only protein, Bid, which facilitates the leakage of cytochrome c (136).  
Fatty acids, in particular saturated fatty acids, induce apoptosis (i.e. lipoapoptosis) in various cell 
types including hepatocytes (138, 139). The differences between the efficacy of saturated and 
unsaturated fatty acids to induce apoptosis might be due to their innate properties. Namely, 
unsaturated fatty acids are more readily esterified to form triglycerides, which decreases their 
toxicity (140). In fact, unsaturated fatty acids rescue apoptosis induced by the saturated fatty acid, 
palmitate by enhancing the conversion of palmitate to triglyceride (134). In hepatoma cells, fatty 
acid-induced apoptosis is dependent on the phosphorylation of c-Jun N-terminal kinase (JNK), 
which directly activates the proapoptotic Bcl-2 family of proteins (139). Moreover, JNK mediates 
saturated fatty acid-induced up-regulation of death receptor expression in hepatoma cells, and thus 
sensitizes the cells to further insult via the death (141). In addition, saturated fatty acids also induce 
ER stress, which plays an essential role in the induction of lipoapoptosis, as shown in hepatoma 
cells (142, 143). In NAFLD patients with severe form of disease, lipoapoptosis in hepatocytes of 
the liver is accompanied by an increase in the expression of cell surface death receptors (144, 145). 
Furthermore, the presence of plasma markers specific for hepatic apoptosis in NAFLD patients 
have been proposed to be strong and independent predictors of NASH (146). 
ii- Fatty acid-induced protein kinase C activation 
A role for lipid-mediated activation of protein kinase C (PKC) signaling has been proposed in 
metabolic syndrome and NAFLD (147). Based on the requirement for diacylglycerol (DAG) and/or 
calcium (Ca2+) for enzymatic activity, PKC isoforms are categorized into three groups; classical 
(PKCα, β, and γ), novel (PKC ε, η and θ) and atypical (PKC ζ and λ) kinases (148). The activation 
of classical PKC isoforms requires both Ca2+ and DAG, while the novel PKC isoforms require only 
DAG. Atypical PKC isoforms do not require DAG or Ca2+ for enzymatic activity (149). G protein-
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coupled receptors and receptor tyrosine kinases, which are the classical PKC activators, induce the 
hydrolysis of phosphatidylinositol 4, 5-bisphosphate via phospholipase C for the production of 
DAG. DAG then activates specific PKC isoforms, as mentioned above (150). However, in cases of 
insulin resistance and metabolic syndrome, DAG levels are increased due to elevated de novo 
lipogenesis and fatty acid production (151, 152). Feeding of rodents with high-fat diets has been 
shown to result in increased hepatic DAG levels and the activation of PKC was associated with the 
development of insulin resistance (153). In a mouse model where NASH was induced by the 
administration of a methionine-and choline-deficient (MCD) diet, the levels of PKC activation were 
elevated in the liver (154). Similarly, in hepatoma cells, saturated, but not unsaturated, fatty acids 
induced production of DAG, which was accompanied by the activation of PKC (155, 156). The 
molecular mechanisms of PKC activation and its contribution to NAFLD pathogenesis are not 
completely understood. Nevertheless, a role for PKC, in particular novel class PKC isoforms (e.g. 
PKC ε), in insulin resistance has been proposed (147). A study conducted with liver biopsies from 
patients undergoing bariatric surgery has shown that hepatic DAG and PKCε content are the 
strongest predictors of insulin resistance (157). Furthermore, a rat model of PKCε knockdown was 
protected against high-fat-feeding-induced hepatic insulin resistance (158). PKCε has also been 
reported to inhibit insulin signaling through its integration with the insulin receptor and impairing 
its kinase activity (158). 
2.7.2 Ceramide-induced signaling 
In connection with lipid accumulation and inflammatory signaling, the production of lipid 
derivative, ceramide is stimulated in NAFLD livers (see section 2.5 of this chapter). Patients with 
type II diabetes have also been reported to exhibit elevated levels of ceramide in the blood stream 
(97, 98). There are only limited number of studies showing ceramide production in the livers of 
NAFLD patients (159). The liver however has been suggested to be a key organ for ceramide 
synthesis (90). Similarly, studies with high-fat diet-fed mice have also reported elevated hepatic 
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ceramide content (101, 102). The precise role of ceramide in the pathogenesis of NAFLD and 
metabolic syndrome are not well understood. Some studies have shown that ceramide, by 
antagonizing Akt (i.e. insulin) signaling, can participate in the development of insulin resistance in 
skeletal muscle and fat tissues (160, 161). Other studies have reported the involvement of ceramide 
in different signaling pathways related to inflammation. In an in vitro model of human fibroblasts, 
JAK/STAT3 signaling pathway has been shown to be activated by elevated ceramide levels, which 
was dependent on JAK2 kinase isoform (162). Similarly, the DNA-binding activity of NF-κB has 
been shown to be stimulated by ceramide treatment of various cancer cell lines (163, 164). 
Furthermore, ceramide and its derivatives have been shown to activate NF-κB in HepG2 human 
hepatoma cells (165). Studies using tissue culture cells have reported a role for stress-activated 
kinase, JNK in mediating the effects of ceramide analogs (166–168). The signaling pathways 
activated by ceramide in hepatocytes will be further discussed in later chapters (see chapter V). 
3 REGULATION OF IRON METABOLISM AND ITS RELATIONSHIP TO NAFLD 
This section will provide a brief review of iron physiology and the proteins involved in the 
regulation of iron homeostasis with an emphasis on the role of central iron regulator, hepcidin. The 
relationship of iron to NAFLD pathogenesis will also be discussed. 
3.1 Physiology of Iron 
Iron is an essential element for all living organisms from bacteria to humans (169). An adult human 
body contains an average of 3 to 4 g of iron per kg of body weight distributed in different parts of 
the body (170). Most of it is integrated into hemoglobin for red blood cell synthesis in bone marrow. 
As red blood cells are essential for the tissue delivery of oxygen, iron is connected with cellular 
respiration. Similarly, iron is also utilized for the synthesis of muscle oxygen-binding protein, 
myoglobin. Oxygen is required for aerobic respiration in mitochondria to generate ATP. Enzymes 
in the electron transport chain of aerobic respiration harbor conserved iron sulfur (Fe-S) clusters, 
which are important for their biological function. Iron is also associated with DNA replication, 
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DNA repair, cell cycle and growth. Ribonucleotide reductase is a pivotal enzyme for DNA 
synthesis and needs iron as a cofactor for optimal activity. In mammalian cells, iron deprivation 
has been shown to attenuate ribonucleotide reductase activity and arrest cell growth (171).  
Iron however can act like a double-edged sword. Despite being indispensable for fundamental 
biological functions, as mentioned above, excess free iron can also be deleterious. As a transition 
metal, iron shuttles between ferric (Fe3+) and ferrous (Fe2+) forms by accepting and donating 
electrons, and takes part in Fenton reaction. The interaction of iron with H2O2 results in the 
production of a highly reactive oxygen species called hydroxyl radical (•OH) (28). •OH can attack 
DNA backbone and other macromolecules including proteins and lipids thereby causing lipid 
peroxidation, DNA damage and injury to cellular membranes (172). The levels of iron in the human 
body must therefore be tightly regulated.  
The regulation of iron homeostasis is achieved at multiple sites in the body (173). Dietary iron is 
absorbed by the enterocytes in the duodenum. On the other hand, macrophages of the 
reticuloendothelial system are responsible for recycling iron from hemoglobin by phagocytosing 
senescent erythrocytes. The transport of iron in the circulation is carried out by the transferrin 
protein (174). One molecule of transferrin has the capacity to bind two atoms of Fe3+. This 
facilitates safe transport of iron to distant organs via transferrin binding to transferrin receptors 1 
and 2. Transferrin receptor 1 is ubiquitously expressed whereas transferrin receptor 2 is primarily 
expressed in the liver. Transferrin receptor 2 displays less affinity for transferrin compared to 
transferrin receptor 1 (175). 
The liver is an important organ for iron metabolism for various reasons some of which will be 
discussed later. Most importantly, the liver carries the major burden of iron overload by serving as 
the prominent storage organ for excess iron, and thereby protecting the body from its harmful 
effects (176). Tissue iron is stored in the iron-storage protein, ferritin. Each ferritin molecule has 
the capacity to store up to 4,500 atoms of Fe3+ in its spherical structure, which is available for 
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recycling (177). Both transferrin and ferritin proteins are also frequently used in the clinic as 
diagnostic markers to assess the iron status of patients. In the last two decades, novel proteins such 
as multi-transmembrane iron transporter proteins and soluble regulators have been discovered, 
which revolutionized our understanding of iron metabolism. These proteins will be discussed below. 
3.2 Iron import and export pathways 
Iron from the diet is absorbed mostly in the form of inorganic ferric iron or heme on the apical site 
of enterocytes in the duodenum (173). The intestinal uptake of dietary heme is not well understood. 
A role of heme carrier protein 1 (HCP1) has been suggested (178) but the specificity of HCP1 for 
heme uptake is controversial. The iron is subsequently released from the heme molecule via heme 
oxygenase-1 (HO-1) (179). On the other hand, the mechanisms of inorganic iron uptake are well 
defined. Prior to uptake, ferric iron is reduced to soluble ferrous iron by a ferric reductase on the 
apical surface of enterocytes (180). The apical divalent metal transporter 1 (DMT1) is then 
responsible for the transport of ferrous iron into the enterocyte (181). DMT1 is a Fe2+/H+ co-
transporter (182), and its transport of Fe2+ is dependent on a proton gradient. Once within the 
enterocyte, iron is either incorporated into ferritin (see above) for intracellular storage or exported 
via the basolateral site into to the circulation. Basolateral iron export is accomplished by the only 
known mammalian iron exporter protein, ferroportin. DMT1 and ferroportin have similar structures, 
both being multi-transmembrane proteins (173).  
Unlike enterocytes, macrophages of the reticuloendothelial system take up iron via phagocytosis, 
and digestion of senescent erythrocytes (see above). Iron released from heme molecules via HO-1 
is subsequently exported by ferroportin. Due to its overlapping role in different organs, ferroportin 
is a major determinant of circulating iron levels. The regulation of this iron exporter was better 
understood after the discovery of the central iron-regulatory hormone, hepcidin. The interaction 
between ferroportin and hepcidin resembles the interaction of a circulatory hormone (i.e. hepcidin) 
with its receptor (ferroportin), which will be discussed further below.  
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3.3 Hepcidin, the key iron regulatory hormone 
Since iron homeostasis is regulated at multiple distant sites, the presence of soluble factors, which 
play a key role in controlling the cross-talk between these sites, was long suspected. This hypothesis 
was confirmed by the discovery of hepcidin. The fact that hepcidin is mainly synthesized in 
hepatocytes also gave the liver center stage in the regulation of iron metabolism (Figure 1.4). 
Hepcidin was discovered independently by different laboratories (183–185). Krause et al. and 
Hunter et al. have identified hepcidin as a small peptide with weak antimicrobial activity in the 
human blood ultrafiltrate (183) and urine (184), respectively. The involvement of hepcidin in iron 
metabolism was indicated by Pigeon et al., who have shown the induction of hepcidin mRNA in a 
mouse model with iron loading (185). Interestingly, the coincidental disruption of surrounding 
chromosomal regions in a USF2 knockout mouse model (186) has been reported to result in iron 
overload. This observation then led to the discovery that, hepcidin gene (HAMP), which was co-
deleted due to its proximity to USF2 gene (185), is responsible for the regulation of iron 
homeostasis. A direct role of USF2 in iron regulation was however excluded because a USF2 
knockout mouse model from another laboratory, which does not have disruption of HAMP gene, 
does not display an iron overload phenotype (187). The important role of HAMP in iron metabolism 
was also supported by human studies with primary genetic iron overload disorders. Mutations in 
HAMP gene was identified in patients with juvenile hemochromatosis, a severe early-onset form 
of genetic iron overload disorder associated with hemojuvelin (HJV) gene (188). Similarly 
attenuated HAMP expression, which was unresponsive to oral iron administration, was observed  
in genetic hemochromatosis (GH) patients harboring mutations in GH gene, Hfe (189). The 
regulation of hepcidin by iron and its effect on iron homeostasis has been depicted in Figure 1.5. 
Although humans express a single hepcidin gene, HAMP, mice expresses two hepcidin genes, 
Hamp and Hamp2. Various studies, including the one from our laboratory (190), indicate, that 
Hamp mouse gene is the equivalent of human HAMP gene regarding the regulation of iron 
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metabolism (187, 191). Overexpression of Hamp, but not Hamp2, resulted in severe iron deficiency 
and anemia (187, 191). Studies with different Hamp and Hamp2 knockout mouse lines generated 
in our laboratory have also shown, that further ablation of Hamp2 gene in Hamp knockout mice 
did not exacerbate the iron-overload phenotype observed with Hamp deletion (190).  
Hepcidin is synthesized as an 84 amino acid pre-prohepcidin protein with an N-terminal 24-amino 
acid signal sequence, which is cleaved to yield prohepcidin protein (173). The prohepcidin 
precursor protein is subsequently cleaved by proteases, such as furin-like prohormone convertases 
(171), at the C-terminus to form the 25-amino acid mature, hepcidin peptide. This soluble form is 
released into the circulation to function as a biologically active protein (Figure 1.6). Furthermore, 
shorter (truncated at the N-terminal) forms of 20- and 22-amino acid hepcidin peptides have been 
detected in human serum and urine (184, 192).  
Hepatocytes are the major site of hepcidin synthesis (193). Other cell types such as adipocytes in 
obesity (194) and macrophages (195) have been reported to exhibit very low levels of hepcidin 
mRNA expression. In accordance with the importance of hepatocytes as the major site of synthesis, 
liver-specific hepcidin knockout mice have been shown to display similar levels of systemic iron-
overload as the global hepcidin knockout mice, which lacked hepcidin expression in all of the 
organs (190, 196). 
Biologically active hepcidin peptide harbors intramolecular disulfide bridges. It adopts a simple 
hairpin structure with 4 disulfide bonds forming between the 8 cysteine residues (197). The five N-
terminal amino acids are critical for the biological function of hepcidin (198). By contrast, the 
disruption of the C-terminal amino acids and the mutation of any of the cysteine residues have been 
reported to exert negligible effects on the function of hepcidin (198). 
The mechanistic insight into the function of hepcidin in iron metabolism was first described by 
Nemeth et al. (199). Using a stable cell line expressing GFP-tagged ferroportin, they have shown 
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that hepcidin induced the internalization and lysosomal degradation of ferroportin on the plasma 
membrane through a direct and specific interaction, which resembled the binding of a ligand to its 
receptor. Further reports have shown that hepcidin-induced internalization of ferroportin is 
dependent on tyrosine phosphorylation, while the degradation process involved ubiquitination 
(200). By inducing the degradation of ferroportin, hepcidin interferes with cellular iron transport, 
and ultimately decreases serum iron levels. Vice versa, a decrease in hepcidin expression will cause 
an increase in cellular iron transport resulting in elevated levels of serum iron (Figure 1.5). 
After a pivotal role has been established for hepcidin as the master switch of iron metabolism, 
intensive investigations were performed to understand the regulation of its expression. The 
evidence for the circulatory hepcidin protein to be regulated at the level of secretion is not strong 
(201). The growing consensus however was that hepcidin is regulated at the mRNA level (202–
204). Accordingly, several studies have shown that hepcidin is transcriptionally regulated by iron 
loading, inflammatory signals, erythroid activity, endoplasmic reticulum (ER) stress and growth 
factor signaling (205–208). A brief overview of the pathways relevant to this dissertation has been 
presented below. 
Besides being an iron-regulatory protein itself, the expression of hepcidin is strictly regulated by 
iron (Figures 1.5). Bone morphogenic protein (BMP) receptor and SMAD signaling pathways play 
a central role in the feedback regulation of hepcidin in response to iron loading. Hepcidin has been 
shown to be stimulated by various BMP ligands (209, 210). BMP6 knockout mice exhibited severe 
iron overload with very low hepcidin expression levels, which highlighted the specificity of BMP6 
ligand in iron homeostasis (211). Liver-specific SMAD4 knockout mice also exhibited a dramatic 
decrease in hepcidin expression levels accompanied by iron overload (207). Furthermore, the 
ablation of SMAD4 in these mice abrogated the response of hepcidin transcription to iron loading 
(207). Overexpression of SMAD4 stimulated the transcription of hepcidin gene through the BMP-
response elements in the promoter (207, 212). As mentioned above, hemochromatosis patients with 
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mutations in hemochromatosis gene, HFE, transferrin receptor 2 (TRF2) or hemojuvelin (HJV) 
genes display decreased hepcidin expression (202). These studies suggest that the hepatocyte cell 
surface proteins encoded by these genes are upstream regulators of hepcidin in response to iron 
loading. The exact mechanisms underlying cellular iron sensing are still unclear but the modulation 
of BMP/SMAD signaling pathway by TRF2, HFE or HJV might be one of the potential 
mechanisms (202, 204). 
Besides being an iron-regulatory protein, hepcidin also serves as an acute phase protein, and is 
associated with innate immunity and infection. As an antimicrobial peptide, the regulation of 
hepcidin by inflammatory cytokines has already been established (213, 214). Mediators of 
inflammation, such as LPS, turpentine, and interleukins, IL-1 and IL-6 have been shown as potent 
stimulators of hepcidin mRNA expression (213–215). IL-6 is one of the best studied mediators of 
hepcidin up-regulation in response to inflammatory stimuli. IL-6 knockout mice have been reported 
to exhibit decreased responsiveness to turpentine (213). IL-6 activates HAMP promoter through 
JAK/STAT3 signaling pathway and the subsequent binding of STAT3 to the cis-element in the 
promoter (205, 216). Inflammation-induced hepcidin up-regulation has been accepted as the major 
contributor in the development of anemia of chronic disease (217). 
Oxidative and endoplasmic reticulum stress play a role in the pathogenesis of liver diseases (218). 
Endoplasmic reticulum (ER) stress, also called unfolded protein response (UPR), is the response 
of the cell to the accumulation of unfolded or misfolded proteins in the ER (218). A chemical 
inducer of ER stress, tunicamycin, has been shown to up-regulate hepcidin expression at the 
transcriptional level in human hepatoma cells and mice livers (219). One of the underlying 
mechanisms has been shown to be the activation of cyclic AMP response element–binding protein 
H (CREBH) and its trans-activation of the hepcidin gene promoter (219). Oxidative stress, on the 
order hand, has previously been shown by us to induce the suppression of hepcidin transcription in 
the liver by alcohol exposure (220).  
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Although studies up-to-now concentrated on the transcriptional regulation of hepcidin, post-
transcriptional mechanisms can also be involved. MicroRNAs have recently been shown to regulate 
hepcidin mRNA expression. The microRNA, miR-122 indirectly regulates the transcription of 
mouse hepcidin genes by targeting 3’UTR regions of HFE and Hjv mRNA, which are upstream 
regulators of hepcidin expression (see above) (221). By using an iron deficiency mouse model and 
human hepatoma cells, Zumbrennen-Bullough et al. have reported, that an increase in miR-130a 
levels exerts a negative effect on BMP-6-induced HAMP transcription by reducing the mRNA 
stability of ALK2 gene, which encodes for BMP type I receptor (222). Although these studies 
investigated post-transcriptional mechanisms, the primary focus was still the transcriptional 
regulation of hepcidin gene. Hence, the confirmation for molecular mechanisms, which directly 
target the 3’UTR of hepcidin mRNA is still lacking. We present evidence and discuss such 
mechanisms in this study (see Chapter IV)  
3.4 The relationship between iron and NAFLD pathogenesis 
Elevated iron levels are frequently observed in patients with NAFLD and metabolic syndrome 
(223). About one third of the NAFLD patient population exhibit elevated levels of serum iron 
markers, such as serum ferritin (29, 224). Multiple large-scale population studies in different 
regions of the world confirmed an association between hyperferritinemia and type 2 diabetes (225–
227). An association between serum ferritin levels and the increase in the number of features, which 
are indicative of metabolic syndrome, has been reported, suggesting a link between serum iron 
marker elevation and the progression of metabolic disease (30). 
As explained above, the liver plays an important role in iron metabolism and protects the body from 
harmful effects by serving as the central iron storage organ. Valenti et al. reported that in a 
European population of NAFLD patients, iron accumulation in hepatocytes was associated with 
more severe liver damage and fibrosis (31). Concurrently, Nelson et al. have shown that different 
patterns of iron overload in the liver (i.e. hepatocellular, reticuloendothelial or mixed phenotype) 
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were observed in 34.5% of patients in the “Nonalcoholic Steatohepatitis Clinical Research Network” 
(32). In contrast to previously published studies, Nelson et al. further reported that patients with 
reticuloendothelial iron deposition phenotype in the liver are more likely to display more advanced 
NASH pathology with elevated hepatic inflammation and injury, and higher levels of fibrosis (32). 
Despite the inconsistencies in iron deposition patterns, which might be due to the differences in 
patient groups, these studies established a strong association between hepatic iron content and 
NAFLD disease progression. 
The mechanisms by which iron overload and hepatic iron deposition contribute to the development 
of metabolic syndrome and NAFLD are unclear. Iron overload-induced production of reactive 
oxygen species might serve as an important secondary risk factor, which exacerbates NAFLD 
pathogenesis. In support of this theory, oxidative stress levels are elevated in NAFLD patients with 
hepatic iron overload compared to those without (228). High-fat diet-feeding induced higher levels 
of oxidative stress, as well as severe fibrosis and NASH pathology in HFE knockout mice, as 
compared to wild-type counterparts (229). Furthermore, a role for iron in insulin signaling has been 
proposed (230). Accordingly, phlebotomy has been reported to improve insulin sensitivity in 
patients with NAFLD (231) and chelating iron restored insulin receptor signaling in tissue culture 
cells (232). In addition, iron has been suggested to modulate lipid metabolism and steatosis (233, 
234), which is further discussed in Chapter VI of the dissertation. 
3.5 Modulation of hepcidin expression in NAFLD  
Although a clear connection has been established between iron and NAFLD progression, the 
regulation of hepcidin has not been widely investigated. By using severely obese patients 
undergoing bariatric surgery, Bekri et al. reported that the increase in hepcidin mRNA levels in 
adipose tissue is associated with elevated inflammation markers but not with obesity or NASH 
conditions (194). However, the conclusions drawn from this study are inconclusive due to the study 
design and the emphasis put on adipocytes, which express negligible levels of hepcidin compared 
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to hepatocytes (194). Weiss et al. examined hepcidin mRNA expression in liver biopsies of NAFLD 
patients and reported significantly increased levels of hepatic hepcidin expression (33). Similarly, 
in a large scale patient study, Martinelli et al. have reported a linear relationship between serum 
hepcidin levels, measured by mass spectrometry analysis and the increase in characteristic features 
of metabolic syndrome (30). Another independent study with NAFLD patients from Turkey 
established an association between an increase in serum hepcidin levels and lipid parameters (235). 
Hamza et al. reported similar findings, namely that hepcidin-25 levels in the serum of obese 
children are significantly up-regulated compared to age- and sex-matched controls (236). However, 
it should be noted that elevated hepcidin expression levels were not detected in all the studies 
performed with obese diabetic individuals. Serum concentrations of hepcidin was decreased in 
patients with type 2 diabetes in association with insulin resistance (237). Moreover, hepatic 
hepcidin expression was significantly suppressed in a high-fat diet mouse model (238). Despite all 
these studies, the mechanisms which regulate hepcidin expression in NAFLD are not well 
understood. Certain factors, such as inflammatory cytokines or iron loading, have been proposed 
as potential contributors (33, 194, 239). The direct roles of lipids and/or lipid intermediates in the 
regulation of hepcidin expression, have however not been investigated. 
Nevertheless, it is important to point out that, since hepcidin is the master switch of iron metabolism, 
any changes in hepcidin expression (i.e. inhibition or induction), will result in altered iron 
accumulation and sequestration in the livers of NAFLD patients contributing to disease progression. 
Namely, induction of hepcidin will ultimately inhibit ferroportin and iron export thereby 
sequestering iron in Kupffer cells of the liver, triggering oxidative stress, inflammation and 
fibrogenic signaling. On the other hand, hepcidin inhibition will lead to elevated iron absorption, 
due to elevated ferroportin and iron export, and excess iron will ultimately cause hepatocyte injury 
and exacerbate NAFLD pathology. 
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Figure 1.1. Illustration of fatty acid structure and metabolic pathways: (A) The structure of 
fatty acids. Saturated fatty acids, palmitic and stearic acid, and unsaturated fatty acid, oleic acid 
are shown as representative structures. Triacylglycerol is synthesized from glycerol and three 
molecules of fatty acids through esterification reactions. (B) Schematic diagram of metabolic 
pathways induced by fatty acids. Dietary fats, absorbed by the enterocytes, enter circulation in the 
form of chylomicrons, which are digested by lipoprotein lipases (LPL) present in the peripheral 
vascular beds to release fatty acids (FA). The remnants are readily taken up by the liver. In the 
adipose tissue, triacylglycerol (TAG) is hydrolyzed through a two-step reaction by adipose 
triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL) to release FA. Hepatocytes take 
up circulating FA through passive diffusion or transporter-dependent mechanisms. Dietary 
glucose furthermore stimulates de novo lipogenesis in the liver for the production of FAs. The 
liver disposes of FAs by oxidation or secretion in the form of very low density lipoproteins 
(VLDL). Microsomal triglyceride transfer protein (MTP) plays a key role in the assembly and 
secretion of VLDL. Additionally, FAs serve as substrates for the synthesis of lipid intermediates, 
as represented by ceramide. 
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Figure 1.2. Ceramide synthesis pathways: The de novo synthesis pathway produces ceramide 
through a four-step sequential reaction cascade. Serine palmitoyltransferase (SPT) catalyzes the 
initial rate-limiting step. Alternatively, ceramide can be synthesized from the hydrolysis of 
sphingomyelin located in the cell membrane by sphingomyelinase (SMase) (SMase pathway) and 
from the recycling of spingosine into ceramide (Salvage pathway). Ceramide also serves as a 
substrate for the production of sphingomyelin, spingosine and ceramide-1-phosphate. 
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Figure 1.3. Mechanisms of hepatic lipid accumulation: Peripheral insulin resistance (e.g. 
insulin resistance in myocytes) hinders the uptake and utilization of glucose by the tissues and 
elevates serum glucose, which in turn stimulates de novo fatty acid (FA) synthesis in the liver. 
Insulin resistance in adipocytes accelerates lipolysis by desensitizing lipases to insulin and results 
in elevated serum FA, which are then taken up by the hepatocytes. Additionally, dietary fats are a 
major source of hepatic FA. FA is esterified to form non-toxic triglycerides. FA oxidation in 
mitochondria and triglyceride secretion in the form of VLDL are the major FA disposal 
pathways. Steatosis develops when the capacity of FA disposal in the liver is overwhelmed by the 
increased levels of FA input and de novo lipogenesis.  
 
 
 
 
 
 
 
  
50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 
 
 
 
 
 
 
  
51 
 
Figure 1.4. The function and synthesis of hepcidin: (A) Hepatocytes are the major site of 
hepcidin synthesis. After initial processing of pre-prohepcidin, the 25-amino acid biologicaly 
active mature hepcidin peptide is secreted into the circulation. As the central iron-regulatory 
protein, hepcidin inhibits iron absorption from the enterocytes in the duodenum and iron release 
from the reticuloendothelial macrophages, and thereby decreases circulating iron levels. Hepcidin 
accomplishes this regulatory function by binding to and inducing the internalization and 
lysosomal degradation of the only known iron exporter, ferroportin. (Image adopted from World J 
Gastroenterol. 2009 Mar 14; 15(10): 1186–1193 with permission). (B) Schematic diagram of 
pre-prohepcidin. Hepcidin is synthesized as an 84 amino acid pre-proprotein. The N-terminal 24-
amino acid signal sequence is cleaved to produce prohepcidin, which is further cleaved by furin-
like prohormone convertases to yield the 25-amino acid mature hepcidin peptide.  
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Figure 1.5. Regulation of iron homeostasis by hepcidin: (A) Under normal physiological 
conditions, hepcidin is expressed at the basal level. Enterocytes absorb dietary iron at the apical 
site and export it into the circulation through ferroportin at the basolateral membrane. Iron in 
senescent red blood cells are phogocytosed by macrophages and recycled into circulation via 
ferroportin. The liver stores excess iron in hepatocytes and Kupffer cells. (B) In iron deficiency, 
hepcidin expression is reduced, which leads to elevated levels of ferroportin, duodenal iron 
transport and iron egress by macrophages. (C) In iron overload, hepcidin expression is induced, 
which reduces ferroportin levels and limits duodenal iron transport and iron release by 
macrophages to restore iron homeostasis. (Figure adopted from Annu Rev Pathol. 2009;4:489-
515. with permission) 
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1 CELL CULTURE 
The cells were grown in a MCO-17AIC CO2 incubator (Sanyo, Moriguchi, Osaka, Japan) with 5% 
CO2 and humidified atmosphere at 37
oC. HepG2 cells, a human hepatoma cell line, were obtained 
from the Biochemistry Department of University of Adelaide in Australia. HepG2 cells were 
cultured in a high glucose (4.5 g/L glucose) Dulbecco’s modified Eagle’s medium supplemented 
with glutamine (2 mM) and 10% fetal calf serum (Atlantic Biologicals, GA., USA). Cell culture 
medium was replenished every 2-3 days. For sub-culturing, cells were detached by incubating with 
a 0.25% trypsin-1 mM EDTA (Life Technologies., CA., USA) solution for 2 min. at 37oC. For the 
studies described in later sections, 1.3×106 or 3.9 ×106 cells were seeded in 25 cm2 or 75 cm2 flasks, 
respectively, 12-24 h. prior to the start of the experiment. 
2 ANIMAL MODELS 
Animal experiments were approved by the Institutional Animal Care and Use Committee at the 
University of Nebraska Medical Center. The wild-type mice strains used in this dissertation 
include C57BL/6J (the Jackson Laboratory, ME., USA), C57BL/6NCR (National Institute of 
Health, USA). Hamp Floxed and Hamp Knockout mice on C57BL/6J genetic background were 
generated in our laboratory in cooperation with a commercial company (Ozgene Pty. Ltd., Perth, 
Australia), as published previously (1). The mouse colonies were maintained in a controlled 
environment behind a sterile barrier at the Animal Care facility at the University of Nebraska with 
constant temperature, humidity and 12:12-h light-dark cycle. Free access to food and water was 
provided. Transgenic mice were genotyped, as described below (see section 16 of this chapter). At 
the end of experiments, mice were anesthetized with a Ketamine (100 mg/kg b.w.) and Xylazine 
(10 mg/kg b.w.) solution and sacrificed to harvest organs and cardiac blood. 
Serum was isolated from clotted blood by centrifuging at 1300 RPM for 15 min. at room 
temperature. The harvested livers were kept frozen at -80°C ultra-freezer for RNA extraction or 
protein lysate preparations. For histological analysis, fresh liver tissues were fixed in 10% Buffered 
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Formalin (Thermo Fisher Scientific, Waltham, MA, USA) and delivered to the Tissue Science Core 
Facility at the University of Nebraska Medical Center for paraffin-embedding, and subsequent 
sectioning and staining with Hematoxylin and Eosin (H & E). 
3 RNA EXTRACTION  
Procedures involving RNA studies were performed using RNase-free tubes (Ambion®, Life 
Technologies) and pipette tips with barriers (ARTTM, Thermo Fisher Scientific) to avoid RNA 
degradation. For RNA extractions, 50mg of liver tissue or 4–5x 106 HepG2 cells were re-suspended 
in 1 mL. TRIzol reagent (Invitrogen, CA., USA). Prior to re-suspension in Trizol, the liver tissues 
were cut into fine pieces in a sterile petri dish on ice using clean disposable razor blades. To re-
suspend HepG2 cells, 1 mL of TRIzol reagent was directly pipetted onto the cells attached to the 
tissue culture flasks, which were rinsed twice with sterile 1X phosphate-buffered saline (PBS) 
solution (Invitrogen).The TRIzol suspensions of tissues or cells were then incubated at room 
temperature for 5 min. prior to the addition of 200 μL of chloroform. The tubes were vortexed 
vigorously for 15 seconds and incubated at room temperature for 3 min. The organic and aqueous 
phases were separated by centrifugation at 12000 x g for 15 min. at 4 oC. The aqueous phase, which 
contained RNA, was carefully removed into a clean RNAase-free tube, and mixed with 500 μL of 
isopropanol, and incubated at room temperature for 10min. To pellet RNA, the tubes were 
centrifuged at 12000 x g for 10 min. at 4 oC. To remove salt contamination, RNA pellets were re-
suspended in 1 mL of 75% ethanol and centrifuged at 7500 x g for 5 min. To dry out residual 
ethanol, the tubes containing RNA pellets were kept at room temperature. Subsequently, RNA were 
dissolved in 30–50 μL of diethylpyrocarbonate (DEPC)-treated RNAase-free distilled water 
(Thermo Fisher Scientific) by incubating at 45 oC for 10 minutes. The quality and purity of 
extracted RNA were validated by agarose gel electrophoresis. RNA concentrations were 
determined by measuring the absorption at 260 nm with Biomate3 spectrometer (Thermo Fisher 
Scientific). RNA suspensions were aliquoted and kept at -80 oC ultrafreezer for further use.  
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4 cDNA SYNTHESIS AND QUANTITATIVE REAL-TIME PCR 
cDNA was synthesized from 3 μg of isolated RNA (see above) using 6.25 μM random hexamers 
(Applied Biosystems, Life Technologies) and Superscript II reverse transcriptase enzyme 
(Invitrogen) according to the manufacturer’s instructions. cDNA was diluted with 60 μL of 
autoclaved distilled water and separated into 3 aliquots for real time PCR experiments. Real-time 
PCR (qPCR) reactions were performed in triplicates using either Taqman universal PCR master 
mix (Life Technologies) or iTaq Universal SYBR Green Supermix (Bio-Rad, CA, USA) with 
StepOnePlus instrument (Life Technologies). Taqman fluorescent probe (5’ 6-[FAM]; 3’ 
[TAMRA-Q]) and primers, spanning through exon boundaries, were designed with Primer Express 
1.0 Program (Applied Biosystems) and synthesized commercially (Sigma-Aldrich, PA., USA and 
Thermo Fisher Scientific). Pre-designed primers used for SYBR green qPCR were obtained from 
PrimerBank (2). Glyceraldehyde dehydogenase (GAPDH) gene was used as the endogenous 
control for qPCR experiments. The qPCR assays were performed with ABI PRISM 7700 Sequence 
Detection System (applied Biosystems) with the following cycling conditions: Taqman [50oC 
2min., 95 oC 10min., 40 cycles of (95 oC 15sec., 60 oC 1min)]; SYBR green [50 oC 2min., 95 oC 
30sec., 40 cycles of (95 oC 15sec., 60 oC 1min)]. Melting curve analysis was performed for SYBR 
green qPCR assays to validate the specificity of the primers. Gene amplification was calculated 
using comparative CT method, as described (3). The sequences of Taqman probe and primers, and 
SYBR green primers, which were used for the experiments in this dissertation, are shown below 
(see Table 2.1 and Table 2.2). 
5 RNA HALF-LIFE MEASUREMENT 
HepG2 cells were treated with palmitic acid (PA) or solvent (isopropanol) in the presence of the 
transcription inhibitor, actinomycin D for indicated time points. The level of HAMP mRNA 
expression, as measured by qPCR (see above), was expressed as fold-change of that in control cells, 
which were treated with solvent in the presence of DMSO, at corresponding time points. Rate 
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constant for RNA decay (kdecay) was determined with linear regression (least-square) analysis. RNA 
half-life was calculated with the equation: t1/2 = ln2 / kdecay. 
6 XBP1-SPLICING ASSAY 
XBP1-splicing assay is based on the fact that spliced form of XBP1 mRNA lacks the recognition 
sequence for Pst1, which is present in the unspliced form. In brief, PCR was performed with cDNA 
using a specific primer set for XBP1: (forward: 5’-AAACAGAGTAGCAGCTCAGACTGC-3’ 
reverse: 5’-TCCTTCTGGGTAGACCTCTGGGAG-3’). The amplicons 448 bp and 474 bp, which 
indicate spliced and unspliced forms of XBP-1, respectively were subsequently digested with Pst I 
at 37oC for 2 hours. Following digestion, unspliced XBP1 amplicon (474 bp) yielded 290 bp and 
183 bp fragments. The digested products were subjected to DNA agarose gel electrophoresis. 
GAPDH was amplified with the following primers as loading control: forward: 5’- 
TGGTATCGTGGAAGGACTC-3’ reverse: 5’- AGTAGAGGCAGGGATGATG-3’. 
7 WHOLE CELL LYSATE ISOLATION AND SUBCELLULAR FRACTIONATION 
OF CELLS 
To prepare whole cell lysates, HepG2 cells or liver tissues were incubated for 15 min. in lysis buffer 
[10 mM Tris-HCl (pH 7.4), 100 mM NaCl, 5 mM EDTA and 10% glycerol] supplemented with 1 
mM PMSF, 0.5% Triton X-100, protease inhibitor cocktail, pepstatin A (Sigma-Aldrich), and 
activated sodium orthovanadate (ACROS Organics, Thermo Fisher Scientific). The lysates were 
sonicated (50% amplitude, 3 x 5 sec. cycles) with ultrasonic dismembrator 150T (Thermo Fisher 
Scientific) to facilitate cell lysis. Following centrifugation at 3000 x g for 5 min. (4°C), supernatants 
were collected and used for western blotting. 
To isolate cytosolic and nuclear fractions, HepG2 cells were trypsinized and washed twice with 1 
X PBS. The cell pellets were subsequently re-suspended in a hypotonic buffer (10 mM Tris-HCl, 
10 mM NaCl, 2.5 mM MgCl2) and incubated on ice for 5 min. Following centrifugation at 1700 x 
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g for 10 min. (4°C), supernatants were collected and used as cytosolic fractions. The nuclei pellets 
were then washed twice with hypotonic buffer to eliminate residual cytosol contamination. Washed 
pellets were re-suspended in an extraction buffer (50 mM Tris-HCl, 420 mM NaCl, 2.5 mM MgCl2, 
1% Igepal, 0.5% deoxycholate) and sonicated (30% amplitude, 3 x 5 sec. cycles). Sonicated lysates 
were centrifuged at 2800 x g for 10 min. (4°C) to remove cell debris. The supernatants were utilized 
as nuclear fractions. The protein concentrations in whole cell lysates or cellular fractions were 
determined by a commercial protein assay dye reagent (BioRad) based on Bradford-dye-binding 
method. 
8 WESTERN BLOTTING 
The cell lysate proteins (10-50 μg) were resolved with SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) using Mini-PROTEAN gel electrophoresis system (Bio-Rad). The resolved proteins 
were subsequently transferred onto polyvinylidene fluoride (PVDF) membranes (Bio-Rad) via 
electrophoresis in a transfer buffer (Thermo Fisher Scientific) containing 10 % methanol overnight 
at 4°C with constant 20 volts, followed by 1 h. of 40 volts transfer the next day. PVDF membranes, 
which were washed briefly with 1 x Tris-buffered saline (TBS) solution (Sigma-Aldrich), were 
blocked with 2% nonfat milk (BioRad) dissolved in 1 x TBS buffer for 1 h. at room temperature. 
Blocked and TBST (1 x TBS supplemented with 0.1% TWEEN-20)-washed membranes were then 
incubated with respective primary antibodies (as listed in Table 2.5) overnight rotating at 4°C in 
heat-sealed plastic pouches (Thermo Fisher Scientific). The next day, membranes were washed 
twice with TBST and incubated with corresponding secondary (anti-mouse or anti-rabbit) 
antibodies (Cell Signaling, MA., USA) for 1 h. at room temperature. Immune-reactive bands were 
detected by the ImmunStar-AP Substrate (Bio-Rad Laboratories) using Genemate films (Thermo 
Fisher Scientific). 
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9 CASPASE-3/7 ACTIVITY ASSAY 
The livers harvested from mice or cultured HepG2 cells were homogenized in a lysis buffer [20 
mM KCl, 20 mmol/L MOPS, 2 mM MgCl2, 1 mM EDTA, 0.5% Triton X-100, (pH 7.2)] and 
incubated for 30 min. on ice. The lysates were centrifuged at 14500 x g for 30 min. at 4 °C, to 
collect supernatants, which were used for the assay. Caspase-3/7 enzyme activity was measured by 
using 5 μg Ac-DEVD-AMC caspase-3 fluorogenic substrate (BD Biosciences, NJ., USA). The 
amount of AMC released in the assay was quantified with a Perkin-Elmer Luminescence 
Spectrophotometer LS 55 (Perkin Elmer, MA., USA). A standard curve was generated by using 
commercially-obtained free AMC reagent (Sigma-Aldrich). Caspase-3 enzyme activity is 
expressed as nmoles of AMC released per mg of protein. The protein concentrations in liver lysates 
were determined, as described above (see section 7 of this chapter). 
10 LIPID DROPLET STAINING 
Following treatment with fatty acids, HepG2 cells were washed twice with 1 X PBS solution and 
fixed with 4% paraformaldehyde (Sigma-Aldrich) at room temperature for 15 min. The fixed cells 
were stained with 0.2 mg/mL Nile Red (ACROS Organics) for 5 min. at room temperature. The 
nuclei were counter-stained with Hoechst 33342 dye (Invitrogen). Fluorescent images were 
obtained with a Nikon Eclipse E400 fluorescence microscope with red and UV filter sets for Nile 
Red and Hoechst 33342 dye, respectively (Nikon, NY, USA) using a CC-12 digital camera 
(Olympus, NY, USA) and analySIS software (Olympus Soft Imaging System). 
11 IMMUNOFLUORESCENT STAINING 
HepG2 cells were seeded onto poly-L-lysine-coated coverslips in 24-well plates. After treatments, 
cells were washed twice with 1 X PBS solution and fixed with 4% paraformaldehyde (Sigma-
Aldrich) for 15 min. at room temperature. Fixed cells were permeabilized with 0.5% Triton X-100 
for 15 min. prior to blocking with 5% BSA (Sigma-Aldrich) for 1 h. After washes with 1x PBS, 
cells were incubated with an anti-HuR primary antibody (1:50 dilution, sc-5261, Santa Cruz, CA, 
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USA) by rotating overnight at 4°C. Control cells were incubated in parallel with normal mouse IgG 
(Santa Cruz). The next day, cells were washed three times with 1X TBS buffer supplemented with 
0.1% TWEEN-20 (TBST) and incubated with a secondary Texas Red-conjugated horse anti-mouse 
IgG (1:300 dilution, Vector Laboratories) for 1 h. at room temperature. Subsequently, coverslips 
were washed with 1X TBST 3 times and mounted with VECTASHIELD® Hard-Set Mounting 
Medium with DAPI (Vector Laboratories, CA, USA). 
Fluorescent images were obtained, as described above (see section 10 of this chapter). ImageJ 
software (National Institutes of Health, USA) was used to process microscopic images. The 
merging of HuR and DAPI images into a two-channel image was performed for co-localization 
analysis using ImageJ plug-in Squassh (4). The percentage of nuclei-localized HuR (Csignal) was 
calculated by computing the percentage of HuR pixels, which are co-localizing with DAPI pixels. 
The percentage of cytosolic HuR was subsequently calculated by using the formula, 100% -Csignal. 
12 CHROMATIN IMMUNOPRECIPITATION (ChIP) 
50 x 106 HepG2 cells were fixed with 1% formaldehyde (Sigma-Aldrich) for 10 min. at room 
temperature. The cross-linking was stopped with 0.1375M glycine (Thermo Fisher Scientific) 
solution. The cells were subsequently washed twice with ice-cold 1 x PBS and lysed with ChIP 
lysis buffer [5 mM PIPES (pH 8.0), 85 mM KCl, 0.5% Nonidet P-40 (NP-40)] supplemented with 
protease inhibitors (see section 7 of this chapter above). Nuclear fractions, which were collected 
by centrifugation at 1000rpm for 10 min. at 4°C, were lysed on ice for 10 min. with lysis buffer [50 
mM Tris-Cl (pH 8.0), 10 mM EDTA, 1% SDS] supplemented with protease inhibitors. The lysates 
were sonicated using ultrasonic Dismembrator 150T (Thermo Fisher Scientific) to shear chromatin 
using the following settings: 50% amplitude, 6 x 30 sec. cycles with 1 min. incubation on ice in 
between cycles. The shearing efficiency of chromatin was analyzed using standard techniques and 
DNA-Agarose Gel electrophoresis. For immunoprecipitation, 100 μg of sheared chromatin was 
first pre-cleared for 2 hours at 4°C with 50 μL protein A-Agarose beads (Santa Cruz), which were 
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blocked with Herring Sperm DNA (Promega, WI, USA). 5 μL of pre-cleared chromatin solution 
was saved as Input DNA control for further analysis (see below). The rest of pre-cleared chromatin 
was then incubated with anti-STAT3 (Cell Signaling, #9132), anti-NF-κB p65 (Cell Signaling, 
#4764) or anti-c-Jun (Santa Cruz, #sc-45) primary antibodies by rotating overnight at 4°C. Normal 
rabbit or mouse IgG (Santa Cruz) was used as negative controls. The next day, chromatin and IgG 
complexes were captured by incubating with 50 μL of blocked protein A-Agarose beads for 2 hours 
at 4oC. Immunoprecipitates were subjected to several round of washes as follows: 1x with low salt 
buffer [20 mM Tris/HCl (pH 8.0), 2 mM EDTA, 150 mM NaCl, 0.1% SDS and 1% Tritonx-100], 
1 X with high salt buffer [20 mM Tris/HCl (pH 8.0), 2 mM EDTA, 500 mM NaCl, 0.1% SDS and 
1% Tritonx-100], 1X with lithium chloride wash buffer [10 mM Tris/HCl (pH 8.0), 1 mM EDTA, 
250 mM LiCl, 1% Triton x-100, 1% Igepal and 1% deoxycholic acid] and 3x with 1x TE buffer. 
Chromatin was subsequently eluted using a freshly-prepared elution buffer (100 mM NaHCO3 and 
1% SDS). Cross-linking of eluted chromatin and Input DNA controls (see above) was reversed by 
incubating overnight in 200 mM NaCl at 65°C. The reverse-cross-linked samples were treated with 
DNase-free RNase (0.1 mg/mL Thermo Fisher Scientific) and proteinase K (0.1 mg/mL, Thermo 
Fisher Scientific) solutions and subsequently purified by a commercial Qiaquick PCR purification 
kit (Qiagen, MD, USA). Purified chromatin solutions were used as a template in PCR reactions to 
amplify HAMP promoter using specific primers designed with Primer-BLAST (NCBI), as listed in 
Table 2.4 and Taq polymerase (Thermo Fisher Scientific). The ChIP method was validated by using 
IL-6-treated HepG2 cells as positive control. 
13 RIBONUCLEOPROTEIN IMMUNOPRECIPITATION ASSAYS 
Ribonucleoprotein immunoprecipitation (RNP-IP) assays were performed, as described (5). Briefly, 
30 µg of HuR antibody (RN004P, MBL International, MA, USA) or normal rabbit IgG (Santa Cruz) 
was pre-conjugated to 100 µL of protein A-Agarose beads (Santa Cruz) overnight at 4°C. HepG2 
cells were trypsinized and lysed to isolate cytosolic fractions with lysis buffer containing 0.5 mM 
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Tris-HCl (pH 7.4), 100 mM NaCl, 2.5 mM MgCl2. Cytosolic proteins were first pre-cleared with 
50 µL of plain protein A-Agarose for 30 min. at 4°C. For immunoprecipitation (IP), pre-cleared 
lysates were mixed with 100 µL of antibody-conjugated protein A-Agarose and incubated at 4°C 
for 3 h. Following centrifugation at 5,000 x g for 5 min. at 4oC, the supernatants were discarded 
and the beads were subsequently washed twice with wash buffer [50 mM Tris-HCl (pH 7.5), 150 
mM NaCl, 1 mM MgCl2 and 0.05% NP-40]. 10 µl of IP aliquots were saved for further 
immunoblotting analysis. Immunoprecipitated RNA were then eluted using 0.1% SDS and 
proteinase K (0.1 mg/ mL, Thermo Fisher Scientific), and purified with TRIzol (Life Technologies). 
HAMP mRNA was quantified by qPCR, as described above (see section 4 of this chapter). 18s 
rRNA, which has been shown not to interact with HuR (6, 7), was used as a negative control for 
RNP-IP assays.  
14 GENERATION OF PLASMID DNA CONSTRUCTS AND DUAL LUCIFERASE 
REPORTER ASSAYS 
1.5 kbp or 0.6 kbp HAMP promoter regions were amplified by PCR using Phusion High-Fidelity 
DNA Polymerase (Thermo Scientific) and specific primers, as listed in Table 2.3. Following 
restriction enzyme digestions, PCR products were inserted into pGL3-Basic Luciferase Reporter 
Vector (Promega Corp.). The ligated plasmids were electroporated into competent DH5α bacterial 
cells with a MicroPulse electroporator system (BioRad) and plated on antibiotic-containing LB-
agar plates using standard techniques. DNA, isolated from bacterial colonies, were subsequently 
sequenced to verify correct plasmid clones harboring HAMP promoter sequences in the forward 
direction. The 101 bp full length HAMP 3’UTR region was also amplified by PCR using specific 
primers harboring a 5’phosphate group (see Table 2.3). PCR amplicons were inserted into PmeI 
site of the pMIR-REPORT reporter vector (Life Technologies) by a standard blunt end cloning 
technique. The plasmid clone harboring 3’UTR in the “forward” direction was confirmed by DNA 
sequencing.  
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Mutagenesis of a specific cis-element in the HAMP promoter or 3’UTR regions was performed 
with a commercial mutagenesis kit (Quickchange II Site-Directed Mutagenesis. Agilent 
Technologies, CA., USA) using specific primers, as listed in Table 2.3 below. 
Plasmid DNA were purified using a commercial kit (Plasmid Maxi Prep, Qiagen). HepG2 cells 
were transfected with either empty (as control) or recombinant reporter vectors using lipofectamine 
3000 reagent (Life Technologies). pRL-SV40 plasmid encoding renila luciferase was co-
transfected to standardize the transfection efficiency. Dual luciferase reporter assays were 
performed according to manufacturer’s instructions (Promega). IL-6 treatment was employed as a 
positive control to validate the assay system. 
15 TRANSFECTION OF miRNA MIMIC AND siRNA 
30 pmol of negative control miRNA or miR-214 mimic (Life Technologies) were introduced into 
HepG2 cells with Nucleofector transfection apparatus (Lonza, IL, USA). Plasmids and siRNA were 
transfected by using Lipofectamine 3000 or Lipofectamine RNAiMax (Life Technologies), 
respectively, according to the instructions of the manufacturer. For siRNA experiments, two 
consecutive transfections were performed to increase transfection efficiency. 
16 GENOTYPING of Hamp KNOCKOUT (KO) MICE 
Genotyping was performed using genomic DNA, isolated from mice tails by a commercial kit 
(Promega Corp.), as a template in PCR reactions. PCR was performed using allele-specific primer 
sets. The diagnosis of wild-type (860 bp) Hamp allele was performed by using primers, 5’-
ACTCTAATGAGGAAGGACCAGAGG-3’ and 5’-CTGTCTCATCTGTGAAAGCAGAAG-3’, 
which also amplified wild-type Hamp2 allele (968 bp). Null Hamp allele (439 bp) was amplified 
by using primers, 5’-ACTCTAATGAGGAAGGACCAGAGG-3’ and 5’-
AGTACTGATATCATCGATGGCG-3’. PCR conditions were: 1 cycle of 95°C for 5 min., 35 
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cycles of [95°C for 30 sec., 58°C for 1.5 min., 72°C for 30 sec.], and 1 cycle of final extension at 
72°C for 5 min. 
17 INDUCTIVELY COUPLED MASS SPECTROMETRY (ICP-MS) 
To quantify tissue iron, mice livers were analyzed by ICP-MS at the Redox Biology Center of the 
University of Nebraska in Lincoln. Tissues were weighed and digested with metal-grade nitric acid 
for 2–3 h at room temperature followed by overnight digestion at 80°C. The digestions were 
subsequently cooled and diluted 20-fold prior to ICP-MS analysis. Gallium (50 ppb) was added as 
internal standard. Iron was quantitated by measuring at m/z = 56 and 57Fe was used for 
confirmation. Helium (5 mL/min) was employed as collision gas for the elimination of polyatomic 
interferences. Each sample was analyzed in triplicate. 
18 QUANTIFICATION OF HEPATIC TRIGLYCERIDES  
Triglycerides were quantified in Dr. K. Kharbanda’s laboratory at Omaha VA Medical Center, as 
published previously (8, 9). Briefly, 50 mg of mice liver tissues were homogenized using a 
tissuemizer (Tekmar Ultra-Turrax) in 2 mL CHCl3:MeOH (2:1) solution. Residual tissue particles 
were filtered through Whatman #1 filter paper (Thermo Fisher Scientific). The total volume of 
filtered lysates were brought to 2.5 mL with CHCl3:MeOH (2:1). After the addition of 0.5 mL of 
water containing 0.04% CaCl2 (i.e. total volume of 3 mL), the samples were thoroughly mixed by 
vortexing and then centrifuged at 3,000 rpm for 5 min. at room temperature. The upper aqueous 
phase was removed and lower organic phase was washed thrice with 1mL of an organic 
solution/water mix (3.06 % chloroform, 48.98 % methanol, 47.94% water and 0.02% CaCl2). After 
sequential separation of phases to eliminate non-lipid substances, the organic solution mix 
containing the lipids was evaporated using a centrivac apparatus overnight. The next day, dried 
samples were hydrolyzed in 0.25 mL of 95% ethanol and 25 μL of 8.0 M KOH solution by 
incubating for 20 min. at 65oC. The triglyceride content was determined by using a commercial kit 
(Thermo DMA kit 2750) according to manufacturer’s instructions (Thermo Scientific), and 
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measuring absorbance at 510nm wavelength with a DU-640 Spectrophotometer (Beckman Coulter). 
The final hepatic triglyceride amount was calculated by standardizing the amount in the whole liver 
to the body weight, and expressed as μmol per liver per 100 gram body weight (µmol/L/100 g b.w.). 
19 SIRIUS RED STAINING AND QUANTIFICATION 
Paraffin-embedded liver tissues were prepared as described above (see section 2 of this chapter). 
Tissue sections were de-waxed with sequential incubations in organic solutions (3x in xylene for 
3min., 2 X in 100% ethanol for 2 min., and 1X each in 95%, 80%, and 50% ethanol for 2 min). 
They were then stained with a Picrosirius Red solution (0.1% Sirius Red in saturated picric acid) 
for 60 min. The sections were subsequently washed twice with acetic acid for 2 min. and thrice 
with 100% ethanol followed with three cycles of xylene washes, each for 3 min. The washed 
sections were mounted using a ShandonMount mounting medium (Thermal Fisher Scientific). 
Images of Sirius Red-stained mice livers were obtained using a Nikon Eclipse E400 light 
microscope with a CC-12 digital camera and analySIS software. The quantification of the images 
was performed with ImageJ software using 10 independent images (10 x magnification) obtained 
from each stained section. Briefly, the microscopic images were split into red, green, and blue 
channels with the RGB stack command. The green channel was selected and threshold was 
manually set for each image to correctly reflect the staining in the original image. 10 non-
overlapping fields in each image were selected and the staining was quantified with the ROI 
manager of ImageJ. 
20 STATISTICAL ANALYSIS  
The significance of differences between groups was determined by Student’s t-test or one-way 
ANOVA with Tukey's HSD post-hoc test by using SPSS software (IBM, Armonk, NY). A value 
of P < 0.05 was accepted as statistically significant. 
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Table 2.1. Taqman qPCR Fluorescent Probe and Primer Sequences of human (Hu) and 
mouse (Mu) genes 
Gene 
Forward Primer  
(5'-3') 
Reverse Primer  
(5'-3') 
Taqman Probe (5’-3’) 
Hu-HAMP 
TGCCCATGTTCCAGAG
GC 
CCGCAGCAGAAAATG
CAGAT 
AAGGAGGCGAGACAC
CCACTTCCC 
Hu-GAPDH 
TGAAGGTCGGAGTCA
ACGG 
AGAGTTAAAAGCAGC
CCTGGTG 
TTTGGTCGTATTGGGC
GCCTGG 
Mu-Hamp 
TGCAGAAGAGAAGGA
AGAGAGACA 
CACACTGGGAATTGTT
ACAGCATT 
CAACTTCCCCATCTGC
ATCTTCTGCTGT 
Mu-Hamp2 
GCGATCCCAATGCAGA
AGAG 
TGTTACAGCACTGACA
GCAGAATC 
AGGAAGAGAGACATC
AACTTCCCCATCTGC 
Mu-GAPDH 
TCACTGGCATGGCCTT
CC 
GGCGGCACGTCAGATC
C 
TTCCTACCCCCAATGT
GTCCGTCG 
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Table 2.2. SYBR qPCR primer sequences of mouse (Mu) genes 
Gene  Forward Primer (5’-3’) Reverse Primer (5’-3’) 
Mu-MTP CTCTTGGCAGTGCTTTTTCTCT GAGCTTGTATAGCCGCTCATT 
Mu-CPT1 CTCCGCCTGAGCCATGAAG CACCAGTGATGATGCCATTCT 
Mu-FSP27 ATGAAGTCTCTCAGCCTCCTG AAGCTGTGAGCCATGATGC 
Mu- G6PC CGACTCGCTATCTCCAAGTGA GTTGAACCAGTCTCCGACCA 
Mu-PCK1 CTGCATAACGGTCTGGACTTC CAGCAACTGCCCGTACTCC 
Mu-PPARα AGAGCCCCATCTGTCCTCTC ACTGGTAGTCTGCAAAACCAAA 
Mu-SREBP-1C GCAGCCACCATCTAGCCTG CAGCAGTGAGTCTGCCTTGAT 
Mu-Col1a1 GCTCCTCTTAGGGGCCACT CCACGTCTCACCATTGGGG 
Mu-SAA3 GCCTGGGCTGCTAAAGTCAT  TGCTCCATGTCCCGTGAAC 
Mu-IL-6 CTGCAAGAGACTTCCATCCAG AGTGGTATAGACAGGTCTGTTGG 
Mu-GAPDH GTGGAGATTGTTGCCATCAACGA CCCATTCTCGGCCTTGACTGT 
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Table 2.3. Sequences of primers used for cloning and site-directed mutagenesis experiments 
Gene  Forward Primer (5’-3’) Reverse Primer (5’-3’) 
1.5 kbp HAMP 
promoter 
GGACGCGTCTGGGCCTGGTA
GTGGAAAG 
GACTCGAGTGAGCTTGCTCTG
GTGTCTG 
0.6 kbp HAMP 
promoter 
GGACGCGTTGTCATTTATGGC
CAAAAGTTTGCT 
GACTCGAGTGAGCTTGCTCTG
GTGTCTG 
0.6 kbp HAMP 
promoter ΔSTAT3 
CTGTCTCATTTCCAGGTGGTG
GCGCCGAAAA 
TTTTCGGCGCCACCACCTGGA
AATGAGACAG 
HAMP 3’UTR AACCTACCTGCCCTGCCC 
TTTGGAAAACAAAAGAACCA
GCC 
HAMP 3’UTR ΔARE 
CTGGGGCAGCAGGAATTAAG
GAAGGGAGGG 
CCCTCCCTTCCTTAATTCCTGC
TGCCCCAG 
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Table 2.4. The sequence of primers employed in ChIP assays specific for human (Hu) and 
mouse (Mu) gene promoters 
Gene  Forward Primer (5’-3’) Reverse Primer (5’-3’) 
Hu-STAT3 GAGGGTGACACAACCCTGTT ACCGAGTGACAGTCGCTTTT 
Hu-NF-κB 
TCATTTATGGCCAAAAGTTTGC
T 
CAAGCATCAGCGTGTGCC 
Hu-c-Jun/AP-1 TGAGGGTGACACAACCCTGT CTGCTGGGTCTTGAGCTTGC 
Mu-Hamp GCCATACTGAAGGCACTGA GTGTGGTGGCTGTCTAGG 
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Table 2.5. Primary antibodies used for western blotting 
Antigen Company Catalog number Dilution 
P-SMAD 1/5 Cell Signaling #9516 1:1000 
HuR Santa Cruz sc-5261 1:2000 
P-JNK Cell Signaling #9251 1:1000 
P-STAT3 (Ser 727) Cell Signaling #9134 1:1000 
P-STAT3 (Tyr 705) Cell Signaling #9131 1:1000 
STAT3 Cell Signaling #9132 1:1000 
P-NF-κB p65 Cell Signaling #3033 1:1000 
NF-κB p65 Cell Signaling #4764 1:1000 
αSMA Sigma A2547 1:2000 
Histone H3  Active Motif #39163 1:4000 
gapdh Millipore MAB374 1:4000 
 
 
74 
 
 
 
 
 
 
Chapter III 
 
Apoptosis Induced by Fas Signaling Does Not Alter Hepatic Hepcidin Expression 
 
 
 
 
This chapter has been adopted from 
Lu, S., Zmijewski, E., Gollan, J., and Harrison-Findik, D. D. (2014) Apoptosis induced 
by Fas signaling does not alter hepatic hepcidin expression. World J Biol Chem. 5, 387–
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1 ABSTRACT 
A connection between hepcidin expression and lipid metabolism in non-alcoholic fatty liver disease 
(NAFLD) has been implicated. Our studies with hepatoma cells also indicated induction of 
hepcidin expression by saturated fatty acids. Fatty acids are well-recognized for promoting 
apoptosis, which contributes to the pathogenesis of NAFLD. However, the direct effect of apoptosis 
on hepcidin is unknown. We therefore investigated whether apoptosis induced via Fas ligand 
directly affects hepcidin expression in HepG2 cells and the livers of wild-type male C57BL/6J and 
C57BL/6NCR mice. HepG2 cells were treated with CH11, an activating antibody for human Fas 
receptor, for 12 hours to induce extrinsic apoptotic pathway. Mice were injected with sublethal 
doses (0.2 µg/g b.w.) of Jo2, an activating antibody for mouse Fas receptor. Although CH11 
promoted apoptosis in HepG2 cells, as shown by significant activation of caspase-3/7, it did not 
alter the expression of human hepcidin gene, HAMP. Jo2 treatment of mice for 6 hours, but not 1 
hour, induced significant apoptosis, acute phase reaction and IL-6 expression in the liver. Similar 
to HepG2 cells, Jo2 did not affect hepatic mRNA expression of mouse hepcidin gene, Hamp. IL-6 
is a strong activator of JAK/STAT signaling pathway and STAT3 is known to induce hepcidin 
transcription. Accordingly, Jo2-induced phosphorylation (i.e. activation) of STAT3 in the liver. 
However, no interaction of STAT3 with Hamp promoter was observed, as confirmed by chromatin 
immunoprecipitation assays. The effect of Jo2 was stronger in the livers of C57BL/6J than 
C57BL/6NCR mice. C57BL/6J mice exhibited more prominent activation of apoptosis, liver injury 
and acute phase reaction. However, C57BL/6J mice did not display any changes in hepatic Hamp 
expression. Taken together, the results obtained with our in vitro and in vivo experimental models 
strongly suggest that neither human nor mouse hepcidin genes are regulated by apoptosis induced 
through Fas receptor activation in the liver. 
2 INTRODUCTION 
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Apoptosis is involved in the pathogenesis of various liver diseases (1). Hepatocyte apoptosis can 
be activated via the extrinsic apoptotic pathway through the binding of ligands to death receptors 
such as Fas, TNF Receptor 1 (TNFR1), TRAIL receptor 2 (TRAIL-R2) and TRAIL receptor 1 
(TRAIL-R1). Upon ligand binding, the receptor will trimerize and the C-terminal death domain 
will recruit Fas-associated protein with death domain (FADD) to form death-inducing signaling 
complex (DISC), which subsequently recruits procaspase-8 and induces its self-cleavage and 
activation. Activated caspase-8 can directly cleave and activate caspase-3/7, the executioner 
caspase, which is responsible for the cleavage of target proteins to execute apoptosis. Caspase-3/7 
activation is frequently used as a marker for apoptosis. Flice-Inhibitory Protein Long form (FLIPL) 
blocks apoptosis by inhibiting the recruitment and auto-proteolytic cleavage of procaspase-8. In 
addition, in hepatocytes, the signal from death receptor can be amplified through the mitochondrial 
apoptotic pathway. Activated caspase-8 can cleave Bcl-2 family protein, Bid. The truncated form 
of Bid (tBid) then activates pro-apoptotic Bcl-2 family proteins, and induces permeabilization of 
the mitochondrial outer membrane and the leakage of mitochondrial content, including cytochrome 
c. Cytochrome c in turn forms a complex with apoptotic peptidase activating factor 1 (APAF-1), 
and recruits and activates caspase-9, which subsequently cleaves caspase-3/7 and executes 
apoptosis.  
A role for apoptosis has been suggested in hepcidin regulation (2, 3). Hepcidin is the central iron-
regulatory hormone. It is synthesized primarily by the liver, as an 84 amino acid precursor 
antimicrobial peptide. Pre-propeptide is subsequently cleaved to 25 amino acid biologically active 
circulatory form of hepcidin. Unlike humans with one copy of hepcidin gene, HAMP, mice express 
two hepcidin genes, Hamp and Hamp2. Hamp has been shown to be the equivalent of human gene. 
Our studies with different Hamp transgenic mouse lines have also confirmed the function of Hamp 
as the key iron regulator (4). The exact role of Hamp2 is as yet unknown. Hepcidin exerts its 
regulatory function by blocking the transport of dietary iron in the intestine and the release of iron 
from macrophages. The suppression of hepcidin expression in the liver therefore leads to systemic 
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iron overload whereas its induction causes iron deficiency and anemia. Besides its role as an iron-
regulatory hormone, hepcidin also serves as an acute phase protein and is connected to innate 
immunity (5–7). Inflammatory cytokines such as IL-6, endotoxin and infections trigger hepcidin 
transcription in the liver. The effect of IL-6 is mediated through the activation of JAK/STAT3 
pathway and the binding of STAT3 to the hepcidin gene promoter (8, 9). Fas receptor signaling 
and apoptosis are involved in controlling inflammatory innate immune responses (10). Apoptosis 
also plays a major role in the pathogenesis of liver diseases including NAFLD (11, 12). It is 
therefore important to investigate the regulation of hepcidin by Fas signaling and apoptosis in the 
liver. 
Weizer-Stern et al. have demonstrated that p53, a tumor suppressor and inducer of apoptosis, 
participates in the regulation of hepcidin (13). In their study, a putative p53 response element on 
the hepcidin gene promoter has been identified and validated by chromatin immunoprecipitation 
assays. Over-expression of p53 in hepatoma cells has been shown to induce hepcidin gene 
transcription and conversely, the silencing of p53 resulted in down-regulation of hepcidin 
expression (13). It is however unclear whether p53-mediated apoptosis is involved in the regulation 
of hepatic hepcidin expression (13). On the other hand, Li et al. have suggested a role for Fas 
signaling in the regulation of hepcidin expression in tissue culture cells and female mouse livers 
(14). A lethal dose of anti-Fas activating antibody, Jo2 has been reported to exert an immediate 
stimulatory and a late suppression effect on Hamp mRNA expression in the liver (14). Although a 
relationship between FLIPL, IL-6, STAT3 and hepcidin expression has been shown, they did not 
however establish a direct correlation between apoptosis and hepcidin. Besides causing cell death, 
Fas induced DISC formation also participates in the activation of cell signaling pathways, including 
IL-6 and NF- κB (15). As mentioned above, hepcidin transcription is induced by inflammatory 
cytokine signaling (5–7), which is mediated through the activation of JAK/STAT3 pathway (8, 9). 
As an iron regulatory protein, hepcidin is also regulated by the signals from iron sensors, such as 
bone morphogenetic protein 6 (BMP6) (16–18). The BMP receptor-specific Smad pathway (via 
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the phosphorylation of transcription factors, Smad1/5/8) has been shown to be involved in the up-
regulation of hepcidin transcription. BMP6 knockout mice exhibit iron overload and reduced 
hepcidin expression (19–21). Similarly, mice lacking the expression of the common Smad protein, 
Smad4 exhibit iron overload and a dramatic decrease in the expression of hepcidin in the liver (22). 
In addition, growth factors such as epidermal growth factor and hepatocyte growth factor suppress 
the expression of hepcidin by inhibiting the signaling of the BMP-Smad pathway (23).  
The main aim of the studies described in this chapter is to investigate the causal relationship 
between Fas-signaling-induced effector caspase activation and apoptosis, and the regulation of 
human and mouse hepcidin gene transcription. These studies will help us to further understand the 
regulation and the role of hepcidin in liver diseases including NAFLD.  
3 RESULTS 
3.1 Effect of fatty acids and apoptosis on HAMP expression in HepG2 cells. 
We first validated whether saturated fatty acid, palmitic acid (PA) induced apoptosis in HepG2 
cells under our experimental conditions. For these experiments, HepG2 cells were treated with 0.1-
0.3 mM palmitic acid and 0.3 mM unsaturated fatty acid, oleic acid (OA, as control), for 8 hours. 
The effect of isopropanol (i.e. the solvent for fatty acids) was also examined. The levels of apoptosis 
in these cells were determined by caspase-3/7 activity assays (Figure 3.1A). In agreement with 
previous reports (24, 25), PA, but not OA, induced apoptosis in HepG2 cells, as shown by 
significantly elevated caspase-3/7 activity levels (Figure 3.1A). The effect of PA on apoptosis was 
concentration-dependent (Figure 3.1A). Due to the fact, that PA is capable of inducing other 
signaling pathways besides apoptosis (26), we selected a better defined system of apoptosis to study 
its direct effect on hepcidin regulation. For these studies, CH11 antibody, an activating antibody 
for human Fas receptor, was selected to induce apoptosis in HepG2 cells. CH11 antibody treatment 
for 12 hours induced apoptosis in HepG2 cells in a concentration-dependent manner, as confirmed 
by caspase-3/7 activity assays (Figure 3.1B). A significant induction of caspase-3/7 activity was 
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observed with all concentrations of CH11 (50-500 ng/mL) (Figure 3.1B). The level of apoptosis 
detected with 500 ng/mL CH11 treatment was similar to that observed with cells incubated with 
0.3 mM palmitic acid (Figure 3.1A and 3.1B). To test the effect of PA or CH11-induced apoptosis 
on HAMP mRNA expression, we performed qPCR experiments (Figure 3.1C). HAMP expression 
in 0.3 mM PA-treated cells was significantly up-regulated compared to solvent-treated control cells. 
Unlike PA, CH11-induced apoptosis did not significantly alter the level of HAMP mRNA 
expression compared to control cells treated with PBS (Figure 3.1C). These findings exclude a 
role for Fas-mediated apoptotic pathway in the regulation of HAMP transcription in hepatoma cells. 
This also strongly suggests that the induction of HAMP expression observed in PA-treated cells is 
facilitated by mechanisms other than PA-mediated apoptosis signaling pathways. 
3.2 The effect of short-term and long-term Jo2 treatment on apoptosis, acute phase response 
and mouse Hamp expression in the livers of C57BL/6NCR mice 
Since activation of human Fas did not alter human hepcidin gene expression, we performed 
experiments with Jo2, which is an activating antibody specific to mouse Fas. In our animal studies, 
we used a sublethal (0.2 µg/g b.w.) dose of Jo2 antibody to eliminate complications such as massive 
liver injury and mortality. In agreement, this dose of Jo2 did not cause mortality in any of our time-
points studied. Since previous studies (14) suggested a time-dependent effect of Jo2 on hepcidin 
expression, we injected male C57BL/6NCR strain wild-type mice with Jo2 or NaCl (control), and 
sacrificed after either 1 (short-term) or 6 (long-term) hrs. The macroscopic appearances of mouse 
livers after 6 h Jo2 treatment did not present any significant changes compared to NaCl-injected 
control mice livers (Figure 3.2). 
Following 1 hr. of Jo2 treatment, no significant increase in caspase-3/7 activity in the liver was 
observed compared to control mice (Figure 3.3A). The activation of acute phase reaction in the 
livers of these mice was evaluated by determining the levels of IL-6 and SAA3 mRNA expression 
by qPCR. Similar to caspase-3/7 activity, no significant changes were observed with the expression 
of these acute phase reaction genes (Figures 3.3B and C). The mRNA expression of Hamp in mice 
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livers was unaltered by Jo2 exposure either, as confirmed by qPCR (Figure 3.3D). In contrast, 1 
hour Jo2 treatment induced a small but significant increase in Hamp2 mRNA expression (Figure 
3.3E). By comparison, C57BL/6NCR mice sacrificed 6 hours after Jo2 injections displayed a 
significant increase in caspase-3/7 activity in the livers compared to NaCl-injected control mice 
(Figure 3.3A). Similarly, the expression of acute phase reaction markers, IL-6 and SAA3 were also 
elevated in mice exposed to Jo2 for 6 hours compared to control mice (Figures 3.3B and C). The 
levels of Hamp and Hamp2 mRNA expression in mice treated with Jo2 for 6 hours were not 
significantly different from that in control mice (Figures 3.3D and E).  
3.3 Jo2-mediated STAT3, SMAD1/5 activation and Hamp promoter occupancy 
The cytokine, IL-6 is known to activate hepcidin transcription via the JAK/STAT3 signaling 
pathway (8, 9). We therefore investigated the activation of STAT3 in mice treated with Jo2 or NaCl 
(control) for 1 or 6 hours. Six hours, but not 1 hour of Jo2 exposure, was sufficient to induce the 
phosphorylation of STAT3 in the livers of mice, compared to respective control mice (Figure 3.4). 
Despite the activation of STAT3, we did not observe any significant changes in STAT3 binding to 
Hamp promoter in Jo2-treated mice compared to control mice, as determined by chromatin 
immunoprecipitation (ChIP) assays (Figure 3.5).  
NF-κB is one of the prominent transcription factors activated by Fas ligand binding. NF-κB 
activates the transcription of inflammatory cytokines including IL-6 (1). We therefore investigated 
the phosphorylation of the p65 subunit of NF-κB in mice treated with Jo2 for 1 or 6 hrs. time 
periods. In contrast to STAT3, Jo2 induced a fast and transient activation of NF-κB. The 
phosphorylation of p65 in the liver was observed within 1 hour after Jo2 injection and was absent 
at 6 hours after Jo2 exposure (Figure 3.4).  
Besides JAK/STAT3 pathway, hepcidin is also regulated by bone morphogenetic protein 6 (BMP6) 
and SMAD pathway. This pathway has also been suggested to play a negative role in growth factor-
induced regulation of hepcidin expression in the liver (23). We therefore determined the activation 
of transcription factors, SMAD1 and SMAD5, which are activated downstream of BMP signaling 
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pathway. Similar to NF-κB, Jo2 treatment induced an early and transient activation of SMAD1/5 
in the liver. The induction in SMAD1/5 phosphorylation observed by 1 hr. Jo2 exposure was 
significantly weakened by 6 hr. after Jo2 injection (Figure 3.4). The binding of SMAD4, the 
common mediator of SMAD signaling, to mouse Hamp promoter was also examined by ChIP 
assays. No significant increase in SMAD4 occupancy of Hamp promoter region harboring a 
SMAD4 binding site was observed at 6 hrs. after Jo2 injection, as compared to controls (Figure 
3.5).  
3.4 The effect of long-term Jo2 treatment on apoptosis, acute phase response and mouse 
hepcidin gene expression in the livers of C57BL/6J mice  
In order to investigate the effect of Jo2 further, we employed a sub-strain of C57BL/6 mice. Of 
note, C57BL/6NCR and C57BL/6J strains exhibit substantial genetic differences (27). In contrast 
to C57BL/6NCR mice, the macroscopic appearances of C57BL/6J livers after 6 h Jo2 treatment 
were significantly different than control livers (Figure 3.2). Compared to that observed with 
C57BL/6NCR, C57BL/6J mice treated with a sublethal dose of Jo2 (0.2 µg/g b.w.) for 6 hours 
exhibited a significantly higher elevation of caspase-3/7 activity (Figure 3.6A). Similar robust 
activation was also observed with the expression of acute phase marker genes, IL-6 and SAA3 
(Figures 3.6B and 3.6C). However, despite stronger apoptosis and acute phase reactions, Jo2 
treatment did not induce any significant changes in the expression of both Hamp and Hamp2 in the 
livers of C57BL/6J mice, as was the case with C57BL/6NCR mice (compare Figures 3.6D, E and 
3.3D, E). Furthermore, we tested the effect of an even higher concentration of Jo2 (0.32 µg/g b.w.). 
Although this concentration of Jo2 caused mortality (40 %), it did not induce any changes in the 
mRNA level of Hamp. (Figure 3.6D). In contrast to the effect of sublethal Jo2 dose in 
C57BL/6NCR mice (Figure 3.2E), the treatment with 0.32 µg/g of Jo2 induced a significant 
suppression of Hamp2 mRNA expression in C57BL/6J mice livers (Figure 3.6E). 
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3.5 The effect of Jo2 on liver enzymes in C57BL/6J and C57BL/6NCR mice 
 Since Jo2-induced apoptosis and acute phase reactions were stronger in the livers of C57BL/6J 
mice, compared to C57BL/6NCR mice, we measured the serum levels of ALT and AST. These 
liver enzymes are commonly used as diagnostic markers in the clinic to determine liver injury. The 
sublethal dose of Jo2 (0.2 µg/g) did not cause a significant elevation of serum ALT or AST levels 
in C57BL6/NCR mice (Figures 3.7A and B). However, the sera of C57BL/6J mice injected with 
this concentration of Jo2 exhibited a dramatic increase in both ALT and AST levels, compared to 
controls (Figures 3.7A and B). The injection of C57BL/6J mice with a higher dose of Jo2 (0.32 
µg/g) induced further increase in serum ALT and AST levels (data not shown). These findings with 
ALT and AST further support our previous findings that Fas ligand activation and apoptosis do not 
alter hepatic hepcidin gene expression. 
4 DISCUSSION  
Apoptosis is one of the key factors which contribute to the pathogenesis of liver diseases including 
NAFLD (1, 11, 28). Apoptosis not only causes hepatocyte death directly but also induces 
inflammation and hepatic fibrosis (29, 30). The inhibition of caspase enzymes via known caspase 
inhibitors has been shown to effectively alleviate hepatocyte apoptosis and tissue damage in animal 
models of liver injury (31). Due to its highly reactive nature, and the liver serving as the major 
storage organ for it, iron is considered an important secondary risk factor in the progression of 
various liver diseases (32, 33). Therefore, it is of great importance to understand the interaction 
between apoptosis and iron metabolism. Since hepcidin is the central regulator of iron homeostasis 
and is primarily synthesized in the liver, this study investigated the effect of apoptosis on the 
regulation of hepcidin expression in the liver. Previously, Weizer-Stern et al. have elegantly 
demonstrated that p53, a tumor suppressor gene and an inducer of apoptosis, elevates human 
hepcidin gene transcription in HepG2 cells by binding to the corresponding response elements in 
hepcidin gene promoter (13). They have also reported that the overexpression of p53 blunts the 
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stimulatory effect of IL-6 on hepcidin gene expression. Although indirect, these findings, for the 
first time, suggested a relationship between apoptosis and hepcidin and thereby the regulation of 
iron metabolism. However, due to various reasons, the in vivo relevance of this potential interaction 
is unclear. First, apoptosis signaling in cancer cell lines is frequently distorted and secondly, forced 
overexpression of p53 might have caused artificial effects. However, in a recent study, Li et al. 
have investigated the relationship between Fas-activated apoptosis signaling and expression of 
hepcidin gene expression (14). Fas activation decreased both mouse and human hepcidin mRNA 
expression in vitro. They have also shown that Balb/C3 female mice injected with a lethal dose of 
Jo2 antibody (which killed mice within 4 hours) exhibit a biphasic regulation of mouse hepcidin 
mRNA expression in the liver. Namely, an immediate elevation (observed within 0.5-1 hour) was 
followed by a suppression (observed within 4 hours). They suggested that these changes in hepcidin 
expression correlate with the changes in FLIPL and IL-6 expression, as well as the activation of 
the transcription factors, NF-κB, and STAT3. The knock-down or over-expression of FLIPL 
exerted a negative and a positive effect, respectively, on hepcidin expression. Based on their data, 
Li et al. have proposed a model suggesting that the stimulatory effect of Fas on hepcidin expression 
is achieved via IL-6 and STAT3, which themselves are activated by FLIPL and NF-κB. However, 
Li et al. did not establish a direct association between Fas-induced apoptosis and hepcidin up-
regulation. Thus, it is unclear whether Fas-mediated apoptosis is directly involved in the regulation 
of hepcidin gene expression in the liver. 
We examined the effect of Fas signaling on hepatic hepcidin gene expression both in vivo and in 
vitro. In our in vitro studies, the effect of CH11 was evaluated on human hepcidin gene, HAMP 
expression in HepG2 hepatoma cells. Despite the induction of apoptosis by CH11 in a concentration 
dependent manner, as confirmed by the increased caspase-3/7 activity, HAMP expression was not 
significantly altered in HepG2 cells. Although we cannot exclude the possibility that Fas-mediated 
signaling in HepG2 cells might be different than primary human hepatocytes, our findings strongly 
suggest that hepatic HAMP expression does not correlate with the significant induction of caspase 
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activation. Of note, the liver is composed of various cell types and it is therefore feasible that not 
only hepatocytes, but other cells such as Kupffer cells, might be involved in the regulation of 
hepcidin gene by apoptosis. Hence, an in vivo experimental model whereby male C57BL/6NCR 
mice are injected with Jo2 antibody to specifically activate Fas-mediated apoptosis was employed 
to study hepcidin gene expression in the whole liver. Male mice were chosen for these studies 
because unlike humans, female mice express higher levels of hepcidin compared to male mice (34). 
As described in Results section above, a sublethal concentration of Jo2 antibody was chosen based 
on reports showing, that this dose is optimal to specifically study the activation of Fas-mediated 
apoptosis in liver diseases (35). This was also confirmed by the lack of lethality in our experiments. 
The absence of significant changes both in caspase activation and acute phase gene expression 
indicates that short-term (1h) Jo2 treatment is not sufficient to promote apoptosis or acute phase 
responses in mice livers. Accordingly, no macroscopic changes in the livers were observed, as 
compared to control mice. Further, mouse hepcidin gene, Hamp expression in the liver was also 
not altered. In contrast, longer (6 h) treatment significantly induced apoptosis and acute phase 
reactions. Concurrently, the livers of these mice displayed macroscopic differences, such as a 
darker color, suggesting the presence of hepatic hemorrhage and liver injury. Interestingly, these 
changes did not correlate with the level of Hamp mRNA expression in the liver. Similar to short-
term, the longer treatment of mice with Jo2 did not alter the level of hepcidin gene expression. 
It is well known that hepcidin gene transcription is strongly stimulated by IL-6 and JAK/STAT3 
signaling pathway. Since, we have shown that long-term, but not short-term, Jo2 treatment can 
induce acute phase reactions in the liver, the phosphorylation status of STAT3 was investigated to 
confirm its activation. In accordance with our acute phase gene expression findings, we observed 
STAT3 phosphorylation following 6 hours, but not 1 hour, of Jo2 treatment. Taken together, our 
findings show that the activation of IL-6/ STAT3 axis by Fas is not sufficient to induce Hamp 
transcription and strongly suggest the presence of inhibitory mechanisms. This is also supported 
by our ChIP findings, which show that the occupancy of Hamp promoter by STAT3 is similar in 
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the livers of both Jo2-treated and control mice, despite the differences in the activation status of 
STAT3. In contrast to STAT3, the phosphorylation of NF-κB was observed with short-term, but 
not long-term, Jo2 treatment. NF-κB is involved in inflammatory cytokine production in the liver 
including IL-6 (28). It is therefore possible that Jo2-mediated early phase activation of NF-κB 
subsequently facilitates the induction of IL-6 transcription and consequent activation of STAT3, 
which was observed in the livers of mice with longer Jo2 treatment.  
Hepcidin is also activated by BMP/Smad pathway and SMAD4 knockout mice display reduced 
hepcidin expression (22). However, 6 hour Jo2 administration did not significantly alter the 
phosphorylation of SMAD1/5 proteins, which are transcription factors known to be activated by 
BMP pathway. Growth factors have been shown to suppress the signaling of BMP/SMAD pathway 
and its stimulatory effect on hepcidin gene expression in the liver (23). Of note, liver injury is 
known to stimulate the expression of growth factors as part of the liver regeneration process. It is 
therefore feasible that Fas-induced liver injury might suppress Smad activation and thereby 
counteract the stimulation of Hamp transcription by STAT3. However, it should also be noted that 
despite significant differences in the level of liver injury, acute phase response and apoptosis, both 
C57BL/6J and C57BL/6NCR mice (under similar experimental conditions) did not display any 
significant changes in liver Hamp expression. This suggests that mechanisms other than growth 
factors and inhibitory SMADs might play a role in this process. Jo2-induced liver damage 
accompanied by DNA damage and the activation of p53 might be involved since p53 has been 
shown to suppress the stimulatory effect of IL-6 on hepcidin gene expression (13). Furthermore, 
we observed differential regulation of Hamp2 expression by Jo2 in the liver. Since the function of 
Hamp2 is yet unknown, the significance of this finding and its potential role in liver injury and 
disease require further future studies.  
In our current study presented in this chapter, we validated that hepatic expression of hepcidin is 
not altered by apoptosis induced through Fas signaling. We therefore believe that, palmitic acid-
mediated activation of hepcidin expression in hepatoma cells was mediated by mechanisms other 
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than apoptosis. Apoptosis is widely recognized as a secondary risk factor in NAFLD/NASH 
pathogenesis. However, the findings presented in this chapter exclude a role for apoptosis in the 
regulation of hepcidin and iron metabolism in NAFLD.   
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Figure 3.1. Caspase-3/7 activity and human hepcidin gene (HAMP) expression. (A) HepG2 
cells were treated with 0.1- 0.3mM palmitic acid (PA) or 0.3mM oleic acid (OA) for 8 hours. 
Untreated (unt.) and solvent (isopropanol)-treated (solv.) cells were employed as control. 
Caspase-3/7 activity was determined, as described in the experimental procedures (see Chapter 
II) and was expressed as nanomole of flurogenic substrate cleaved per milligram of cell lysate 
(nmol/mg). (B) HepG2 cells were treated with 50,100,150 and 500 ng/mL of CH11 antibody for 
12 hours. Induction of apoptosis was confirmed by measuring caspase-3/7 activity. (C) cDNA, 
synthesized from RNA isolated from CH11-treated, PA-treated and respective control cells, was 
employed as a template in Taqman qPCR assays to determine HAMP mRNA expression, as 
described in experimental procedures. HAMP expression in CH11-treated or 0.3mM PA-treated 
cells was expressed as fold expression of that in respective control cells.  
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Figure 3.2. Macroscopic analysis of livers from Jo2-treated mice. C57BL/6J and 
C57BL/6NCR strain wild-type male mice, which were injected with Jo2 antibody (0.2 µg/g b.w.) 
or NaCl (as control), were sacrificed 6 hours later. Representative images are shown. 
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Figure 3.3. Caspase-3/7 activity, and the expression of acute phase response genes and 
mouse hepcidin genes, Hamp and Hamp2 in the liver. C57BL/6NCR strain wild-type male 
mice, which were injected with Jo2 antibody (0.2 µg/g b.w.) or NaCl (as control), were sacrificed 
1 hr. or 6 hrs. later. (A) Caspase-3/7 activity was measured, as described in experimental 
procedures. IL-6 (B), SAA3(C), Hamp (D) and Hamp2 (E) gene expression was determined by 
qPCR and mRNA expression in Jo2-treated mice expressed as fold change of that in 
corresponding control mice.  
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Figure 3.4. Phosphorylation of STAT3, NF-κB (P65) and SMAD 1/5 in the liver. Whole cell 
lysates prepared from the livers of C57BL/6NCR mice injected with Jo2 (0.2 µg/g b.w.) and 
sacrificed after 1 or 6 hours were employed for western blotting using anti-phospho-STAT3 (P-
STAT3), anti-total STAT3, anti-phospho-P65 (P65) and anti-phospho-SMAD1/5 antibodies, as 
described in experimental procedures with specific antibodies (see Chapter II TABLE 2.5). Anti-
gapdh antibody was used as protein loading control. 
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Figure 3.5. Chromatin Immunoprecipitation (ChIP) assays. The binding of STAT3 or 
SMAD4 to the HAMP promoter in the livers of C57BL/6NCR mice, which were injected with 
Jo2 (0.2 µg/g b.w.) or NaCl (control) and sacrificed 6 hours later, was determined by ChIP 
assays, as described in experimental procedures. Total input DNA was used as control to evaluate 
the amount of chromatin. 
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Figure 3.6. The effect of Jo2 on apoptosis, acute phase response, and Hamp and Hamp2 gene 
expression in C57BL/6J mice. C57BL/6J male mice (n = 21) were injected with 0.2 µg/g b.w. 
and 0.32 µg/g b.w. Jo2 or saline and sacrificed 6 hours later. Cell lysates and RNA isolated from 
the livers were employed in caspase-3/7 assays (A) or to synthesize cDNA as a template for SYB 
green qPCR assays to determine IL-6 (B) or SAA3 (C) gene expression. Hamp (D) and Hamp2 
(E) mRNA expression was determined by Taqman qPCR. Gene expression in Jo2 injected mice 
was expressed as fold change of that in control mice.  
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Figure 3.7. Comparison of liver enzyme levels in sera of Jo2 injected C57BL/6J and 
C57BL/6NCR mice. Mice injected with Jo2 (0.2µg/g b.w.) were sacrificed 6 hours later. Serum 
ALT (A) and AST (B) enzymes were measured at Clinical Chemistry Laboratory of University of 
Nebraska Medical Center.  
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Chapter IV 
Saturated Fatty Acids Induce Post-transcriptional Regulation of HAMP mRNA via 
AU-rich Element Binding Protein, HuR in Human Hepatoma Cells 
 
 
 
 
This chapter has been adopted from a publication re-submitted to Journal of Biological Chemistry 
(S.L. et. al, Manuscript ID.JBC/2015/648212). 
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1 ABSTRACT 
Iron is implicated in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). Hepcidin, 
synthesized primarily in the liver, is the master switch of iron metabolism. The aim of this study 
is to investigate the regulation of human hepcidin gene, HAMP expression by fatty acids in 
HepG2 human hepatoma cells. For these studies, both saturated fatty acids, palmitic or stearic 
acid, and unsaturated fatty acid, oleic acid were used. Palmitic acid and to a lesser extent stearic 
acid, but not oleic acid, up-regulated HAMP mRNA levels, as determined by qPCR. Published 
studies up-to-now have mainly described the transcriptional regulation of HAMP. To understand 
whether fatty acids regulate HAMP mRNA at the transcriptional or post-transcriptional level, we 
employed the transcription inhibitor, actinomycin D in our experiments. Palmitic acid-mediated 
induction of HAMP mRNA expression was not blocked by actinomycin D. Furthermore, palmitic 
acid activated HAMP 3’UTR, but not promoter, activity, as shown by reporter assays. HAMP 
3’UTR harbors a single AU-rich element (ARE). Mutation of this ARE abolished the effect of 
palmitic acid suggesting the involvement of ARE-binding proteins (ARE-BP). The ARE-BP, 
HuR stabilizes mRNA through direct interaction with AREs on 3’UTR. HuR is regulated by 
phosphorylation-mediated nucleo-cytoplasmic shuttling. Palmitic acid activated this process. The 
binding of HuR to HAMP mRNA was also induced by palmitic acid in HepG2 cells. Silencing of 
HuR by siRNA abolished palmitic acid-mediated up-regulation of HAMP mRNA levels. Protein 
kinase C is known to phosphorylate HuR. Staurosporine, a broad-spectrum protein kinase C 
inhibitor inhibited both saturated fatty acid-mediated translocation of HuR and induction of 
HAMP expression. Similarly, rottlerin, a novel class protein kinase C inhibitor, abrogated 
palmitic acid-mediated up-regulation of HAMP expression. In conclusion, our findings clearly 
show that saturated, but not unsaturated, fatty acids control post-transcriptional regulation of 
HAMP through novel protein kinase C- and HuR-dependent mechanisms. The studies in this 
chapter are also demonstrating for the first time that HAMP is directly regulated at 3’UTR by a 
functional AU-rich element sequence and RNA-binding proteins. 
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2 INTRODUCTION 
Due to the increasing prevalence of obesity worldwide, metabolic syndrome, characterized by 
visceral adiposity, dyslipidemia and insulin resistance is becoming a major public health problem. 
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome. 
The accumulation of fat in the liver, which occurs in the absence of significant alcohol 
consumption, is a key feature of NAFLD (1). Increased lipolysis as a result of insulin resistance 
and lipid uptake from the diet contributes to the elevated levels of free fatty acids (FFA) in the 
circulation. The increase in both the uptake of FFA by hepatocytes and de novo FA synthesis 
leads to fat accumulation in the livers of NAFLD patients (see Chapter I for detailed overview) 
(2). 
Although lipid accumulation alone may be benign, more aggressive forms of NAFLD can 
develop. Iron has been shown to be one of the risk factors in the pathogenesis of NAFLD (3). 
Clinical studies with NAFLD patients have shown a clear correlation between hepatic iron 
deposition and more advanced disease stages with liver fibrosis (4–6). Iron acts as a risk factor by 
inducing oxidative stress and mitochondrial dysfunction (3). Hepcidin is the key iron-regulatory 
protein, which is primarily synthesized in the liver (7). Humans express a single hepcidin gene, 
HAMP. It controls iron absorption from the duodenum and iron release from macrophages by 
inhibiting the iron exporter, ferroportin (8). Besides being an iron-regulatory protein, hepcidin 
also acts as an acute phase protein. In NAFLD patients, HAMP expression has been suggested to 
be regulated by both systemic iron levels (6, 9) and inflammation (10). A role for lipids in the 
regulation of HAMP expression has not been established. A microarray study however reported 
that the saturated fatty acid, palmitic acid (PA) modulates HAMP expression in HepG2 cells but 
the underlying mechanisms are unknown (11).  
Previous studies on hepcidin expression have mainly focused on the transcriptional regulation of 
HAMP. Inflammatory cytokines, serum transferrin, erythropoiesis signaling and elevated hepatic 
iron stores have all been shown to stimulate the promoter activities of both human and mouse 
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hepcidin genes via the activation of specific transcription factors (12–15). It should however be 
noted that other iron-regulatory proteins, transferrin receptor 1 and ferritin are regulated at the 
post-transcriptional and translational level, respectively by iron-regulatory RNA-binding proteins 
(IRP), IRP1 and IRP2 (16). Although no IRP recognition sequences have been identified in 
HAMP mRNA, the involvement of post-transcriptional mechanisms warrant further investigation.  
In addition to transcriptional regulation, post-transcriptional regulation serves the purpose of 
modulating gene expression by regulating the half-life of specific transcripts or changing the rate 
of translation (17). Both proteins and non-coding RNAs (ncRNAs) participate in post-
transcriptional regulation by direct interaction with specific sequences in the target mRNA. 
MicroRNAs (miRNAs) are small (~22nt) RNAs that are processed from endogenous hairpin 
structured precursor transcripts by Dicer (18). Upon being fully processed, mature miRNAs are 
mounted onto RNA-induced silencing complex (RISC) and thereby guide the latter to target 
sequences by pairing of nucleotides 2 to 8 of the miRNA (seed sequence) with corresponding 
sequences in the 3’UTR of target mRNA, and degrade or sequester the latter (19). miRNA is a 
very versatile post-transcriptional regulator targeting transcripts of genes involved in different 
biological processes such as cancer development and metabolism (20, 21). In addition, AU-rich 
element (ARE) (i.e. AUUUA pentamer embedded in a U-rich context) in the 3’UTR of mRNA is 
also a well-recognized cis-element in the regulation of mRNA stability targeted by AU-rich 
element binding proteins (ARE-BPs) (17). ARE-BPs include human antigen R (HuR), 
tristetraprolin (TTP), butyrate response factor 1 (BRF1), ARE/poly(U)-binding/degradation factor 
1 (AUF1), and KH-type splicing regulatory protein (KSRP) among others (17). Unlike other 
ARE-BPs, which mostly act as negative regulators and induce mRNA decay, HuR, has however 
been shown to exert a stabilization effect on the target mRNA (17). Phosphorylation is important 
for HuR function. HuR harbors several phosphorylation sites for various kinases including AMP-
activated kinase (AMPK), p38-MAPK (mitogen-activated protein kinase), and protein kinase C 
(PKC) (22). Following phosphorylation, HuR translocates from the nucleus to the cytoplasm (17, 
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22). The phosphorylation-mediated nucleo-cytoplasmic shuttling of HuR is essential for its 
mRNA stabilization function (22).  
The limited studies conducted up-to-now examined mainly the role of microRNAs in the 
regulation of hepcidin genes. An indirect role for miR-122 and miR-130a has been reported in the 
regulation of mouse and human hepcidin gene expression. Namely, miR-122 and miR-130a 
modulated HAMP expression by altering the mRNA stability of transcriptional activators, which 
are known to activate HAMP transcription (23, 24). Other post-transcriptional regulation 
mechanisms besides microRNAs directly targeting HAMP 3’UTR have not been identified. 
HAMP 3’UTR harbors a single AU-rich element (ARE) but its functional role in the post-
transcriptional regulation of HAMP expression is unknown.  
Saturated fatty acids have been shown to activate various signaling pathways in hepatoma cells 
including protein kinase C isoforms (25–29), which, as mentioned above, is a potent HuR 
activator. However, the role of HuR or PKC in HAMP regulation has not been investigated. The 
objective of the studies in this chapter is to understand the mechanisms by which hepatic HAMP 
mRNA expression is regulated by saturated fatty acids. As described below, we have identified a 
functional role for a single ARE in HAMP 3’UTR and the ARE-binding protein, HuR in post-
transcriptional regulation of HAMP expression by lipids in human hepatoma cells. These findings 
will help us to further understand the role of hepcidin and iron in obesity and fatty liver disease 
pathogenesis. 
3 RESULTS 
3.1 Regulation of HAMP mRNA expression by fatty acids in HepG2 cells 
For these studies, HepG2 cells were treated with saturated fatty acids, palmitic acid (PA) and 
stearic acid (SA) or unsaturated fatty acid, oleic acid (OA). Most of the studies reported in the 
literature use fatty acids which are conjugated to bovine serum albumin (BSA) to facilitate their 
uptake by hepatocytes. Our preliminary studies however have shown that BSA by itself 
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dramatically suppresses the basal hepcidin expression in HepG2 cells. We observed this effect 
with different commercial BSA preparations including high quality tissue culture-grade BSA 
(data not shown). We therefore performed all the experiments described in this chapter using un-
conjugated fatty acids. We also chose 0.1 and 0.3 mM fatty acid concentrations for our studies 
based on the studies reported in the literature, which describe optimal lipid signaling in tissue 
culture cells (30, 31). 
Hepatocytes take up free fatty acids through diffusion and specific transporters such as CD36 and 
fatty acid transport polypeptide (FATP) (32). In order to validate that un-conjugated fatty acids 
were taken up by HepG2 cells under our experimental conditions, the intracellular lipid content 
was examined by Nile Red staining, as described in experimental procedures (Figure 4.1). A 
significant increase in lipid content was observed in cells treated with 0.3 mM saturated fatty 
acids, PA and SA or unsaturated fatty acid, OA, as compared to control cells treated with solvent 
(isopropanol) (Figure 4.1). In contrast to PA or SA-treated cells, OA-treated cells exhibited 
punctate lipid droplet-like structures (Figure 4.1). This is consistent with previous reports 
showing that unsaturated fatty acids are more readily esterified to produce triglycerides (33, 34).  
To investigate the role of fatty acids in the regulation of HAMP expression, HepG2 cells were 
treated with different concentrations of PA, SA or OA for 8 h. Control cells were treated with 
solvent, as described in experimental procedures. HAMP mRNA expression was determined by 
real-time PCR (qPCR), as described in experimental procedures (see Chapter II). Cells treated 
with PA displayed a concentration-dependent increase in HAMP mRNA expression compared to 
solvent-treated control cells (Figure 4.2A). Similar concentrations of SA exerted a less prominent 
induction than PA. In contrast to PA and SA, OA treatment did not significantly alter HAMP 
expression compared to control cells (Figure 4.2A). In accordance with HAMP mRNA 
expression, PA treatment also elevated the level of hepcidin protein expression compared to 
control cells treated with solvent, as determined by western blotting (Figure 4.2B). These 
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findings strongly suggest a role for saturated fatty acids, in particular PA, but not saturated fatty 
acids in the regulation of hepatic hepcidin expression. 
Earlier studies mainly concentrated on the regulation of HAMP expression at the transcriptional 
level (12–15). We therefore examined the effect of fatty acids on HAMP transcription by 
performing luciferase reporter assays. For these studies, HepG2 were cells transfected with pGL-
3 Basic vector harboring 1.5 kbp HAMP promoter (HAMP Prom-Luc), which contains consensus 
DNA-binding sequences for various transcription factors implicated in the regulation of HAMP 
transcription (12–15). As control, HepG2 cells were also transfected with empty vector, as 
described in experimental procedures. HepG2 cells transfected with the recombinant vector 
displayed higher luciferase activity compared to cells transfected with the empty vector (Figure 
4.2C). However, the levels of HAMP promoter activity were similar in HepG2 cells treated with 
PA or solvent control (Figure 4.2C). These reporter assay studies indicated that PA did not 
stimulate 1.5 kbp HAMP promoter activity and therefore suggested that transcriptional 
mechanisms might not be responsible for HAMP regulation by saturated fatty acids. In order to 
investigate this further, we treated HepG2 cells with the transcription inhibitor, actinomycin D. as 
expected, actinomycin D by itself significantly inhibited basal HAMP mRNA expression in 
HepG2 cells (Figure 4.2D). On the other hand, HepG2 cells treated with PA in the presence of 
actinomycin D exhibited a significant increase in HAMP mRNA expression compared to cells 
treated with actinomycin D and solvent control (Figure 4.2E). Actinomycin experiments yielded 
results, which were in agreement with reporter studies in that despite the inhibition transcriptional 
mechanisms, saturated fatty acids can activate HAMP expression. This prompted us to investigate 
post-transcriptional regulation mechanisms. 
First we conducted experiments to investigate the effect of palmitic acid on HAMP mRNA 
stability. For these investigations, time course experiments (0-10 h.) were performed with HepG2 
cells treated with PA or solvent in the presence of actinomycin D. From 4 h. onwards, PA-treated 
cells displayed significantly higher levels of HAMP mRNA compared to solvent treated control 
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cells (Figure 4.2F). The half-lives of HAMP mRNA, calculated as described in experimental 
procedures, were 2.70 ± 0.08 and 4.44 ± 0.01 h. in solvent and PA-treated cells, respectively 
(Figure 4.2G). Our findings strongly suggest that palmitic acid stabilized HAMP mRNA in 
HepG2 cells. We then conducted further studies to investigate the mechanisms by which saturated 
fatty acid, PA regulates HAMP expression at the post-transcriptional level, which are described 
below.  
3.2 The role of palmitic acid in HAMP 3’UTR regulation  
3’UTR regions of mRNA are important in the regulation of mRNA stability by various post-
transcriptional pathways (17). The effect of PA on the 3’UTR region of HAMP was therefore 
investigated by reporter assays. For these studies, the entire (101bp) 3’UTR region of HAMP 
gene was inserted downstream of the luciferase gene in pMIR reporter vector, as described in 
experimental procedures (see Chapter II). To perform dual luciferase reporter assays, HepG2 
cells, transfected with either the empty pMIR vector (control) or recombinant pMIR vector 
harboring HAMP 3’UTR (HAMP 3’UTR), were co-transfected with the reference plasmid, pRL-
SV40. Treatment with PA significantly stimulated luciferase activity in cells transfected with the 
HAMP 3’UTR but not with empty vector (Figure 4.3A). Our reporter assay experiments strongly 
suggested the involvement of 3’UTR in the regulation of HAMP mRNA expression by PA.  
3.3 Functional role of AU-rich element (ARE) in HAMP 3’UTR 
AU-rich element binding proteins (ARE-BP) regulate mRNA stability through the recognition of 
AU-rich elements (ARE) in 3’UTR (17). The examination of HAMP 3’UTR revealed a single 
ARE (Figure 4.3B). We performed mutagenesis with the ARE by deleting the “UUU” in the 
AUUUA sequence. Recombinant pMIR vector harboring mutant HAMP 3’UTR (3’UTR ΔAU) 
was employed in luciferase reporter assays. Unlike in cells transfected with wild-type 3’UTR, PA 
failed to up-regulate luciferase activity in cells transfected with mutant HAMP 3’UTR (3’UTR 
ΔAU) (Figure 4.3C). Mutagenesis experiments strongly suggest a functional role for HAMP 
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3’UTR ARE in PA-mediated up-regulation of HAMP RNA expression. Since we have established 
a clear functional role for this single ARE-sequence within HAMP 2’UTR, we explored the role 
of RNA-binding proteins that may bind to HAMP 3’UTR for post-transcriptional regulation of 
hepcidin expression, as described below. 
3.4 AU-rich element RNA-binding proteins (ARE-BP) and HAMP 3’UTR activation  
The ARE-BP, HuR is well-known for its role in enhancing mRNA stability (17). The activation 
of HuR is achieved via phosphorylation and subsequent nucleo-cytoplasmic shuttling (22). We 
therefore examined the sub-cellular distribution of HuR in HepG2 cells treated with either PA or 
solvent by immunofluorescent staining. Cells stained with normal mouse IgG as negative control 
did not display any specific signal (Figure 4.4A). In solvent-treated control cells, HuR protein 
was mainly located in the nucleus (Figure 4.4A). Upon PA treatment, HuR shuttled from nucleus 
to the cytosol and exhibited a more diffuse distribution (Figure 4.4A). In contrast, unsaturated 
fatty acid (OA) did not induce the translocation of HuR to the cytosol (Figure 4.4A). The 
percentage of HuR localized in the cytosol was quantified, as described in experimental 
procedures. In HepG2 cells treated with solvent, PA or OA, 8.01 ± 2.56%, 35.33 ± 3.89% and 
10.07 ± 3.16% of HuR resided in the cytosol, respectively (Figure 4.4B).  
The PA-induced nucleo-cytoplasmic shuttling of HuR was further supported by western blotting 
performed with whole cell lysates, and nuclear and cytosolic fractions isolated from control or 
PA-treated HepG2 cells. PA treatment did not affect the basal protein expression levels of HuR 
(Figure 4.5). PA-treated cells displayed a significant increase in the level of cytosolic HuR 
protein compared to that in control cells (Figure 4.5). Accordingly, the expression level of HuR 
protein in the nucleus was decreased following PA treatment (Figure 4.5). Both 
immunofluorescent staining and western blotting experiments indicate that nucleo-cytoplasmic 
shuttling of HuR protein is induced by saturated fatty acids in hepatoma cells. 
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Phosphorylation by protein kinases including protein kinase C (PKC) is important for the 
shuttling and activation of HuR (22). Independently, PA has also been shown to induce the 
activation of multiple isoforms of PKC (25–29). We therefore examined the role of PKC in post-
transcriptional regulation of HAMP by PA. For these studies, HepG2 cells were first treated with 
staurosporine, a potent broad-spectrum protein kinase C inhibitor (35, 36). The level of HuR 
shuttling was determined in HepG2 cells treated with PA in the presence of 0.2 µM staurosporine 
or DMSO as control. PA-induced nucleo-cytoplasmic shuttling of HuR was abolished in cells 
treated with staurosporine, but not with DMSO, as confirmed by immunofluorescent staining and 
further quantification (Figures 4.6A and 4.6B). Cells treated with PA in the presence of DMSO 
as control displayed a significant increase (from 7.51 ± 2.67% to 38.55 ± 5.18%) in the level of 
cytosolic HuR (Figure 4.6B). In contrast, HepG2 cells treated with PA and staurosporine did not 
exhibit a significant change (from 9.30 ± 4.83% to 11.76 ± 6.48%) in HuR translocation 
compared to cells treated with solvent and staurosporine (Figure 4.6B). Contrary to DMSO, 
staurosporine treatment significantly blocked PA-mediated induction of HAMP mRNA 
expression in HepG2 cells. (Figures 4.7A and 4.7B).  
Both classical and novel classes of PKC isoforms have been suggested to phosphorylate HuR (22). 
We therefore employed PKC inhibitors, Go6976 and rottlerin, which have been shown to block 
classical or novel class of PKC isoforms, respectively (28, 37). Rottlerin (10 μM), but not 
Go6976 (1 μM), treatment abolished PA-induced HAMP mRNA increase in HepG2 cells 
(Figures 4.7C and 4.7D).  
3.5 The effect of HuR silencing on HAMP mRNA expression 
To determine the direct role of ARE and HuR in HAMP mRNA regulation by PA, we employed a 
commercial human HuR siRNA pool, comprised of four different specific siRNAs, as described 
in experimental procedures, to suppress HuR expression. In parallel, HepG2 cells were 
transfected with control siRNA (Figures 4.8A and 4.8B). The expression levels of HuR mRNA 
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and protein in cells transfected with control or HuR siRNA was determined by qPCR and western 
blotting (Figure 4.8A). Significant inhibition of HuR was achieved in HuR siRNA-transfected 
cells compared to control cells under our experimental conditions. Subsequently, transfected 
HepG2 cells were treated with 0.3 mM PA or solvent and HAMP mRNA expression was 
determined by qPCR. In solvent-treated HepG2 cells, the basal expression level of HAMP mRNA 
was down-regulated by HuR siRNA compared to control siRNA (Figure 4.8B). PA-induced 
increase in HAMP mRNA levels was significantly abrogated in HuR siRNA-transfected cells 
compared to cells transfected with control siRNA (Figure 4.8B). Our siRNA experiments clearly 
show that HuR is required for PA-mediated up-regulation of HAMP mRNA expression. 
3.6 The Physical Interaction of HuR with HAMP 3’UTR 
To confirm the direct interaction of HuR with HAMP mRNA, ribonucleoprotein 
immunoprecipitation (RNP-IP) assays were performed, as described in experimental procedures 
(see Chapter II). For these assays, we used cytosolic fractions, which were isolated from HepG2 
cells, as described in experimental procedures. Specific immunoprecipitation of HuR proteins by 
our anti-HuR antibody was confirmed by western blotting (Figure 4.9A inset). The amount of 
HAMP mRNA in HuR or control IgG co-precipitated total RNA was quantified by qPCR. The 
level of HAMP mRNA present in control IgG immunoprecipitates was not different between PA 
and solvent-treated HepG2 cells (Figure 4.9A). In contrast, 8.58 ± 0.51-fold more HAMP mRNA 
was detected in HuR-immunoprecipitates of PA-treated HepG2 cells compared to those from 
solvent-treated cells (Figure 4.9A). To confirm specificity, the presence of 18s rRNA in HuR 
immunoprecipitates was determined, as a negative control. PA treatment did not significantly 
alter the level of 18s rRNA validating our RNP-IP assays (Figure 4.9B). 
3.7 The regulation of microRNAs by palmitic acid and its effect on HAMP mRNA  
Micro RNAs (miRNAs) are negative regulators of mRNA stability and translation (38, 39). We 
therefore determined whether PA-mediated up-regulation of HAMP mRNA involves the 
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suppression of miRNAs, which might potentially target HAMP 3’UTR. Online algorithms (e.g. 
TargetScan, miRGen, RNA22) for in silico identification of miRNA targets were employed to 
scan HAMP 3’UTR sequence. The results obtained from different databases commonly identified 
miR-214. Previous studies have also shown that miR-122 indirectly regulates HAMP gene 
expression by targeting 3’UTR of other upstream iron-regulatory genes, such as Hfe and Hjv (23). 
We therefore included these two microRNAs in our investigations and determined the expression 
levels in PA or solvent-treated HepG2 cells by qPCR, as described in experimental procedures. 
PA elevated the expression of miR-214 but not miR-122 (Figures 4.10A and 4.10B). Contrary to 
our hypothesis, PA treatment did not suppress, but induced, the expression of miR-214. 
Nevertheless, we further investigated the potential role of miR-214 in HAMP regulation by 
transfecting HepG2 cells with miR-214 mimic or negative control miRNA. HAMP mRNA 
expression was determined 24 h. after transfections. In parallel, the mRNA expression level of 
mitogen-activated protein kinase kinase 3 (MEK3), which is a validated miR-214 target (40), was 
also determined by qPCR. Compared to negative control miRNA, miR-214 mimic significantly 
elevated HAMP mRNA expression (Figure 4.10C). However, the expression of MEK3 mRNA 
was significantly suppressed by miR-214 mimic confirming its specificity under our experimental 
conditions (Figure 4.10D). These findings in concert with the defined role of miRNAs as mRNA 
destabilizers strongly suggest that miR-214, despite being regulated by PA, is not directly 
involved in the induction of HAMP mRNA expression in PA-treated HepG2 cells. 
4 DISCUSSION 
Hepatic iron overload in NAFLD patients has been shown to be associated with disease severity 
(3–5). Clinical studies have also reported changes in the expression levels of hepcidin, the key 
iron regulator, in the liver and sera of NAFLD patients (6, 9). However, the underlying 
mechanisms are unclear. Hepcidin expression has been suggested to respond to changes in iron 
levels or obesity-mediated inflammatory cytokines (6, 9, 10). Obesity and NAFLD are associated 
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with dysregulated lipid metabolism. This study investigated the regulation of human hepcidin 
gene, HAMP by fatty acids in hepatoma cells. Our findings have not only clearly shown that 
saturated fatty acids, particularly palmitic acid, stimulate hepcidin expression in human liver cells 
but also revealed that HAMP expression can be regulated at the post-transcriptional level. This 
post-transcriptional pathway utilizes a single AU-rich element (ARE) in HAMP 3’UTR. 
Furthermore, we have identified an additional role for the ARE-binding protein, HuR in the 
regulation of iron homeostasis. Interestingly, our findings also suggested an association of novel 
class protein kinase C isoforms with HAMP and iron metabolism. Collectively, we have shown 
unique mechanisms, which connect iron homeostasis with lipid metabolism in hepatoma cells, 
and have implications for the pathogenesis of fatty liver disease and obesity.  
Previous studies have particularly focused on the transcriptional regulation of HAMP. Unlike 
other iron-regulatory proteins such as ferritin and transferrin receptor 1, which are regulated by 
RNA-binding proteins, IRP1 and IRP2, our knowledge on the post-transcriptional regulation of 
HAMP is very limited. An indirect role for microRNAs has been suggested in the regulation of 
mouse and human hepcidin genes via the targeting of transcriptional activators (23, 24). In 
agreement, our findings in this study have also indicated that miR-214 participates in HAMP 
regulation by saturated fatty acids, which likely occur through similar indirect mechanisms. In 
fact, miR-214 mimic up-regulated HAMP expression, which is in contrast to the widely accepted 
miRNA function. Namely, as explained in Introduction section above, microRNAs have been 
shown to destabilize mRNA by binding to their 3’UTR (21, 39). It is possible that miR-214 may 
have inhibited an as yet unidentified suppressor of HAMP. Nevertheless, our and other studies do 
not support a direct role for miRNAs in the regulation of human or mouse hepcidin gene 
expression. Further studies are required to accurately characterize the role of miR-214 in HAMP 
regulation. In this study we have shown other post-transcriptional mechanisms, which directly 
target and regulate the 3’UTR of HAMP. 
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Our studies with actinomycin D confirmed the post-transcriptional regulation of HAMP by 
saturated fatty acids. Namely, despite blocking transcription with actinomycin D, palmitic acid 
treatment induced HAMP up-regulation, which was similar to that in cells incubated with palmitic 
acid in the absence of actinomycin D. Accordingly, palmitic acid treatment significantly extended 
the half-life of HAMP mRNA. Furthermore, palmitic acid did not stimulate HAMP promoter, as 
shown by reporter assays using a construct harboring a 1.5 kbp HAMP promoter region. Similar 
results were obtained with shorter (0.6 and 0.9kbp) versions of HAMP promoter (data not shown). 
In contrast, palmitic acid directly stimulated HAMP 3’UTR, as shown by dual luciferase assays. 
Taken together, these findings clearly indicated that post-transcriptional mechanisms are 
responsible for the induction of hepatic HAMP mRNA by saturated fatty acids.  
Numerous studies using different experimental models have clearly shown that palmitic acid 
treatment activates both the classical and novel class isoforms of protein kinase C (PKC) (26–28, 
41). Our experiments suggested a role for these kinases in the regulation of HAMP by saturated 
fatty acids. The fact that palmitic acid treatment activated HAMP 3’UTR and that PKC inhibition 
abrogated saturated fatty acid-mediated HAMP mRNA up-regulation, prompted us to investigate 
the role of ARE-binding proteins, which are regulated by PKC signaling. The ARE-BP, HuR has 
been shown to be involved in the post-transcriptional regulation of genes mediating inflammatory 
reactions and tumorigenesis by targeting AU-rich elements (17, 22). Nucleo-cytoplasmic 
shuttling of HuR, regulated by phosphorylation, is crucial for its function (22). Both classical 
(PKCα) and novel (PKCδ) PKC isoforms have been shown to phosphorylate HuR at serine 
residues within or adjacent to the HuR-nucleo-cytoplasmic shuttling sequence (HNS) and thereby 
activate its translocation to the cytoplasm (42, 43). Saturated, but not unsaturated, fatty acids 
clearly induced the nucleo-cytoplasmic shuttling of HuR, which was confirmed both by 
immunofluorescence studies and subcellular fractionation of HepG2 cells. Accordingly, PKC 
inhibitors blocked both HuR translocation and induction of HAMP expression by palmitic acid. 
Inhibitor studies have also suggested that palmitic acid induces HAMP mRNA expression through 
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the activation of novel class of PKC isoforms. Further studies are required to confirm that the 
direct phosphorylation of HuR by PKC is essential for saturated fatty acid-mediated up-regulation 
of HAMP mRNA levels. 
To further understand whether HAMP is a potential target of HuR, we analyzed HAMP 3’UTR 
and identified one classical AU-rich element (ARE). Mutation of this ARE completely abolished 
palmitic acid-mediated activation of HAMP 3’UTR, as shown by reporter assays, and thereby 
confirmed the importance of this cis-element. The direct role of HuR was subsequently confirmed 
by various experiments. RNP-IP assays indicated the physical interaction of HuR with HAMP 
mRNA. Further proof was obtained by HuR siRNA studies, which successfully knocked down 
HuR in HepG2 cells. HuR inhibition by siRNA abolished PA-induced elevation of HAMP mRNA. 
These findings confirm that HAMP is a target of HuR, which mediates the regulation of HAMP 
by saturated fatty acids. Although HuR binding is sufficient for HAMP activation, the interaction 
of other post-transcriptional regulators with HuR on HAMP 3’UTR cannot be excluded. 
Interestingly, we detected the presence of miR-214 in immune complexes pulled down with our 
anti-HuR antibody in HepG2 cells. Further investigations are required to understand the 
importance of ARE-BP and microRNA interaction in the regulation of HAMP mRNA stability. 
In summary, we have identified a novel regulatory mechanism for human hepcidin gene 
expression, which occurs at the post-transcriptional level through AU-rich element RNA-binding 
protein, HuR and protein kinase C signaling. These findings have implications for understanding 
the role of iron metabolism in the pathogenesis of fatty liver disease and obesity. Since this ARE 
sequence is also present in 3’UTR of mouse hepcidin genes, mouse models of NAFLD can be 
used for further studies. Targeting of AU-rich element RNA-binding proteins might also provide 
novel therapeutic approaches for the treatment of diseases associated with metabolic syndrome.  
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Figure 4.1. Fatty acid-induced lipid accumulation in HepG2 cells. HepG2 cells cultured on coverslips 
coated with poly-lysine were treated with 0.3 mM palmitic acid (PA), stearic acid (SA), oleic acid (OA) 
or solvent control (Solv.) for 8 h. Intracellular lipid content was stained with Nile Red and nuclei 
counterstained with Hoechst 33342, as described in experimental procedures (see Chapter II). The images 
obtained with Nikon Eclipse E400 fluorescence microscope were processed and overlaid with ImageJ. 
Representative fluorescent images are shown (X 40). 
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Figure 4.2. Post-transcriptional regulation of HAMP by saturated fatty acids. (A) HepG2 cells were 
treated with 0.1 mM or 0.3 mM PA, 0.3 mM SA and OA for 8 hours (h). cDNA synthesized from RNA 
was employed in Taqman qPCR to determine HAMP mRNA expression. Gene expression in fatty acid-
treated cells was expressed as fold change of that in solvent-treated control cells. The inset shows 
hepcidin protein expression in solvent or PA-treated cells, as determined by western blotting. (B) 
Hepcidin protein expression levels in PA or solvent-treated cells were determined by western blotting. (C) 
pGL-3 Basic vector harboring a 1.5kb HAMP promoter region (HAMP Prom-Luc) or empty pGL-3 Basic 
vector was transfected into HepG2 cells together with pRL-SV40 plasmid as a reference for transfection 
efficiency. 24 h. after transfections, the cells were treated with 0.3 mM PA or solvent for 8 h. Dual 
luciferase reporter assays were performed, as described. The relative luciferase levels were expressed as 
fold change of that in solvent-treated cells transfected with empty vector. (D) HepG2 cells were treated 
with DMSO or 1µg/mL actinomycin D (ACTD) for 8 hours. HAMP mRNA expression, determined by 
qPCR, in ACTD-treated cells was expressed as fold change of that in DMSO-treated controls. (E) HepG2 
cells were treated with 0.3 mM PA or solvent in the presence of ACTD for 8 h. HAMP mRNA expression, 
determined by qPCR, in PA and ACTD-treated cells was expressed as fold change of that in cells treated 
with solvent and ACTD (F) HepG2 cells were treated with solvent (solid line) or 0.3 mM PA (dashed line) 
in the presence of 1µg/mL actinomycin D (ACTD). Control cells were treated with solvent in the 
presence of DMSO. Cells were harvested every 2 h until 10 h. HAMP mRNA expression at different time 
points was expressed as fold change of that in respective control cells. (G) The half-life of HAMP mRNA 
in HepG2 cells treated with solvent or 0.3 mM PA was calculated, as described in experimental 
procedures and expressed in hours. Asterisks indicate statistical significance (p<0.05). 
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Figure 4.3. The role of palmitic acid (PA) in the regulation of HAMP 3’UTR. (A) HepG2 cells, 
transfected with pMIR vector harboring 3’UTR of HAMP gene (3’UTR) or empty pMIR vector, were 
treated with PA or solvent. pRL-SV40 vector was co-transfected as a reference for transfection efficiency. 
Dual luciferase assays were performed, as described in experimental procedures. The relative luciferase 
levels were expressed as fold change of that in solvent-treated cells transfected with empty vector. (B) 
HAMP 3’UTR region harboring a single AU-rich element (ARE) is shown as a schematic diagram. The 
position of ARE sequence (AUUUA) is underlined. (C) Mutagenesis of AU-rich element in HAMP 
3’UTR region was performed by deleting the UUU base pairs by site-directed mutagenesis, as described 
in the experimental procedures. HepG2 cells were transfected with pMIR vector harboring wild-type 
3’UTR or 3’UTR with mutated AU-rich element (3’UTR ΔAU) to perform dual luciferase assays, as 
described above.  
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Figure 4.4. PA-induced nucleo-cytoplasmic shuttling of HuR protein (immunofluorescent staining). 
(A) HepG2 cells cultured on coverslips were treated with 0.3 mM PA, OA or solvent (Solv.). HuR protein 
expression was detected with an anti-HuR primary antibody and secondary Texas Red-conjugated horse 
anti-mouse IgG. Normal mouse IgG was employed as negative control for the immunofluorescent 
staining. Nuclei were counterstained with DAPI. The images obtained with Nikon Eclipse E400 
fluorescence microscope were processed and overlaid with ImageJ. Representative fluorescent images are 
shown (X 40). (B) Four independent 20X fluorescent images (120 ± 22 cells in each image) from each 
treatment group were analyzed with Squassh plugin of ImageJ. The percentage of cytosolic HuR signal 
intensity was calculated, as described in experimental procedures. Asterisks indicate statistical 
significance (p<0.05).  
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Figure 4.5. PA-induced nucleo-cytoplasmic shuttling of HuR protein (western blotting). Whole cell 
lysate, cytosolic and nuclear fractions were isolated from HepG2 cells treated with solvent (Solv.) or 0.3 
mM PA for 8 h. The protein lysates were employed for western blotting to detect HuR protein expression 
with an anti-HuR primary and an anti-mouse secondary antibody in each fraction. An anti-gapdh or anti-
histone H3 (H3) antibody was used as cytosol or nucleus marker, respectively.  
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Figure 4.6. PA-mediated shuttling of HuR was abolished by staurosporine. (A) Immunofluorescent 
staining was performed with HepG2 cells treated with solvent or 0.3 mM PA in the presence of 0.2 µM 
staurosporine (STAU) or DMSO as control, as described. Representative fluorescent images are shown 
(X 40). (B) Quantification of HuR nuclear localization was performed, as described in experimental 
procedures.  
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Figure 4.6 
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Figure 4.7. PA-mediated HAMP mRNA induction was abolished by PKC inhibitors. HAMP mRNA 
expression in HepG2 cells treated with solvent (Solv.) or 0.3 mM PA either in the presence of DMSO (A), 
0.2µM staurosporine (STAU) (B), 1 µM Go6976 (C) or 10 µM rottlerin (D) was determined by qPCR. 
Gene expression in treated cells was expressed as fold expression of that in control cells incubated with 
solvent. Asterisks indicate statistical significance (p<0.05). 
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Figure 4.8. PA-induced up-regulation of HAMP expression was inhibited by HuR siRNA. HepG2 
cells were transfected with 50 nM of HuR siRNA SMART pool or control siRNA, as described in 
experimental procedures. (A) The level of HuR mRNA expression in transfected cells was determined by 
qPCR. The inset shows HuR protein expression determined by western blotting. (B) The level of HAMP 
mRNA expression in siRNA-transfected cells treated with solvent or 0.3 mM PA for 8 h. was determined 
by qPCR. Asterisks indicate statistical significance (p<0.05).  
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Figure 4.9. The physical interaction of HuR with HAMP mRNA. RNP-IP assays were performed to 
detect the binding of HuR to HAMP mRNA in HepG2 cells treated with solvent or 0.3 mM PA, as 
described in experimental procedures. (A) RNA isolated from control IgG or HuR immunoprecipitates 
was used to synthesize cDNA to determine HAMP expression by qPCR. HAMP expression in 
immunoprecipitates from PA-treated cells was expressed as fold change of that in corresponding solvent-
treated cells. Asterisks indicate statistical significance (p<0.05). Inset: Detection of HuR protein in HuR 
or control IgG immunocomplexes by western blotting. (B) 18s rRNA expression in HuR 
immunoprecipitates was determined by qPCR as a negative control.  
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Figure 4.10. The regulation of microRNAs by PA and its effect on HAMP mRNA. The expression 
levels of miR-122 (A) and miR-214 (B) in PA or solvent-treated HepG2 cells were determined by qPCR. 
(C) miR-214 mimic and negative control (Neg.) was transfected into HepG2 cells and the expression 
levels of HAMP (C) and MEK3 (D) mRNA were determined by qPCR 24 h. after transfections. Asterisks 
indicate statistical significance (p<0.05).  
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Chapter V 
Ceramide Regulates Human Hepcidin Gene Transcription through JAK/STAT3 
Signaling Pathway 
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1 ABSTRACT 
Hepcidin is both an acute phase and iron-regulatory protein, synthesized in the liver. As an acute 
phase protein, its expression is induced by inflammation and infection. Inflammatory processes in 
the liver play a major role in the pathogenesis of liver diseases including nonalcoholic fatty liver 
disease (NAFLD). Changes in iron metabolism and hepcidin expression in NAFLD patients have 
been observed but the causes and significance of these changes are unclear. It might be mediated 
by iron or inflammatory signaling in the liver. Transcription of the human hepcidin gene, HAMP 
is known to be activated by inflammatory cytokines, IL-1 and IL-6. The lipid intermediates such 
as ceramide, which are also generated in livers with lipid accumulation (i.e. NAFLD), have also 
been shown to induce inflammatory responses. Despite this knowledge, neither the role of 
ceramide and other and lipid intermediates in NAFLD nor their effect on HAMP transcription has 
been investigated. In the current study, we examined the regulation of HAMP expression by 
ceramide. For these studies, HepG2 human hepatoma cells were treated with two different cell-
permeable ceramide analogs. They both significantly activated HAMP mRNA expression in a 
concentration-dependent manner. The effect of ceramide on HAMP expression was mediated at 
the transcriptional level because it was abolished with the transcription inhibitor, actinomycin D. 
Accordingly, ceramide significantly stimulated HAMP promoter activity, which occurred within 
the 0.6 kb HAMP promoter region proximal to the transcription start site. The transcription 
factors, STAT3, NF-κB and c-Jun/AP-1 play important roles in inflammation. Ceramide 
specifically induced the binding of STAT3, but not NF-κB or c-Jun/AP-1, to the HAMP promoter, 
as shown by chromatin immunoprecipitation assays. In fact, ceramide exerted a negative effect on 
c-Jun/AP-1 binding. Similarly, a chemical inhibitor of c-Jun N-terminal kinase (JNK) did not 
abolish the effect of ceramide on HAMP expression. Ceramide stimulated the phosphorylation of 
STAT3 on tyrosine 705 residue, NF-κB p65 subunit protein and JNK in HepG2 cells. These 
findings further confirm the specificity of ceramide-mediated STAT3 interaction with HAMP 
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promoter. To confirm the direct role of this interaction, we mutated the single STAT3 response 
element present within 0.6 kb HAMP promoter region. This deletion significantly abolished the 
activation of HAMP promoter by ceramide. Furthermore, siRNA-mediated silencing of STAT3 
and the inhibition of JAK kinases with a specific chemical inhibitor significantly blunted the 
stimulatory effect of ceramide on HAMP mRNA expression. In conclusion, the studies in this 
chapter confirmed the direct and significant role of ceramide in the regulation of HAMP 
transcription through STAT3. These findings suggest that inflammatory signaling mediated by 
lipid intermediates in the liver may modulate iron metabolism and thereby disease severity in 
NAFLD patients.  
2 INTRODUCTION  
Non-alcoholic fatty liver disease (NAFLD) is the accumulation of fat in the liver of patients with 
no or little alcohol consumption (1). More than one third of the US adult population is estimated 
to have NAFLD and its prevalence is expanding to developing countries and to children (2). 
Benign fat accumulation in the liver (steatosis) can progress to nonalcoholic steatohepatitis 
(NASH) (3), characterized by inflammation (steatohepatitis) and fibrosis. Alternatively, patients 
can present with NASH without previous steatosis (4). If untreated, NASH can eventually lead to 
cirrhosis and hepatocellular carcinoma (5). The mechanisms of NAFLD/NASH progression are 
unclear. A role for secondary risk factors including iron (6, 7) and inflammation (8) has been 
proposed (see Chapter I for detailed overview).  
NAFLD patients frequently display elevated levels of serum iron indices and hepatic iron content 
(9, 10). The deposition of iron in the liver correlates with disease severity and the development of 
fibrosis (11–13). The discovery of hepcidin has helped us to understand the connection between 
inflammation and iron homeostasis (14–17). Hepcidin, mainly synthesized in the hepatocytes of 
the liver, is both an acute phase protein and pivotal regulator of systemic iron homeostasis (14–
17). As an acute phase protein, hepcidin responds to inflammation and its synthesis in the liver is 
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stimulated by inflammatory cytokines, such as IL-1 and IL-6. It has been shown that IL-6 induces 
hepcidin expression at the transcriptional level through the activation of JAK/STAT3 pathway 
(15, 16, 18). The binding of STAT3 to both human (HAMP) and mouse (Hamp) hepcidin gene 
promoters have been demonstrated in different experimental models (15, 16, 18).  
Inflammation plays a major role in NAFLD pathogenesis. Several factors including increased gut 
permeability, adipose tissue derived cytokines and adipokines, Kupffer cell activation, and lipid 
accumulation have all been shown to induce inflammatory reactions in the livers of NAFLD 
patients (8, 19). In a study with overly obese patients undergoing bariatric surgery, a relationship 
between adipose tissue-derived-IL-6 and elevated hepcidin expression in the adipose tissue has 
been shown (20). However, elevated hepcidin expression could also be due to increase in the 
number of adipocytes in obese individuals compared to normal weight controls. Further studies 
investigating the direct effect of hepatic lipid accumulation and inflammation on hepcidin 
expression are therefore required. Although the in vivo relevance needs to be established, we have 
shown a direct effect of saturated fatty acids on hepcidin expression in human hepatoma cells (see 
Chapter IV). Namely, palmitic acid induced hepcidin expression at the post-transcriptional level 
through the activation of protein kinase C signaling and AU-rich element binding protein HuR 
(see Chapter IV). 
Both inflammation and lipid accumulation are potent stimulators of ceramide synthesis in the 
liver through different well-defined pathways (i.e. de novo and sphingomyelinase pathways) (21, 
22). Increased ceramide production and its association with hepatic fat content have been reported 
in obese and/or insulin resistant patients (23, 24). Similarly, animal studies with high fat diet 
feeding have also demonstrated an increase in hepatic ceramide content (25, 26). Despite all these 
observations, the involvement of ceramide in the pathogenesis of NAFLD has not been 
investigated. Nevertheless, weight loss studies have alluded to the importance of liver ceramide 
synthesis in NAFLD (27). Namely, the reversal of NASH pathogenesis correlated with weight 
loss-mediated decrease in pro-ceramide gene expression in the liver (27).  
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Although initially recognized only as a structural component of biomembranes, ceramide in 
recent years has gradually been appreciated as an important signaling molecule (28). Besides 
negatively modulating insulin signaling (29), ceramide also activates inflammatory signaling 
pathways. The tyrosine phosphorylation of the transcription factor, STAT3 and its DNA binding 
activity has been shown to be stimulated by ceramide in a JAK-dependent manner in cultured 
fibroblasts (30). Besides STAT3, ceramide has been reported to activate the transcription factor, 
NF-κB and its down-steam targets in HepG2 and other cells (31–33). The c-Jun N-terminal 
kinase (JNK) is also involved in inflammation. Deletion of JNK has been shown to reverse 
steatohepatitis in mice livers induced by methionine-choline deficient diets (34). JNK is activated 
by phosphorylation, which in turn phosphorylates c-Jun and transactivation of AP-1 enhancer-
containing genes (35). Ceramide has been reported to stimulate JNK activation (36–38). Although 
ceramide has been shown to both modulate and be modulated by inflammation, the effect of these 
changes on hepatic HAMP expression is unknown. Understanding these mechanisms will further 
our knowledge of NAFLD/NASH pathogenesis. In this chapter we present studies, examining 
HAMP regulation by ceramide and the underlying mechanisms in human hepatoma cells. 
3 RESULTS  
3.1 Ceramide analogs-induced transcriptional regulation of HAMP 
In order to study the role of ceramide in the regulation of human hepcidin gene, HAMP 
expression in human hepatoma cells, we treated HepG2 cells with synthetic cell-permeable 
ceramide analogs, C2 and C6 ceramide, which are extensively used for in vitro experiments (21, 
37, 39). We chose 30 μM and 60 μM concentrations based on previous reports, which have 
shown that cells treated with these concentrations of ceramide analogs for 8 hours exhibit over 
90 % cell viability (32, 40). Similar ceramide concentrations have been detected in the plasma of 
human NAFLD patients (41) and rats with acute lipid infusion (42). Control cells were treated 
with solvent (0.1 % DMSO). The effect of ceramide analogs on hepcidin expression was 
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determined by measuring the level of HAMP mRNA by qPCR, as described in the experimental 
procedures (see Chapter II). HepG2 cells treated with 30 μM or 60 μM of C2 ceramide displayed 
an 1.78 ± 0.35 and 3.43 ± 0.39-fold increase in HAMP expression, respectively, compared to 
control cells treated with solvent (Figure 5.1A). Compared to C2, similar concentrations of C6 
ceramide analog induced a less potent but still significant elevation of HAMP mRNA expression 
(Figure 5.1A). We therefore employed C2 ceramide analog for further experiments.  
Studies to this date have concentrated on transcriptional regulation of hepcidin gene expression 
(43–46). However, our recent studies also highlighted the importance of post-transcriptional 
mechanisms in the regulation of hepatic HAMP expression (see Chapter IV). We therefore 
determined whether the induction of HAMP expression by ceramide occurred at the 
transcriptional or post-transcriptional level. For these experiments, HepG2 cells were treated with 
ceramide or solvent in the presence of either actinomycin D (a transcription inhibitor) or DMSO 
control. DMSO by itself did not alter C2 ceramide-mediated induction of HAMP mRNA 
expression (Figure 5.1B). On the other hand. actinomycin D by itself significantly decreased the 
levels of HAMP mRNA in HepG2 cells (Figure 5.1B). Similarly, simultaneous treatment with 
actinomycin D and ceramide completely blocked ceramide-induced HAMP mRNA up-regulation 
(Figure 5.1B and 5.1C). To further confirm the role of transcriptional regulation, we performed 
luciferase reporter assays using a 0.6 kb region of HAMP promoter, which harbors binding sites 
for various transcription factors (46, 47) (Figure 5.1D). HepG2 cells were transfected with either 
empty pGL-3 basic vector or vector containing 0.6kb HAMP promoter (HAMP Prom-Luc). pRL-
SV40 plasmid encoding renila luciferase was co-transfected as a reference for transfection 
efficiency, as described in experimental procedures (see Chapter II). Cells transfected with the 
vector harboring the HAMP promoter exhibited a significantly higher level of luciferase activity 
(Figure 5.1D). Ceramide treatment of HepG2 cells transfected with HAMP Prom-Luc, but not 
with empty vector, resulted in a significant increase of luciferase activity. In conjunction with 
actinomycin D experiments, our reporter assay studies with HepG2 cells indicated that ceramide 
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regulates HAMP expression at the transcriptional level and that this regulation is conveyed 
through cis-elements contained within the 0.6 kb HAMP promoter. 
3.2 Physical interactions between transcription factors and HAMP promoter. 
Various transcription factors such as STAT3, NF-κB and c-Jun/AP-1 are involved in the 
regulation of inflammatory processes (48–50). Recognition sequences for these transcription 
factors have been identified in the 0.6 kb promoter of HAMP (Figure 5.2A). In order to confirm 
the identity of transcription factors physically interacting with HAMP promoter in ceramide-
treated HepG2 cells, chromatin immunoprecipitation (ChIP) assays were performed, as described 
in experimental procedures (Figures 5.2B and 5.2C). For these experiments, specific antibodies 
for transcription factors, STAT3, NF-κB and c-Jun/AP-1, which have been validated for ChIP 
experiments, were employed. Normal rabbit/mouse IgG was used as negative control. The 
primers used for ChIP analysis (Chapter II Table 2.4) amplified promoter sequences spanning 
consensus sites for respective transcription factors (STAT3: -135bp to -143bp, c-Jun/AP-1: -
126bp to -134bp, NF-κB P65: -583bp to -592bp proximal to the start codon, ATG). Ceramide 
treatment significantly increased the binding of STAT3 to HAMP promoter (Figure 5.2B). 
HepG2 cells treated with the cytokine, IL-6 were employed as a positive control (16). The 
binding of STAT3 to HAMP promoter was also induced by IL-6 treatment, which validated our 
anti-STAT3 antibody and ChIP protocol (Figure 5.2C). Unlike STAT3, the binding of NF-κB 
p65 subunit to HAMP promoter was not activated by ceramide treatment (Figure 5.2B). On the 
other hand, the binding of c-Jun/AP-1 to HAMP promoter was weakened in ceramide-treated 
HepG2 cells compared solvent-treated cells (Figure 5.2C). The findings of our ChIP experiments 
were specific because no significant promoter enrichment was observed when similar chromatin 
preparations were incubated with the control IgG (representative images are shown in Figures 
5.2B and 5.2C). Furthermore, the total amount of chromatin input was equal across all samples in 
our ChIP assays (Figure 5.2B and 5.2C).  
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3.3 Phosphorylation and activation of STAT3 and NF-κB in ceramide-treated cells 
Western blots were performed with specific phospho-antibodies, which recognize the 
phosphorylated (i.e. activated) forms of STAT3 and NF-κB proteins to determine the effect of 
ceramide on their activation status (Figure 5.3A and 5.3B). STAT3 is regulated by 
phosphorylation both on serine (Ser 727) and tyrosine (Tyr 705) residues (51). Following 
ceramide treatment, HepG2 cells displayed a significant increase in tyrosine (Tyr 705), but not 
serine (Ser 727), phosphorylation of STAT3 (Figure 5.3A). As a positive control, HepG2 cells 
were also treated with recombinant IL-6. Unlike ceramide, IL-6 treatment stimulated 
phosphorylation of STAT3 both at Tyr 705 and Ser 727 compared to that in PBS-treated control 
cells (Figure 5.3A). Neither ceramide nor recombinant IL-6 altered the expression level of total 
STAT3 protein in HepG2 cells (Figure 5.3A). Similar to STAT3, ceramide also stimulated the 
phosphorylation of NF-κB subunit, p65 (Figure 5.3B). Our findings collectively suggested, that 
despite ceramide inducing the phosphorylation of both transcription factors, only STAT3 (and not 
NF-KB) is capable of binding to and stimulating HAMP promoter activity. 
3.4 The relationship between ceramide-induced JNK phosphorylation and HAMP up-
regulation. 
MAP kinases such as c-Jun N-terminal kinase (JNK) and extracellular signal-regulated protein 
kinases 1 and 2 (ERK1/2) have been suggested to target serine 727 of STAT3 for phosphorylation 
(51). We therefore examined the phosphorylation of JNK and ERK1/2 by western blotting. 
Ceramide suppresses extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) in some (52, 
53) but not all (32) experimental systems. Under our experimental conditions, C2 ceramide 
significantly suppressed the phosphorylation of ERK1/2. IL-6 treatment exerted only a minor 
effect (Figure 5.3A). In contrast, C2 ceramide significantly induced the phosphorylation of JNK 
compared to DMSO (control) (Figure 5.3B).  
To further study the effect of ceramide and JNK on HAMP expression, we employed the chemical 
inhibitor, SP600125, which has been documented to specifically inhibit JNK activation (54). 
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HepG2 cells were treated in the presence of both ceramide and SP600125. In parallel, co-
incubation with DMSO was also performed, as control. Western blotting was performed to 
examine the effect of SP600125 on ceramide-induced JNK phosphorylation (Figure 5.4A). 
DMSO did not have any specific effect on ceramide-induced JNK activation (Figure 5.4A). In 
contrast, SP600125 co-incubation significantly blocked ceramide-induced activation of JNK 
(Figure 5.4A). We then examined the effect of SP600125 co-incubation on ceramide-induced 
HAMP expression by qPCR. The inhibitor by itself did not exert any significant effect on basal 
HAMP mRNA expression (Figure 5.4B). Similarly, SP600125 was not capable of blocking the 
positive effect of ceramide on HAMP mRNA expression (Figure 5.4B). These results indicated 
that although activated by ceramide, JNK is not directly involved in transcriptional regulation of 
HAMP by ceramide in hepatoma cells. 
3.5 The role of STAT3 activation in ceramide-induced HAMP transcriptional regulation.  
To validate the specific role of STAT3 in ceramide-mediated transcriptional regulation of HAMP, 
the STAT3 response element in the 0.6kbp HAMP promoter was mutated, as described in the 
experimental procedures (see Chapter II). Luciferase reporter assays were then performed with 
pGL-3 basic vectors harboring the wild-type or mutated HAMP promoter (Figure 5.5A). 
Mutation of the STAT3 response element (ΔSTAT3) significantly diminished the stimulatory 
effect of ceramide on HAMP promoter, confirming the direct involvement of the STAT3 binding 
site (Figure 5.5A). We validated the mutated promoter construct by IL-6 treatment based on the 
rationale that this STAT3 response element is essential for IL-6-responsiveness of HAMP 
promoter (16, 45). Accordingly, the mutation of STAT3 response element (ΔSTAT3) abolished 
IL-6-induced HAMP promoter activation (Figure 5.5B). 
In order to study the involvement of JAK/STAT3 signaling pathway in ceramide-mediated 
transcriptional regulation of HAMP expression, we employed STAT3 siRNA and a chemical pan-
JAK kinase inhibitor, JAK inhibitor I (55) (Figure 5.6A and 5.6B). The efficacy of STAT3 
siRNA was confirmed by qPCR and western blotting experiments. The level of STAT3 mRNA 
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(Figure 5.6A) and protein (Figure 5.6A inset) expression were significantly inhibited by STAT3 
siRNA, but not control siRNA, in HepG2 cells. The potency of JAK inhibitor I was also validated 
by western blotting. Namely, JAK inhibitor I significantly blocked the ceramide-induced 
phosphorylation of STAT3 at residue Tyr 705 (Figure 5.6B). The effect of JAK inhibitor I on the 
regulation of HAMP mRNA expression by ceramide was determined by qPCR (Figure 5.7A). 
The addition of DMSO, which is the vehicle for JAK inhibitor I, did not affect ceramide-induced 
HAMP up-regulation (3.44 ± 0.41 fold). In comparison, ceramide-mediated induction of HAMP 
expression was significantly attenuated by JAK inhibitor I (2.28 ± 0.23 fold) (Figure 5.7A). The 
inhibition was however incomplete. HepG2 cells were therefore pre-treated with both STAT3 
siRNA and JAK inhibitor I. In parallel, control cells were administered control siRNA and 
DMSO. Both groups of pre-treated cells were then subjected to either ceramide or DMSO 
(control) treatment, and HAMP mRNA expression was determined (Figure 5.7B). Control siRNA 
and DMSO pre-treatment did not alter the effect of ceramide on HAMP mRNA expression levels 
(3.15 ± 0.05 fold increase) (Figure 5.7B). By contrast, the combined pre-treatment with STAT3 
siRNA and JAK inhibitor I decreased the induction of HAMP mRNA expression by ceramide 
(1.57 ± 0.09 fold increase) (Figure 5.7B). The effect of JAK inhibitor I and STAT3 siRNA on 
ceramide-induced HAMP promoter activation was further examined with luciferase reporter 
assays (Figure 5.7C and 5.7D). HepG2 cells, transfected with pGL-3 basic vector harboring 0.6 
kbp HAMP promoter, were treated with ceramide or solvent in the presence of either JAK 
inhibitor I or DMSO as control. Ceramide treatment induced a 2.16 ± 0.32 fold increase in HAMP 
promoter activity, as compared to control cells treated with solvent in the presence of DMSO. In 
contrast to DMSO, the addition of JAK inhibitor I significantly diminished ceramide-induced 
HAMP promoter activation (1.69 ± 0.21 fold) (Figure 5.7C). The level of inhibition was stronger 
with the combined pre-treatment of STAT3 siRNA and JAK inhibitor I (1.39 ± 0.10 fold) (Figure 
5.7D). HepG2 cells pre-treated with control siRNA and DMSO displayed 2.22 ± 0.36 fold 
increase in HAMP promoter activity following ceramide treatment (Figure 5.7D). 
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3.6 The involvement of ER stress in ceramide-induced signaling and HAMP up-regulation.  
ER stress has also been reported to induce HAMP transcription (56) and ceramide is a known 
inducer of ER stress (57–59). We therefore determined the presence of ER stress in ceramide-
treated HepG2 cells by XBP1 assays, as described in the experimental procedures (see Chapter 
II). Briefly, ER stress activates the inositol-requiring enzyme 1 (IRE1) which splices X-box 
binding protein 1 (XBP1) mRNA (60). Spliced form of XBP1, which was detected, as described 
in the experimental procedures, has been employed as ER stress marker. Besides ceramide, cells 
were treated with tunicamycin, a well-known experimental ER stress inducer (61), as a positive 
control. HepG2 cells treated with ceramide did not exhibit any significant changes in the spliced 
and unspliced forms of XBP1, as compared to the solvent-treated control cells (Figure 5.8A). In 
contrast, cells treated with tunicamycin exhibited a significant increase in the spliced form, and a 
decrease in the unspliced form, of XBP1, which confirmed the validity of our assay (Figure 
5.8A). These findings clearly demonstrated that, unlike tunicamycin, ceramide is not capable of 
inducing ER stress in HepG2 cells. Accordingly, the treatment of HepG2 cells with a chemical 
inhibitor of ER stress, salubrinal (57), did not abolish ceramide-mediated up-regulation of HAMP 
expression (Figure 5.8B). 
4 DISCUSSION 
Iron accumulation accompanies NAFLD pathology and contributes to disease severity (6, 7). 
Since hepcidin is the key iron regulatory hormone, a clear understanding of the mechanisms 
which regulate its expression in NAFLD is important. This may enable the development of novel 
treatment strategies to prevent the harmful effects of iron in NAFLD/NASH progression. 
Although we have identified novel molecular mechanisms by which lipids regulate hepcidin 
expression at the post-transcriptional level, the role of lipid-mediated inflammatory processes is 
still unclear. Of note, hepcidin as an acute phase protein is strongly regulated by inflammation. 
Furthermore, excess lipid accumulation in the livers of NAFLD patients elevate the production of 
152 
 
lipid metabolites, such as ceramide, which take part in inflammatory and insulin signaling 
cascades (21, 62, 63). However, the role of these biologically active lipid intermediates either in 
NAFLD pathology or in the hepcidin regulation have so far not been addressed.  
The studies presented in this chapter have collectively shown that the transcription of human 
hepcidin gene, HAMP is significantly activated by ceramide in hepatoma cells. Furthermore, our 
findings clearly confirmed the role of ceramide-activated JAK/STAT3 signaling in this process. 
Interestingly, we have also established a new and unique function for ceramide (i.e. 
sphingolipids), namely the regulation of iron metabolism. This novel role of ceramide was 
mediated through a specific region in HAMP promoter, which was 0.6kb proximal to 
transcription start site, as confirmed by our reporter assays and mutagenesis studies. 
We have further dissected the mechanisms involved in ceramide-mediated activation of STAT3. 
Ceramide has previously been shown to activate the tyrosine-phosphorylation of STAT3 in 
cultured fibroblast cells (30). However, its effect on JAK/STAT3 signaling in hepatoma cells is 
unknown. Under our experimental conditions, ceramide exerted differential effects on STAT3 
phosphorylation. Namely, it stimulated the phosphorylation at tyrosine 705, but not serine 727, 
residue of STAT3. In contrast, IL-6, a classical activator of JAK/STAT3 pathway (and hepcidin 
transcription) (16) induced both serine and tyrosine phosphorylation of STAT3. The published 
studies up-to-now have established a prominent role for tyrosine, but not serine, phosphorylation 
as the key requirement for activation of STAT3 as a transcription factor (51). We therefore 
believe that the induction of tyrosine 705 phosphorylation should be sufficient for STAT3 
activation in ceramide-treated hepatoma cells. The precise role of serine 727 phosphorylation is 
still unclear (64, 65). It has been predicted to support the trans-activation capability of STAT3, as 
a DNA-binding protein (66, 67). Other studies have suggested a role for serine phosphorylation to 
limit the duration of tyrosine phosphorylation by recruiting a phosphatase (65). Although we did 
not observe strong inhibition of serine 727 phosphorylation, a prominent inhibition of ERK 
phosphorylation was detected by ceramide. ERK has been shown to phosphorylate STAT3 on 
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serine 727 (51, 67). However, whether ERK inhibition and STAT3 stimulation by ceramide are 
connected (and the consequences for HAMP transcription) remains to be investigated in future 
studies. The findings of our ChIP assays, which validated ceramide-mediated physical interaction 
between STAT3 and the corresponding cis-element in HAMP promoter, are also in agreement 
with the tyrosine-phosphorylation status of STAT3. Collectively, our data strongly suggest that 
ceramide-mediated binding of STAT3 to HAMP promoter is facilitated by the activation of 
STAT3 via tyrosine phosphorylation.  
The conclusive evidence for the direct involvement of STAT3 in ceramide-induced HAMP 
transcription was provided by the following findings: 1- Mutation of the STAT3 response 
element in HAMP promoter significantly blunted ceramide-induced promoter activation. 2- 
Experiments using a commercial siRNA pool for STAT3 and a pan-JAK inhibitor have 
demonstrated successful inhibition of STAT3 activation in conjunction with the abrogation of 
ceramide-induced HAMP mRNA induction and promoter activation. Taken together, these results 
confirmed the dependence of ceramide-induced HAMP transcription on JAK/STAT3 signaling 
pathway. The reasons, as to why we could not completely block the effect of ceramide on HAMP 
mRNA up-regulation and promoter activation following either siRNA silencing of STAT3 in 
combination with JAK inhibition or mutation of STAT3 response element in HAMP promoter, is 
unclear. It is however feasible that additional signaling pathways may be involved.  
The specificity of JAK/STAT3 signaling was also confirmed by our results with NF-κB and JNK 
activation, which are known to be involved in inflammation. Namely, we confirmed the 
activation (i.e. phosphorylation) of NF-κB and JNK in ceramide treated HepG2 cells, as has been 
previously reported in other cell types (31, 32, 36–38). Despite the activation, NF-κB failed to 
physically interact with the putative response element in the HAMP promoter as shown by our 
ChIP assays. JNK is involved in activation of c-Jun/AP-1 but ceramide decreased the binding of 
c-Jun/AP-1 to HAMP promoter. This might be due to a competition by STAT3 because their 
DNA-binding sites are in close proximity on HAMP promoter (see Results section above). 
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Furthermore, JNK inhibitor studies also confirmed that JNK activation is not required for HAMP 
regulation by ceramide. 
Experimental ER stress models indicated a role for it in the activation of hepcidin gene 
transcription (56). A direct link between dysregulated lipid metabolism in the liver and ER stress 
has been demonstrated in mouse models of obesity (68). Moreover, as shown by in vitro studies 
using various cell lines, a role for ceramide in lipid-mediated ER stress has also been suggested 
(57, 69, 70). We therefore examined whether ceramide-induced HAMP transcription involved ER 
stress. Ceramide did not trigger ER stress in HepG2 cells under experimental conditions. 
Furthermore, ER stress inhibition by salubrinal (57, 58) did not abolish the stimulatory effect of 
ceramide on hepcidin mRNA expression. Taken together, these results excluded the contribution 
of ER stress to the activation of HAMP transcription by ceramide. 
In summary, we have demonstrated a novel role for the lipid intermediate, ceramide in the 
regulation of HAMP expression. Similarly, our findings also demonstrate a unique regulatory 
mechanism for HAMP transcription in liver cells mediated by ceramide. The fact, that ceramide 
could directly achieve this through the activation of JAK/STAT3 signaling in hepatoma cells, has 
clinical implications. Namely, it suggests that the involvement of other inflammatory cells, such 
as Kupffer cells, is not required for this regulation. These findings will therefore help us to 
understand the connection between lipid intermediates and inflammatory processes in the 
regulation of iron metabolism including its relevance to NAFLD/NASH disease progression. 
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Figure 5.1. Ceramide analogs induce HAMP expression at the transcriptional level. (A) HepG2 cells 
were treated with 30 μM or 60 μM of C2 or C6 ceramide for 8 hours. cDNA, synthesized from RNA 
isolated from these cells, were employed as templates in Taqman qPCR to determine HAMP mRNA 
expression, as described in experimental procedures (see Chapter II). HAMP mRNA expression in 
ceramide-treated cells was calculated as fold change of that in solvent (solv.)-treated control cells. (B) 
HepG2 cells were treated with 60 μM C2 ceramide or solvent (solv.) in the presence of 1µg/ mL 
actinomycin D (ACTD) or DMSO, as control. HAMP mRNA expression, determined by qPCR, in 
ceramide and/or ACTD-treated cells was calculated as fold change of that in cells treated with solvent and 
DMSO. (C) HAMP expression in cells treated with ACTD and ceramide was expressed as fold change of 
that in cells treated with ACTD and solvent. (D) HepG2 cells were transfected with pGL-3 basic vector 
harboring 0.6kbp HAMP promoter (HAMP-Prom-Luc) or empty pGL-3 basic vector (vector), as described 
in the experimental procedures. pRL-SV40 plasmid was co-transfected as reference for transfection 
efficiency. The transfected cells were treated with solvent (solv.) or 60 μM C2 ceramide for 8 hours. The 
cells were lysed and dual luciferase report assays were performed, as described. Relative luciferase unit 
was expressed as fold change of that in the empty vector-transfected and solvent-treated cells. 
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Figure 5.2. Ceramide treatment stimulated the binding of STAT3, but not NF-κB subunit p65 or c-
Jun/AP-1, to HAMP promoter. (A) Schematic diagram of 0.6kb HAMP promoter showing recognition 
sequence for NF-κB P65 (P65), STAT3, and c-Jun/AP-1 (AP-1). (B) Chromatin, isolated from ceramide 
or solvent (solv.)-treated HepG2 cells fixed with 1% formaldehyde, was immunoprecipitated with anti-
STAT3, -NF-κB subunit p65 or -c-Jun antibodies or normal IgG , as control, as described in experimental 
procedures. Eluted and purified chromatin fractions, and total input chromatin (equal loading controls) 
were used as templates in PCR to amplify a 0.6 kbb HAMP promoter region using specific primers. PCR 
products were resolved with DNA agarose gel electrophoresis and images captured with Gel Doc XR+ 
system (Bio-Rad). Representative gel images have been shown. (C) HepG2 cells, treated with 
recombinant IL-6 or PBS (control), were employed for ChIP assays using an anti- STAT3 antibody, as 
described above. PCR products were visualized with ethidium bromide staining of DNA agarose gels.  
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Figure 5.3. The effect of ceramide on STAT3, JNK, NF-κB, and ERK1/2 phosphorylation in HepG2 
cells. Whole cell lysates, purified from HepG2 cells treated with solvent (solv.), 60 μM C2 ceramide, 40 
ng/mL recombinant IL-6 or PBS for 8 hours, were employed for western blotting. PVDF membranes 
were incubated with anti-phospho-STAT3 (P-STAT3 Tyr 705), anti-phospho-STAT3 (P-STAT3 Ser 727), 
anti-phospho-ERK1/2 (P-ERK1/2) (A), anti-phospho-P65 (P-P65), -total NF-κB P65 (P-65), and anti-
phospho-JNK (P-JNK) antibodies (B). Immune reactive bands were detected by chemiluminescence, as 
described in experimental procedures. An anti- gapdh antibody was employed as a control for equal 
protein loading. 
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Figure 5.4. Ceramide-induced HAMP mRNA expression is not dependent on JNK activation. 
HepG2 cells were treated with ceramide or solvent (solv.) in the presence of 50 μM SP600125 inhibitor or 
DMSO, as control. (A) Whole cell lysates isolated from these cells were used for western blots performed 
with an anti-phospho-JNK (P-JNK) antibody, as described in experimental procedures. (B) cDNA, 
synthesized from RNA isolated from these cells, were used as templates for Taqman qPCR assays to 
determine HAMP mRNA expression. Gene expression in treated cells were expressed as fold change of 
that in control cells treated with solvent and DMSO.  
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Figure 5.5. The effect of STAT3 response element mutation on HAMP promoter activation by 
ceramide. The single STAT3 response element within 0.6kbp HAMP promoter region cloned in pGL3 
basic vector was mutated, as described in the experimental procedures. HepG2 cells, transfected with 
pGL3-basic vector harboring wild-type (WT) or mutated (ΔSTAT3) 0.6 kb HAMP promoter, or empty 
vector (vector) as negative control, and pRL-SV40 plasmid, as control for transfection efficiency, were 
treated with (A) 60 μM C2 ceramide (C2) and solvent control (solv.) or (B) 40 ng/mL IL-6 and PBS 
control for 8 hours. Dual luciferase reporter assays were performed, as described in the experimental 
procedures. HAMP promoter activity, expressed in relative luciferase units, in treated cells was calculated 
as fold change of that in control cells transfected with empty vector-and treated with solvent. Asterisks 
indicate statistical significance (P<0.05). 
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Figure 5.6 STAT3 expression and ceramide-induced activation of STAT3 were inhibited by STAT3 
siRNA and JAK inhibitor I, respectively. (A) STAT3 mRNA and protein (inset) levels in HepG2 cells 
transfected with STAT3 siRNA or control siRNA were determined by qPCR or western blotting, 
respectively. Asterisks indicate statistical significance (P<0.05). (B) Cell lysates prepared from HepG2 
cells, treated with 60 μM C2 ceramide or solvent (solv.) in the presence of 5 μM JAK inhibitor I or 
DMSO as control, were used for western blotting to detect total or tyrosine-phosphorylated (P-STAT3) 
STAT3 protein levels using specific antibodies. An antibody for gapdh was used as control for protein 
loading.   
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Figure 5.7 Activation of STAT3 signaling was required for the induction of HAMP transcription by 
ceramide. (A) HAMP mRNA expression in HepG2 cells, treated with solvent (solv.) or C2 ceramide for 
8 hours in the presence of either 5 μM JAK inhibitor I or DMSO (control), was determined by Taqman 
qPCR. HAMP expression in treated cells was calculated as fold change of that in respective control cells 
treated with solvent. (B) HepG2 cells, pre-transfected with STAT3 or control siRNA, were treated with 
C2 ceramide or solvent (solv.) in the presence of 5 μM JAK inhibitor I or DMSO. HAMP mRNA levels, 
determined by qPCR, were expressed as fold expression of that in respective controls treated with solvent. 
(C) HepG2 cells, transfected with pGL3-basic vector harboring 0.6 kb HAMP promoter, were treated with 
C2 ceramide or solvent (solv.) for 8 hours in the presence or absence of 5 μM JAK inhibitor I. Dual 
luciferase assays were performed and HAMP promoter activity, calculated as fold change of that in 
corresponding control cells treated with solvent, was expressed in relative luciferase units. (D) HepG2 
cells, pre-transfected with STAT3 or control siRNA, were subsequently transfected with pGL3-basic 
vector harboring 0.6 kb wild-type HAMP promoter. After treatment with solvent (solv.) and C2 ceramide 
in the presence of either JAK inhibitor I or DMSO, dual luciferase reporter assays were performed. 
HAMP promoter activity, expressed as relative luciferase units, was expressed as fold change of that in 
respective control cells treated with solvent. Asterisks indicate statistical significance (P<0.05). 
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Figure 5.7 
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Figure 5.8. ER stress is not involved in ceramide-induced HAMP expression. (A) HepG2 cells treated 
with solvent (solv.), 60 μM C2 ceramide or 10 μg/mL tunicamycin (TUNI) for 8 hours were employed for 
XBP-1 splicing assays, as described in experimental procedures. (B) HepG2 cells treated with solvent 
(solv.), 60 μM C2 ceramide in the presence of 20 μM salubrinal inhibitor or DMSO (control) were used to 
determine HAMP mRNA expression by qPCR, as described in experimental procedures. Gene expression 
in treated cells was expressed as fold change of that in cells treated with DMSO and solvent.  
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Chapter VI 
Molecular Analysis of the Livers from hepcidin Knockout Mice with High-Fat and 
High-Sucrose Intake in Relationship to Nonalcoholic Steatohepatitis Pathology  
177 
 
1 ABSTRACT 
The pathogenesis of nonalcoholic fatty liver disease (NAFLD) remains under ongoing investigation. 
Although current theories consider simple steatosis as benign, it can progress to nonalcoholic 
steatohepatitis (NASH). NASH is an advanced stage of disease characterized by inflammation 
(steatohepatitis), hepatocyte ballooning, fibrosis, which can ultimately lead to cirrhosis, 
hepatocellular carcinoma and mortality. The mechanisms of NAFLD/NASH progression are 
unclear but iron is considered as a risk factor for fibrosis development. The current chapter presents 
investigations on the potential role of iron in NASH pathology using hepcidin (Hamp) knockout 
(KO) mice with high-fat and high-sucrose (HFS) intake, as an experimental model. Hamp KO mice 
displaying primary iron overload were administered a high-fat high-sucrose (HFS) diet for different 
time periods (3 and 7 months) to mimic different stages of NAFLD/NASH pathology. Although 
HFS feeding induced similar increases in body weight in KO and control (Floxed) mice, the liver 
weights were significantly different. HFS intake resulted in pronounced hepatomegaly in control, 
but not in KO, mice. This was also confirmed with histological and biochemical analysis. Namely, 
control, but not KO, mice livers displayed pronounced steatosis and hepatic triglyceride content. 
Furthermore, the activation (i.e phosphorylation) of c-Jun N-terminal Kinase (JNK), which plays a 
role in steatosis, was higher in the livers of control than KO mice. In contrast, the livers from KO, 
but not control, mice exhibited significant level of fibrosis. As shown by Sirius Red staining, liver 
fibrosis in KO mice was detected at 3 months of HFS intake, which exacerbated over time, as 
observed with NASH patients. In agreement, the expression of α-smooth muscle actin protein, a 
marker for fibrogenesis, was more prominent in HFS-fed KO mice compared to controls. To 
understand the reasons behind blunted fat accumulation in the livers of KO mice with HFS intake, 
the expression of genes involved in lipid metabolism were examined by qPCR. Our results strongly 
suggested that lipogenesis and lipid storage capacity of the liver was diminished in Hamp KO mice 
with HFS intake. Namely, the expression levels of sterol regulatory element-binding protein 1c 
(SREBP-1c), a transcription factor controlling de novo lipogenesis, and fat-specific protein 27 
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(FSP27), which facilitates the development of lipid droplets, were significantly attenuated in KO 
mice livers. Furthermore, iron overload per se in Hamp KO mice affected hepatic expression of 
genes related to mitochondrial energy metabolism. In summary, Hamp KO mice with HFS intake 
exhibit a liver pathology similar to NASH and can therefore serve as a novel experimental model 
to study NASH development. Furthermore, our findings highlight a role for hepcidin and iron in 
the regulation of hepatic lipid metabolism, which has implications for NAFLD/NASH pathogenesis.  
2 INTRODUCTION 
NAFLD is a wide spectrum of disease, which ranges from simple steatosis to steatohepatitis and 
fibrosis. Although the large majority of NAFLD patients display simple steatosis, which in itself is 
benign, a small portion of patients present with aggressive nonalcoholic steatohepatitis (NASH). 
NASH pathology is characterized by the presence of lobular inflammation, fibrosis, hepatocellular 
ballooning and Mallory-Denk bodies (1, 2). The frequency of NASH with progressive fibrosis (i.e. 
stage 2 and higher based on Brunt criteria) is low among NAFLD patients but it is strongly 
associated with liver-related morbidity. Advanced fibrosis in NASH patients progresses to cirrhosis 
with severe clinical conditions, such as ascites, portal hypertension and hepatic encephalopathy 
ultimately causing hepatocellular carcinoma and liver failure (1, 3, 4).  
Fibrosis, as observed in the livers of NASH patients, is the excessive accumulation of extracellular 
matrix (ECM) proteins in response to chronic liver injury (5, 6). Activated hepatic stellate cells, 
portal fibroblasts, and myofibroblasts of bone marrow origin play key roles in hepatic fibrosis (6). 
Upon activation by inflammatory cytokines and mitogens, these fibrogenic cells produce ECM 
proteins. The accumulation of ECM proteins changes the structure of hepatic parenchyma by 
forming fibrous scars, which ultimately lead to cirrhosis and end-stage liver disease (Figure 6.1). 
Histological examination and specific staining of ECM proteins are useful tools to determine the 
degree of fibrosis in the liver. Collagen (I, III, IV), fibronectin, elastin, laminin and proteoglycans 
are among the prominent ECM proteins produced by fibrogenic cells (7). In the injured liver, 
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activated hepatic stellate cells (HSC) secrete the major amount of ECM and stimulate ECM 
degradation. Following activation, HSC trans-differentiate into myofibroblast-like cells and 
migrate from the space of Disse into sites of tissue injury and repair (4, 6). Quiescent and activated 
HSC express different sets of cell surface markers. Alpha smooth muscle action (αSMA) is a 
myogenic marker expressed by activated stellate cells. The increased expression of αSMA is 
frequently selected as a marker for liver fibrosis (8, 9). 
The precise mechanisms of NASH development are not well understood. Oxidative stress, 
inflammation and changes in mitochondrial function has been proposed as risk factors (10–13). Of 
note, due to the elevated triglyceride content, the hepatic β-oxidation capacity is challenged in 
NAFLD patients, and they display structural and functional abnormalities in liver mitochondria 
(14).  
Recently, a role for iron has been proposed in NASH pathogenesis (15). Patients with 
NAFLD/NASH frequently display elevated serum iron indices and hepatic iron content (16, 17). 
Most importantly these studies have shown a strong correlation between hepatic iron content and 
the level of liver fibrosis, which determines disease severity in NAFLD/NASH patients (18–20). 
Interestingly, these studies have also suggested that the location of iron deposition in the liver is 
also a strong prognostic factor for disease severity in NASH patients. Independent studies have also 
shown that phlebotomy (iron letting) alleviates insulin resistance in NAFLD patients, which further 
support a role for iron in NAFLD pathogenesis (21).  
The mechanisms by which iron contributes to NAFLD/NASH pathogenesis have mainly been 
attributed to the redox potential of iron, as a transition metal. Iron takes part in Fenton reaction 
promoting the production of highly toxic hydroxyl radicals (see Chapter I for overview) (22). 
Reactive oxygen species and oxidative stress are the most intensely studied secondary risk factors 
in NAFLD/NASH (23). The redox imbalance subsequently induces the peroxidation of intracellular 
lipids and the accumulation of toxic lipid radicals (23). All these changes ultimately cause the 
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activation of stellate cells and fibrotic signaling (24). Accordingly, the level of αSMA expression 
has been shown to be elevated in the livers of patients with genetic haemochromatosis (GH), a 
hereditary iron overload disorder. Following phlebotomy, the livers of GH patients displayed 
significantly decreased levels of αSMA expression further indicating the connection of iron with 
fibrosis (25). Other studies, using dietary experimental models, have suggested that iron modulates 
lipid metabolism. In rats, diet-induced iron overload correlated with a decrease in the level of 
hepatic triacylglycerols (26). In another study where hepatic triglyceride accumulation was induced 
by methionine-choline-deficient (MCD) diet intake, addition of iron into the diet significantly 
inhibited the MCD-induced triglyceride accumulation in rat livers (27). In contrast, a study using a 
mouse dietary model of iron and HFS failed to show any effect of iron on hepatic steatosis (28). 
Furthermore, it should also be noted, that in the MCD diet study where iron ameliorated steatosis, 
it also triggered necroinflammation and fibrosis (27). Taken together, these studies suggest a 
reverse connection between iron and steatosis but the consequences of these changes in liver lipid 
metabolism are unclear. This chapter uses mouse hepcidin-1 gene (Hamp) knockout mice, with 
documented iron overload phenotype, as an animal model to address some of these questions. In 
parallel, these studies will also establish whether Hamp knockout mice may serve as experimental 
NAFLD/NASH models. 
Hepcidin is the central regulator of iron homeostasis. It is primarily synthesized by the hepatocytes 
in the liver and secreted into the circulation. Hepcidin controls iron homeostasis by decreasing iron 
absorption from the absorptive enterocytes in the duodenum and the release of iron from 
macrophages (see Chapter I for overview). The lack of hepcidin expression in hepcidin knockout 
mice, and in human iron disorders, will therefore result in iron accumulation both in the liver and 
other organs (29–31). Unlike humans, which express only one hepcidin gene, HAMP, mice express 
two hepcidin genes, Hamp and Hamp2, which arose from gene duplication (32). Overexpression 
181 
 
and structure analysis studies strongly suggested that Hamp is the mouse equivalent of HAMP, 
which by itself is sufficient to regulate iron metabolism (33).  
NAFLD patients have been reported to show changes in hepcidin levels both in the serum and the 
liver. However, these studies are inconclusive and whether hepcidin and hepcidin-mediated 
changes in iron metabolism contribute to the disease progression in NAFLD is unclear.  
As stated above, we used hepcidin knockout mice to further understand the role of hepcidin in 
NAFLD/NASH. For these studies, we administered a custom-made high-fat high-sucrose (HFS) to 
ubiquitous Hamp knockout mice with global hepcidin deficiency, which were created in our 
laboratory. Since severe forms of NAFLD develop over a long period of time in patients, mice were 
administered these diets for different time points (3 or 7 months). There are a number of animal 
models for NAFLD but the histological changes such as fibrosis, as observed in NASH patients, 
are not reproduced in many of these models. Methionine-choline-deficient diet-fed mice develop 
fibrosis but not the metabolic changes that lead to NAFLD (34). Recently prolonged exposure of 
mice to a western diet has been shown to induce fibrosis (35). Besides investigating the role of iron 
as a secondary risk factor, Hamp knockout mice might also serve as a novel animal model for 
NASH.  
3 RESULTS 
3.1 Generation and characterization of Hamp knockout (KO) mice 
Hamp Floxed (Flx) mice were generated, as published previously (36). The generation of transgenic 
constructs are illustrated in Figure 6.2A. The targeting vector was designed by flanking exons 2 
and exon 3 of Hamp gene with standard loxP sites, and by inserting a neomycin selection cassette 
(PGK-neo), flanked by FRT recognition sequences, downstream of exon 3. The 5’ and 3’ homology 
and loxP arms were generated by PCR from C57BL/6 genomic DNA. The Hamp targeting 
construct was electroporated into a C57BL/6 embryonic stem (ES) cell line, and ES cells with 
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positive homologous recombination were screened by Southern hybridization to be injected into 
Balb/CJ blastocysts. Male chimeric mice were obtained and crossed to C57BL/6J females to 
establish heterozygous germline offspring on C57BL/6 background. The germline mice were 
crossed to a FLP mouse line to remove the FRT-flanked selectable marker cassette. Heterozygous 
targeted mice were bred to generate homozygous Hamp Flx mice. These mice were further crossed 
with PGK-Cre transgenic mice, which ubiquitously express Cre recombinase protein (37), to excise 
the Flox genes. (Figure 6.2A). The F1 heterozygous pups generated from this breeding were 
backcrossed to generate homozygous ubiquitous knockout mice lacking Hamp expression in all the 
organs. The genotyping of these mice was performed by PCR (Figure 6.2B), as described in 
experimental procedures (see Chapter II). For PCR reactions, specific primers recognizing either 
the wild-type (WT) or knockout (KO) Hamp alleles (see Chapter II section 15) were used to 
identify homozygous ubiquitous knockout offspring (Figure 6.2B). Mice harboring both WT and 
KO alleles, or only KO allele were identified as heterozygous or homozygous knockout (KO) mice, 
respectively. The homozygous Hamp knockout mice were used for inbreeding to maintain the strain 
for the studies presented in this Chapter.  
To further validate our experimental model and to confirm the effect of Hamp deletion on iron 
content in the liver, we performed inductively coupled mass spectrometry (ICP-MS) with stable 
56Fe and 57Fe isotopes (Figure 6.3A and 6.3B). Our studies clearly indicated significant level of 
iron accumulation in the livers of Hamp KO, but not Hamp Flx control, mice (Figure 6.3A and 
6.3B), and validated the iron overload phenotype of our Hamp KO mice. Furthermore, Magnetic 
Resonance Imaging (MRI) analysis also confirmed the accumulation of iron in the livers of Hamp 
KO mice (Figures 6.3C and 6.3D). Namely, a characteristic T2* signal loss was observed in KO 
mice livers compared to Flx controls (Figures 6.3C and 6.3D). 
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3.2 Analysis of body and liver weights in Hamp KO and Floxed (Flx) control mice fed with 
high-fat high-sucrose (HFS) or regular diets 
To study the interaction of hepcidin-mediated iron overload and lipid metabolism, 4-6 weeks old 
homozygous Hamp Flx (control) and KO mice were administered custom-made pelleted regular 
(control) diet (17.2% kcal. from fat, 100 g/ kg sucrose) or high-fat and high-sucrose (HFS) diet [42% 
kcal. from fat (54% saturated, 9.7% trans-fat), 0.4% cholesterol, 340 g/kg sucrose]. Similar rodent 
diets, which resemble human fast food, have been shown to induce liver pathology similar to NASH 
after extended periods of administration (35). To differentiate between the short and long-term 
effects of iron and/or HFS intake, mice were fed for 3 or 7 months. Water was given ad libitum, 
and contained sucrose (40 g/L) in HFS-fed groups to imitate the western diet with high-fat and soda 
consumption. The body weights of mice, which were monitored prior to the start of the diet and 
weekly throughout the feeding period, are shown in Figure 6.4A and 6.4B. The increase in body 
weights induced by HFS diet intake were similar in Flx (Figure 6.4A) and KO (Figure 6.4B) mice 
after either 3 or 7 months periods, as compared to respective controls, which were fed with the 
regular control diet. Interestingly, the liver weights of Hamp KO mice fed with regular diet was 
slightly but significantly higher than those of Flx mice at 3, but not 7, months (Figure 6.4C and 
6.4D). This may suggest an initial effect of Hamp deletion (i.e. iron deposition) on basal metabolic 
activity, which is later compensated by the liver. 3 month-long HFS intake resulted in slightly lower 
liver weight increase in KO mice as compared to Flx mice but the difference was not statistically 
significant (Figure 6.4D). However, at 7 months, the liver weight of Flx mice were significantly 
higher (i.e. 3.5 ± 0.46 g) than those of KO mice (i.e. 2.42 ± 0.54 g) (Figure 6.4D). This discrepancy 
suggests that the gradual increase in iron deposition in Hamp KO mice may interfere with steatotic 
processes in the liver. 
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3.3 HFS diet-induced steatosis in Hamp KO and Flx mice. 
To understand the reasons behind the differences observed regarding the body and liver weights of 
HFS-fed Hamp Flx and KO mice, further macroscopic and microscopic analysis of livers from 
mice fed for 3 months (Figure 6.5) and 7 months (Figure 6.6) were performed. The absence of 
Hamp gene altered the appearance of the liver in both mice fed on regular diet for 3 and 7 months. 
Namely, KO mice livers appeared bigger in size and exhibited a darker color compared to Flx mice 
(Figure 6.5A and 6.6A), which is probably mediated by iron deposition in the liver. HFS intake 
resulted in enlarged livers with lighter color, which indicates steatosis, and visceral fat depots in 
both Flx and KO mice, compared to control counterparts fed with regular diet (Figure 6.5A and 
6.6A). However, 3 or 7 month-long HFS-induced hepatomegaly was more pronounced in the livers 
of Flx mice compared to KO mice (Figure 6.5A and 6.6A). This discrepancy was also confirmed 
with hematoxylin and eosin (H&E)-staining of liver sections (Figure 6.5B and 6.6B). Namely, 
both short and long-term HFS intake caused significantly higher levels of steatosis in the livers of 
Flx mice than in those of KO mice.  
In addition to H&E staining, hepatic triglycerides were also quantified by a biochemical assay, as 
described (see experimental procedures in Chapter II). For these studies, lipids were extracted from 
the livers of mice fed with HFS or regular diets for 3 months (Figure 6.7A) or 7 months (Figure 
6.7B). The quantification of liver triglycerides confirmed our histological analysis that HFS intake 
significantly increases hepatic triglyceride content but to different extents in Hamp Flx and KO 
mice (Figures 6.7Aand 6.7B). At the end of 3 month-long HFS intake, the level of hepatic 
triglyceride accumulation (expressed as μmol/L/100 gram b.w.) was 1876.64 ± 370.84 in Flx and 
657.98 ± 186.89 in KO mice (Figures 6.7A). Similar measurements at the end of 7 month-long 
feeding period yielded 1837.71 ± 118.12 in Flx and 886.91 ± 89.51 in KO mice livers. (Figure 
6.7B). The inhibition of HFS-induced lipid accumulation in KO mice livers was higher at 3 months 
than at 7 months (Figures 6.7 A and 6.7B). In summary, the findings of our biochemical analysis 
185 
 
are in alignment with microscopic and macroscopic observations, as presented above. Taken 
together, these findings strongly indicated that the absence of hepcidin expression interferes with 
and suppresses liver triglyceride accumulation in response to HFS exposure.  
3.4 HFS diet-induced fibrosis in Hamp KO and Flx Mice 
Advanced stages of NAFLD pathology involve fibrosis. Animal experiments with MCD-diet 
administration and DGAT2 deletion (38, 39) have suggested a link between the inhibition of hepatic 
fat accumulation and fibrosis. Based on our observations of attenuated steatosis in Hamp KO mice 
(see Figures 6.3-6.6), we examined the presence of fibrosis. The liver sections from Hamp Flx and 
knockout mice fed with HFS or regular diets for 3 (Figure 6.8A) and 7 (Figure 6.9A) months were 
stained with Sirius Red, as described in experimental procedures (see Chapter II). This staining 
technique detects the accumulation of ECM protein, collagen in the liver, as an indication for 
fibrogenesis. The level of fibrosis was also quantified by using ImageJ analysis, as described in 
experimental procedures (see Chapter II) (Figures 6.8B and 6.9B).  
Sirius Red-stained livers from Hamp Flx mice fed with HFS or regular diets for 3 months did not 
display any significant changes (Figures 6.8). After 7 months of HFS intake, Flx mice livers 
exhibited increased levels of basal fibrosis (Figures 6.9). In contrast to Flx mice, Hamp KO mice 
exhibited significant levels of fibrosis both after 3 and 7 month-long HFS intake (Figures 6.8 and 
6.9). However, the highest level of fibrosis was observed in the livers of Hamp KO mice with 7 
months of HFS exposure (Figures 6.9). Although to a lesser extent, elevated level of basal fibrosis 
activity was also observed in Hamp KO mice fed with the regular control diet for 3 and 7 months 
(Figures 6.8 and 6.9). In summary, the quantification of our Sirius Red staining indicated that HFS 
feeding of Hamp KO mice for 3 months is sufficient to initiate fibrogenesis in the liver, which is 
exacerbated at 7 months. Interestingly, elevated hepatic iron content in the livers of Hamp knockout 
mice per se can induce fibrotic reactions. Taken together, our findings indicate that the synergistic 
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action of iron overload, originating from the absence Hamp gene expression, and HFS intake results 
in fibrosis, which gradually increases in severity.  
3.5 JNK activation and αSMA expression in Hamp KO and Flx mice fed with HFS diet. 
The presence of liver fibrosis was further confirmed by examining the expression levels of α smooth 
muscle actin (αSMA), a marker for hepatic stellate cell activation, by western blotting (Figure 
6.10A and 6.10B). The livers of Hamp Flx mice fed with HFS diet for 3 months did not display 
any significant changes in αSMA expression compared to controls fed with regular diet. In contrast, 
Hamp KO mice displayed a significant increase in liver αSMA protein expression following 3 
months HFS feeding. Furthermore, the basal αSMA expression level was also elevated Hamp KO 
mice compared Hamp Flx mice. With 7 month-long HFS intake, the levels of liver αSMA 
expression was elevated in both Hamp Flx and KO mice (Figure 6.10A and 6.10B).  
c-Jun N-terminal kinase (JNK) signaling pathway has been reported to mediate steatosis in mice 
fed with MCD diets (40). JNK is activated by phosphorylation on serine residues (41). The 
expression levels of phosphorylated JNK (P-JNK) protein in the livers of Hamp mice were 
therefore determined by western blotting using specific anti-phospho JNK antibodies, as described 
in the experimental section (see Chapter II) (Figure 6.10C and 6.10D). The livers of Hamp Flx 
mice fed with HFS diet for 3 months displayed an increase in the level of P-JNK protein compared 
to controls fed with regular diet. In contrast, the livers of Hamp KO mice fed under similar 
conditions did not display any significant changes in JNK phosphorylation (Figure 6.10C and 
6.10D). Namely, the level of P-JNK expression was similar in HFS or control diet-fed Hamp KO 
mice. It should however be noted, that after 7 months, the effect of HFS feeding on JNK activation 
was not as prominent as 3 months in Flx mice (Figure 6.10C and 6.10D). Compared to 3 months 
feeding, 7 months of HFS diet feeding slightly elevated P-JNK level in Hamp KO mice (Figure 
6.10C and 6.10D). This suggests the involvement of JNK in the initial stages of the processes that 
underlie the attenuation of steatosis connected to Hamp deletion. 
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3.6 Expression of metabolic genes in HFS or regular diet-administered Hamp KO and Flx 
mice. 
To further investigate the underlying mechanisms of attenuated fat accumulation in the livers of 
Hamp KO mice with HFS intake, mRNA expression levels of genes, which are known to be 
involved in lipid metabolism, were examined by real-time PCR (see Chapter I for detailed review 
of these genes). The results of these studies are presented below (Figures 6.11 and 6.12) 
The transcription factor, sterol regulatory element-binding protein 1c (SREBP-1c) is well known 
for its role in mediating the stimulatory effect of insulin on genes connected to de novo lipogenesis 
pathway. The expression of SREBP-1c itself is also regulated at the transcriptional level (42, 43). 
The liver mRNA expression of SREBP-1c was significantly up-regulated in Hamp Flx mice with 
3 month-long HFS intake compared to mice fed on control diet (Figure 6.11A). The deletion of 
Hamp alleles did not alter basal hepatic SREBP-1c expression (Figure 6.11A). Although to a 
significantly lesser extent than in Flx mice, 3 month-long HFS exposure also elevated liver SREBP-
1c expression in Hamp KO mice compared KO controls (Figure 6.11A). Upon longer (i.e. 7 months) 
HFS exposure, the induction of liver SREBP-1c expression was attenuated but still significant in 
Flx mice (Figure 6.11B). In contrast, KO mice did not display any significant increase in SREBP-
1c expression when fed with HFS diet compared to regular diet-fed controls (Figure 6.11B). Taken 
together, these findings with short and long-term HFS exposure suggested that diet-mediated 
changes in liver SREBP-1c expression are significantly attenuated in Hamp KO mice, which 
becomes more prominent with longer HFS exposure. 
Fat-specific protein 27 (FSP27) plays an important role in lipid droplet formation (44). Similar to 
SREBP-1c, mRNA expression of FSP27 was significantly up-regulated in Hamp Flx mice exposed 
to HFS for 3 months compared to Flx mice fed with the regular diet (Figure 6.11C). In contrast to 
Flx mice, HFS-fed Hamp KO mice displayed a blunted increase in hepatic FSP27 mRNA 
expression (Figure 6.11C). The increase observed in liver FSP27 mRNA expression levels in 
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Hamp Flx mice was not significantly different between 3 and 7 month-long HFS intake. In contrast, 
HFS-induced FSP27 up-regulation is blunted in Hamp KO mice after 7 months of feeding as 
compared to that in Flx mice (Figure 6.11D). Similar to SREBP1-c data, the absence of Hamp in 
KO mice inhibited the induction of FSP27 in the liver.  
Microsomal triglyceride transfer protein (MTP) is responsible for the production and secretion of 
VLDL particles (45). The liver mRNA expression level of MTP was not significantly altered in 
Hamp Flx and KO mice fed on regular or HFS diets for 3months (Figure 6.11E). The deletion of 
Hamp gene did not also affect the basal liver expression level of MTP gene (Figure 6.11F). 
Following 7 month-long HFS exposure, liver MTP expression was significantly suppressed in both 
Hamp Flx and KO mice to the same extent, as compared to Flx controls fed with the regular diet 
(Figure 6.11F). 
Peroxisome Proliferator-Activated Receptor α (PPARα) activates the transcription of genes 
involved in fatty acid β-oxidation regulation (46). After 3 month-long HFS exposure, liver PPARα 
mRNA expression levels were stimulated in both Hamp Flx and KO mice compared to Flx controls 
fed with a regular diet (Figure 6.12A). In contrast, long term HFS exposure significantly inhibited 
PPARα mRNA expression in both Hamp Flx and KO mice compared to corresponding Flx controls 
(Figure 6.12B).  
Carnitine palmitoyltransferase 1 (CPT1) is the rate-limiting enzyme in mitochondrial β-oxidation 
pathway (47). The expression of CPT1 did not significantly change in the livers of either Hamp Flx 
or KO mice after 3 months of HFS intake (Figure 6.12C). Interestingly, the livers of Hamp KO 
mice fed on the regular diet for 7 months expressed higher CPT1 levels compared to Flx mice fed 
under similar conditions (Figure 6.12D). On the other hand, 7 month-long HFS exposure 
significantly suppressed CPT1 expression in KO mice. This decrease was more prominent in Hamp 
KO mice considering the fact that CPT1 basal expression levels were elevated in KO mice (Figure 
6.12D).  
189 
 
Phosphoenolpyruvate carboxykinase 1 (PCK1) and glucose-6-phosphatase (G6PC) both play an 
important role in the regulation of gluconeogenesis. The livers of Hamp Flx and KO mice with 
short or long-term HFS exposure displayed a significant inhibition of PCK1 and G6PC mRNA 
expression (Figure 6.12E-H). These findings suggest that HFS feeding exerts a consistent 
inhibitory of effect on gluconeogenesis in the liver under our experimental conditions. However, 
the basal mRNA expression levels of PCK1 and G6PC were different in the livers of Hamp KO 
and Flx mice (Figure 6.12E-H). Namely, KO mice expressed higher PCK1 and lower G6PC 
expression.  
4 DISCUSSION 
Liver, as an endocrine organ, plays an important role in both lipid and carbohydrate metabolism. 
By synthesizing hepcidin and serving as a major depot for excess iron, liver is also a key organ for 
iron metabolism. It is therefore important to understand the interaction of these pathways in the 
liver. NAFLD/NASH patients have been reported to frequently display changes in serum iron 
parameters and elevated hepatic iron content. The deposition of iron in the liver correlates with 
disease severity in NAFLD/NASH patients (17). The mechanisms by which excess iron contribute 
to NAFLD/NASH pathogenesis is unclear. Independent human and animal model studies have 
identified iron as an important risk factor for fibrogenesis in the liver (25, 48). A role for iron in 
lipid metabolism has also been suggested but the findings in published studies are inconclusive 
(26–28), where some reported stimulatory (28) but others indicated inhibitory (26, 27) effects of 
iron in this process. Although hepcidin is the key regulator of iron metabolism, the role of hepcidin 
in NAFLD/NASH pathogenesis has not been investigated in detail. We therefore examined the 
effect of hepcidin (i.e. iron homeostasis) on fatty liver disease by feeding hepcidin (Hamp) 
knockout (KO) mice with HFS diets. Hamp KO mice, generated in our laboratory, displayed 
significant iron accumulation in the liver, as shown by our MRI an ICP-MS analysis. Short and 
long-term exposure of Hamp KO and Flx controls to HFS diets led to differential changes in the 
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liver, both at macroscopic and microscopic levels, which is similar to the wide spectrum of 
NAFLD/NASH pathology observed in human patients (2). 
The blunted effect of HFS in stimulating liver weight increase in KO mice compared to Flx mice 
indicated the presence of metabolic variations mediated by the absence of Hamp expression. This 
prompted us to conduct further histological and biochemical analysis of livers. Collectively, the 
findings of these studies strongly suggested, that hepatic iron deposition in KO mice, might exert 
an inhibitory effect on liver lipid accumulation. This is in agreement with previous studies showing 
a negative effect of iron on lipid metabolism (25, 26). Interestingly, the apparent amelioration of 
steatosis in Hamp KO mice exacerbated liver pathology. This was based on our observations that 
Hamp KO mice, compared to control counterparts, displayed an earlier and more pronounced 
development of fibrosis in the liver. Histological identification of fibrosis was also confirmed by 
western blotting showing elevated expression of αSMA protein as an indication of hepatic stellate 
cell activation. Our findings are consistent with previous studies using methionine-choline-
deficient diet (MCD)-induced hepatic steatosis as an experimental model (27, 38). It has been 
reported that dietary iron supplementation is associated with decreased hepatic steatosis but 
increased necroinflammation and fibrosis (27). However, as stated above (see Introduction), 
although MCD diet model induces steatohepatitis, it fails to reproduce the metabolic changes 
observed in NAFLD patients, such as peripheral insulin resistance, obesity and dyslipidemia (49, 
50). In fact MCD-diet induces weight loss and not weight gain (41). High-fat-diet experimental 
models are therefore advantageous because they present pathophysiology that is more 
representative of what is observed in NAFLD/NASH patients (50, 51). Furthermore, the dietary 
supplementation of iron as an experimental model has the disadvantage of creating secondary 
effects by indirectly altering hepcidin synthesis in the liver. It is well-recognized that iron is a potent 
stimulator of hepcidin transcription through the activation of bone morphogenic (BMP) and SMAD 
signaling pathway (52–54). Elevated hepcidin will then inhibit the expression of iron exporter, 
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ferroportin and thereby block iron release from macrophages (see Chapter I for detailed review). It 
is therefore feasible that experimental model of dietary iron overload will cause iron deposition in 
Kupffer cells and thereby exert an effect on liver inflammation. Accordingly, the study using rats 
administered an iron-rich diet reported significant iron accumulation in Kupffer cells (27). We 
therefore used a genetic model of iron overload caused by the deletion of key iron-regulatory gene, 
Hamp for the following reasons: 1: Hamp deletion is the direct cause of iron accumulation. 2: 
Artifacts associated with iron signaling (BMP/SMAD) and Kupffer cell iron deposition will be 
avoided due to the lack of hepcidin expression. Furthermore, the prevalence of HFE mutations, 
which are responsible for genetic hemochromatosis and inhibition of hepcidin expression, is high 
in some NAFLD/NASH patients (55). Accordingly this group of patients display lower levels of 
hepcidin, which is associated with increased disease severity (20). We therefore believe that our 
Hamp KO mouse model recapitulates the conditions observed in NAFLD patients with HFE 
mutations (i.e. inhibition of hepcidin expression) and serves as a good experimental model to study 
iron as a secondary risk factor in NAFLD/NASH pathogenesis.  
The lipid accumulation in NAFLD (i.e. simple steatosis) is considered to be a benign condition. 
Studies with animal models of NAFLD have shown that inhibition of triglyceride production 
alleviates steatosis but exacerbates fibrogenesis and liver injury (38). The synthesis of triglycerides 
in the liver therefore serves the purpose of protecting the liver from potential lipotoxicity induced 
by the accumulation of free fatty acids. This has also been confirmed by in vitro studies (56). It is 
therefore possible that the decreased level of steatosis contributes to fibrosis in our HFS-fed Hamp 
KO mice. Nevertheless, the synergistic role of hepatic iron in this process cannot be excluded. 
Future studies, which involve feeding Hamp KO mice with HFS diets containing iron chelators, 
should address these questions directly.  
To further understand the mechanisms leading to attenuated hepatic lipid accumulation in Hamp 
KO mice, we investigated JNK activation. In studies using JNK knockout mice fed with MCD or 
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high-fat diets, the deletion of JNK1, but not JNK2, has been shown to reverse hepatic steatosis (57, 
58). JNK is well-known to be activated following phosphorylation on serine residues (41). Our 
western blotting studies examining the phosphorylation status of JNK indicated highest JNK 
activation in the livers of HFS-fed Hamp Flx mice, which also exhibited high levels of steatosis. In 
contrast, the livers of Hamp KO mice with alleviated steatosis did not display any significant JNK 
phosphorylation (i.e. activation). Interestingly, these findings were only observed with mice with 
short-term (3 months), but not long-term (7 months), HFS intake. Taken together, these findings 
are consistent with a potential role for JNK in inhibition on steatosis observed in Hamp KO mice 
livers with iron overload. This effect however is an early phenomenon because it was not observed 
in later stages of HFS feeding where more injury was developed. Accordingly, the deletion of JNK 
has been shown to reverse steatosis, but not fibrogenesis, in NASH animal models (57, 58). The 
direct effect of JNK and its regulation by hepcidin and iron need to be validated in future studies. 
Lipid and carbohydrate metabolism in the liver is mediated by an intricate web of genes (see 
Chapter I for detailed review). The expression levels of most of these metabolic genes are regulated 
at the mRNA level. We therefore determined liver mRNA expression of important candidate genes 
in HFS-fed Hamp knockout mice. The analysis of genes involved in lipid metabolism (e.g. SREBP-
1c) indicated that iron blunts the induction of genes involved in HFS intake-induced de novo 
lipogenesis in the liver. Furthermore, the expression of FSP27, the gene responsible for lipid droplet 
formation and lipid storage, was less responsive to HFS diet administration in livers with elevated 
hepatic iron content. These findings clearly establish a relationship between iron overload and 
lipogenic gene expression. Studies with rodent models of dietary iron deficiency have shown an 
up-regulation of lipogenic gene expression, which indirectly support our findings with Hamp KO 
mice (59–61). Lipid homeostasis in the liver is also regulated by lipid export, which is mediated by 
VLDL secretion. However, we did not determine any significant changes in the expression of genes 
regulating VLDL secretion (i.e. MTP). This suggests that hepcidin and iron do not have an effect 
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on HFS-mediated lipid vesicle secretion. Thus, the alleviated steatosis observed in high-fat-fed 
Hamp KO mice livers is probably not due to an elevated level of lipid export from the liver. In fact 
MTP expression was attenuated in the livers of both Hamp Flx and KO mice following long-term 
HFS exposure. Future studies should establish whether the inhibition of VLDL by prolonged fat 
intake directly contributes to fibrosis observed in the livers of these mice. Taken together, our data 
suggests that iron decreases steatosis by inhibiting lipid storage but not export. 
Mitochondrial β-oxidation is also an important pathway to maintain hepatic lipid homeostasis. The 
transcription factor, PPARα induces the transcription of genes involved in β-oxidation (62). PPARα 
expression itself is also regulated at the transcriptional level (63). In our studies, we detected a 
time-dependent response of PPARα mRNA expression in the liver in response to HFS intake. 
Namely, short-term (3 months) intake up-regulated but long-term (7 months) intake suppressed 
PPARα expression regardless of Hamp genotype. Increased β-oxidation is essential to alleviate 
extra-hepatic fat burden in NAFLD by disposing of excess lipids in the liver (64). As a by-product 
of the mitochondrial respiratory chain activity, the levels of reactive oxygen species (ROS) in the 
liver are increased due to electron leakage. Of note, ROS is accepted to be a prominent secondary 
hit factor in the development of NASH pathology (65). It is therefore feasible, that the initial up-
regulation of PPARα serves the purpose of disposing excess lipids in the liver via mitochondrial β-
oxidation. The suppression of PPARα observed in later stages might either be a hepatic defense 
mechanism to limit mitochondrial ROS production or an indication of mitochondrial dysfunction 
in fibrotic livers. Similarly, the expression of CPT1, which is also involved in β-oxidation, was 
significantly suppressed in the livers of Hamp KO mice with long-term HFS intake. It is therefore 
possible that iron in conjunction with lipid accumulation exert a burden on mitochondria, which 
ultimately leads to profound mitochondrial dysfunction in the liver. Of note, changes in 
mitochondrial structure and function are regarded as secondary risk factors in NAFLD/NASH 
progression (13).  
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Besides lipid metabolism, changes in the expression of genes involved in gluconeogenesis were 
also observed in the livers of HFS-fed Hamp KO mice. HFS intake induced suppression of 
gluconeogenic gene expression (i.e. PCK1 and G6PC) independent of Hamp genotype and feeding 
period. However the deletion of Hamp by itself (i.e. KO mice fed with the regular diet) exhibited 
opposite effect on the expression of PCK1 and G6PC. Namely, the absence Hamp up-regulated 
PCK1 but suppressed G6PC mRNA levels. Overexpression of the Forkhead Transcription Factor, 
FKHR (a.k.a., FOXO1a) has been shown to stimulate the expression of G6PC, but not PCK1, in 
hepatocytes (66). ROS is known to suppress FOXO1a activity post-translationally (67). It is 
therefore feasible that increased ROS levels in Hamp KO mice may impose differential effects on 
PCK1 and G6PC through the inactivation of FOXO1a. Further studies are however required to 
determine the precise mechanisms of this differential regulation. 
Despite being a useful NAFLD model, there are only limited number of studies with long-term 
HFS feeding of rodents, which have reported only mild levels of liver fibrosis (50). With our current 
model of Hamp KO, fibrosis developed at an early time point (i.e. 3 months) and increased in 
severity at 7 months. Our experimental data strongly suggests that the deletion of Hamp, and 
resultant hepatic iron overload, exacerbate liver fibrosis while decreasing steatosis. Therefore, 
Hamp KO mice might serve as a distinctive experimental model recapitulating NAFLD/NASH 
pathogenesis within a relatively short period of HFS diet administration.  
In summary, our studies with Hamp KO mice established a correlation of increased hepatic iron 
content with both decreased steatosis and increased fibrosis in the liver. Our findings also suggested 
a role for hepcidin in HFS-induced mitochondrial dysfunction. Detailed future studies investigating 
metabolic signaling pathways in HFS-treated Hamp KO mice will enable us to understand the role 
of iron and hepcidin in the regulation of metabolic processes in the liver. We therefore believe that 
Hamp transgenic mice are a good new experimental model to study NAFLD/NASH pathogenesis. 
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Figure 6.1. Pathology of hepatic fibrosis. Chronic liver injury induces inflammatory cell 
infiltration into the liver parenchyma. Hepatocyte apoptosis stimulates the activation of Kupffer 
cells, which releases fibrogenic mediators. Hepatic stellate cells (HSC) proliferate and 
differentiate into myofibroblasts for the production of extracellular matrix (ECM). Excessive 
ECM deposition further hampers liver function by inhibiting the blood flow in the hepatic 
sinusoid and nutrient exchanges. (Image adopted from Bataller, R., and Brenner, D. A. (2005) 
Liver fibrosis. J Clin Invest. 115, 209–218 with permission) 
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Figure 6.2. Hamp Floxed (Flx) and knockout (KO) mice generation and genotyping. (A) The 
schematic illustration of Hamp construct design has been adopted from a previous publication by 
Lu. S. et al (36). (i) The genomic structure of wild-type Hamp loci with exon1, 2, and 3 
represented by gray boxes (E1, E2 and E3, respectively). (ii) Hamp targeting vector flanking E2 
and E3 with loxP and neomycin (PGK-NEO) selection cassette with FRT recognition sequence 
was generated and electroporated into a C57BL/6 embryonic stem (ES) cell line to induce 
homologous recombination. (iii) Null alleles after Cre-mediated recombination excising E2 and 
E3 leaving a single lox P site, which encodes primarily signaling sequence of hepcidin-1. (B) 
Genotyping of wild-type (wt.), heterozygous (het.) and homozygous (hom.) Hamp KO mice were 
performed by PCR, as described in experimental procedures (see Chapter II) using primers 
specific for the corresponding alleles. PCR products were analyzed by DNA agarose gel 
electrophoresis and visualized by ethidium bromide staining. Representative images of DNA 
amplicons corresponding to Hamp wt. or KO alleles are shown. The selected primer pairs also 
amplify mouse wild-type Hamp2 allele, which remained intact in Hamp KO mice. 
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Figure 6.3. Quantification of hepatic iron content in Hamp Flx and KO mice. Inductively 
coupled mass spectrometry (ICP-MS) was performed (A, B) with the liver tissues from Hamp Flx 
and KO mice, as described in experimental procedures. The level of 56Fe (A) and 57Fe (B) 
isotopes, as detected by ICP-MS, are shown. Magnetic resonance imaging (MRI) was performed 
in Bioimaging Core Facility at University of Nebraska Medical Center to examine the iron 
content in the liver in situ (C, D). Single slice examples from 3D ultra-short echo time images 
through the liver of Flx (C) and homozygous KO (D) mice obtained at echo times of 0.02 ms 
(upper panel ) and 3.0 ms (lower panel). The T2* of liver is much shorter in KO mice than in Flx 
mice, causing significant signal loss selectively in the liver by 3.0 ms. 
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Figure 6.4. The initial and end liver weights of Hamp Flx and KO mice fed high-fat and 
high-sucrose (HFS) or regular diets. Average body (A, B) and liver (C, D) weights of Hamp 
Floxed (Flx) (A, C) and knockout (KO) (B, D) mice fed with high-fat and high-sucrose (HFS) or 
regular control (Reg.) diets for 3 or 7 months are shown as gram weight. The average of initial 
(Ini.) body weights of mice in each group at the start of the experiments are also shown. 
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Figure 6.4 
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
40.0
45.0
A
v
er
a
g
e 
B
o
d
y
 W
ei
g
h
t 
(g
ra
m
)
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
40.0
A
v
er
a
g
e 
B
o
d
y
 W
ei
g
h
t 
(g
ra
m
)
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
A
v
er
a
g
e 
L
iv
er
 W
ei
g
h
t 
(g
ra
m
)
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
A
v
er
a
g
e 
L
iv
er
 W
ei
g
h
t 
(g
ra
m
)
A 
B 
Ini.    3m    7m     Ini.    3m     7m  
         Reg                      HFS 
                        Flx 
Ini.    3m    7m     Ini.    3m     7m  
         Reg                      HFS 
                         KO 
Reg      HFS    Reg     HFS  
       3m                  7m 
                  Flx 
C D 
Reg      HFS    Reg     HFS  
       3m                  7m 
                  KO 
* 
* 
* 
* 
* 
* 
* 
* 
208 
 
Figure 6.5. Macroscopic and microscopic changes in Hamp Flx and KO mice fed high-fat 
and high-sucrose (HFS) or regular diets for 3 months. Representative images showing the 
abdominal cavity of mice (A) and H&E staining of formalin-fixed and paraffin-embedded liver 
sections (B) of Hamp Flx and KO mice fed with high-fat and high-sucrose (HFS) or regular diets 
were obtained at the end of 3 month-long feeding period. Microscopic images were obtained with 
a Nikon Eclipse E400 light microscope using a CC-12 digital camera and analySIS software (Soft 
Imaging System), as described in experimental procedures (see Chapter II). Arrows indicate 
steatosis. 
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Figure 6.6. Macroscopic and microscopic changes in Hamp Flx and KO mice high-fat and 
high-sucrose (HFS) or regular diets for 7 months. Representative images showing the 
abdominal cavity of mice (A) and H&E staining of formalin-fixed and paraffin-embedded liver 
sections (B) of Hamp Flx and KO mice fed with high-fat and high-sucrose (HFS) or regular diets 
were obtained at the end of 7 month-long feeding period. Microscopic images were obtained with 
a Nikon Eclipse E400 light microscope using a CC-12 digital camera and analySIS software (Soft 
Imaging System), as described in experimental procedures (see Chapter II). Arrows indicate 
steatosis. 
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Figure 6.6 
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Figure 6.7. Liver triglyceride content in Hamp Flx and KO mice fed high-fat and high-
sucrose (HFS) or regular diets. Hepatic triglyceride content in Hamp Floxed (Flx) and knockout 
(KO) mice fed with regular (Reg.) or high-fat and high-sucrose (HFS) diets for 3 (A) or 7 (B) 
months was quantified using 50 mg of wet liver tissue, as described in the experimental 
procedures (see Chapter II). Liver triglyceride amount was expressed as μmol per liver per 100 g 
body weight (µmol/L/ 100 g b.w.). 
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Figure 6.8. Fibrosis in Hamp Flx or KO mice fed high-fat and high-sucrose (HFS) or regular 
diets for 3 months. (A) Liver fibrosis in Hamp Floxed (Flx) and knockout (KO) mice fed on 
regular (Reg.) or high-fat and high-sucrose (HFS) diets for 3 months was detected by staining 
liver sections with Sirius Red, as described in experimental procedures. Representative 
microscopic images obtained with Nikon Eclipse E400 light microscope using a CC-12 digital 
camera and analySIS software (Soft Imaging System) are shown. (B) 10 images taken from each 
group were quantified using ImageJ software. The collagen proportional area (CPA) was 
determined by calculating the percentage of collagen-occupied pixels against the total pixel 
values. 
 
 
 
 
 
 
 
  
215 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8  
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Figure 6.9. Fibrosis in Hamp Flx or KO mice fed high-fat and high-sucrose (HFS) or regular 
diets for 7 months. (A) Liver fibrosis in Hamp Floxed (Flx) and knockout (KO) mice fed on 
regular (Reg.) or high-fat and high-sucrose (HFS) diets for 7 months was detected by staining 
liver sections with Sirius Red, as described in experimental procedures. Representative 
microscopic images obtained with Nikon Eclipse E400 light microscope using a CC-12 digital 
camera and analySIS software (Soft Imaging System) are shown. (B) 10 images taken from each 
group were quantified using ImageJ software. The collagen proportional area (CPA) was 
determined by calculating the percentage of collagen-occupied pixels against the total pixel 
values. 
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Figure 6.9  
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Figure 6.10. Protein expression levels of P-JNK and αSMA in Hamp Flx and KO mice fed 
HFS diet or regular diet for 3 or 7 months. The expression levels of alpha smooth muscle 
action (αSMA) (A) and phosphorylated of JNK (P-JNK) (C) proteins in the livers of Hamp 
Floxed (Flx) and knockout (KO) mice fed with regular (Reg.) or high-fat and high-sucrose (HFS) 
diets for 3 or 7 months was determined by western blotting using whole liver cell lysates and 
commercial antibodies, as described in experimental procedures. An anti-gapdh antibody was 
used as control to determine equal protein loading. The western blots were quantified with 
densitometric analysis and normalized to gapdh expression. Normalized αSMA (B) and P-JNK 
(D) levels were expressed as fold-change of that in Flx mice fed with regular diet for 3 months.   
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Figure 6.11. Expression of genes involved in lipogenesis, lipid storage and secretion. The 
mRNA expression levels of sterol regulatory element-binding protein-1c (SREBP-1c) (A,B), 
FSP27 (C,D), and microsomal triglyceride transfer protein (MTP) (E,F) in the livers of Hamp 
Floxed (Flx) and knockout (KO) mice fed with regular (Reg.) and high-fat and high-sucrose 
(HFS) diets, was determined by SYBR green qPCR using cDNA synthesized from total liver 
RNA and specific primers. Liver gene expression in HFS-fed Hamp Flx or KO and regular diet-
fed KO mice for 3 (A, C, E) or 7 months (B, D, F) was expressed as fold change of that in Hamp 
Flx mice fed with a regular diet for the same time period.   
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Figure 6.12. Expression of genes involved in β-oxidation and gluconeogenesis. The mRNA 
expression levels of peroxisome proliferator-activated receptor alpha (PPARα) (A, B), carnitine 
palmitoyltransferase 1a (CPT1a) (C, D), phosphoenolpyruvate carboxykinase 1 (Pck1) (E, F) and 
glucose-6-phosphatase (G6PC) (G, H), in the livers of Hamp Floxed (Flx) and knockout (KO) 
mice fed with regular (Reg.) and high-fat and high-sucrose (HFS) diets, was determined by 
SYBR green cDNA synthesized from total liver RNA and qPCR using specific primers. Liver 
gene expression in HFS-fed Hamp Flx or KO and regular diet-fed KO mice for 3 (A, C, E, G) or 
7 months (B, D, F, H) was expressed as fold change of that in Hamp Flx mice fed with a regular 
diet for the same time period.  
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Figure 6.12 
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Chapter VII 
Summary and Future Directions  
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1 SUMMARY AND FUTURE DIRECTIONS 
Hepcidin is the central iron regulatory hormone. Hepcidin expression is frequently elevated 
in patients with obesity and nonalcoholic fatty liver disease (NAFLD). The underlying 
mechanisms are however unknown. Inflammatory cytokines or iron loading in NAFLD 
patients have been suggested to contribute to increased levels of hepcidin (1–3). 
Furthermore, an association between elevated serum hepcidin and lipid content in NAFLD 
patients has also been reported (4). Despite the importance of steatosis in NAFLD 
pathogenesis, the effect of hepatic lipid accumulation on hepcidin expression or iron 
homeostasis has not been investigated. In this dissertation, I have demonstrated novel and 
distinct regulatory mechanisms by which hepatic hepcidin expression is regulated by lipid-
induced signaling. Saturated fatty acids, specifically palmitic acid, induced hepcidin 
mRNA stabilization via the activation and specific binding of AU-rich element binding 
protein, HuR to the 3’UTR of hepcidin mRNA (Figure 7.1). On the other hand, the 
sphingolipid, ceramide regulated hepcidin at the transcriptional level by activating STAT3 
and its binding to HAMP promoter (Figure 7.1). My novel findings therefore confirmed 
the significant role of different lipid species in the regulation of hepcidin expression and 
iron metabolism. They have also elucidated the underlying mechanisms of these unique 
regulatory pathways. Most importantly, my results have for the first time demonstrated a 
direct role for post-transcriptional mechanisms, particularly an AU-rich element-binding 
protein and protein kinase C signaling, in hepcidin regulation.  Moreover, I have confirmed 
the ceramide-specific activation of the JAK/STAT3 signaling pathway in hepatoma cells 
in the absence of inflammatory immune cells, which transcriptionally up-regulated 
hepcidin expression.  
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The elevation of hepcidin expression will subsequently lead to the sequestration of iron in 
Kupffer cells and hepatocytes via the inhibition of iron exporter, ferroportin (Figure 7.2). 
Iron accumulation in the hepatocytes (5) and reticuloendothelial cells (6) have both been 
shown to be associated with severe inflammation, injury and fibrosis in the liver. By using 
Hamp knockout mice, a genetic model of iron overload, I have directly examined the effect 
of iron, and high-fat and high-sucrose (HFS) intake on NAFLD pathogenesis. Compared 
to controls, Hamp knockout mice exhibited significantly attenuated steatosis but more 
prominent fibrosis following HFS administration. My Hamp knockout mice studies further 
supported the conclusion that iron overload correlates with NAFLD disease progression. 
Since hepcidin is the central iron regulator, lipid-mediated changes in hepatic hepcidin 
expression may alter systemic iron homeostasis. The long term effect of hepcidin up-
regulation should not be neglected. Furthermore, my studies with Hamp knockout mice 
have also strongly suggested a role for hepcidin and iron in the regulation of metabolic 
gene expression in the liver. Future studies are therefore required to determine the long-
term in vivo consequences of increased hepcidin expression on iron homeostasis and 
metabolic processes with regard to NAFLD pathogenesis.   
In summary, experiments in this dissertation have demonstrated novel mechanisms by 
which hepatic hepcidin expression is stimulated by lipid signaling. The in vivo relevance 
of these findings needs to be validated with other experimental models and human patients 
of NAFLD. My findings confirming that HFS-fed Hamp knockout mice develop fibrosis 
within 3 months have also underlined the advantages of this novel experimental model in 
the study of NAFLD disease progression. Taken together, the studies in this dissertation 
will improve our understanding of hepcidin regulation by lipid metabolism in the liver, and 
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its significance in NAFLD pathogenesis. Since there are currently no FDA-approved drug 
treatments for NAFLD, the elucidation of these pathways may be beneficial for the 
development of treatment strategies for patients with NAFLD and metabolic syndrome.    
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Figure 7.1. Molecular mechanism of lipid-induced up-regulation of hepcidin. Different 
lipid species induce hepcidin up-regulation through distinct mechanisms. Saturated fatty 
acids activate HuR through PKC signaling. The subsequent binding of HuR to the 3’UTR 
of hepcidin mRNA stabilizes the mRNA of hepcidin and therefore up-regulates steady-
state mRNA level through a post-transcriptional mechanism. Ceramide activates the 
JAK/STAT3 signaling pathway. The binding of STAT3 to the hepcidin promoter activates 
transcription of hepcidin mRNA. 
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Figure 7.2. Biological consequences of elevated hepcidin in the liver. Elevated hepcidin 
level results in the post-translational down-regulation of ferroportin, the iron exporter 
expressed on the plasma membrane of Kupffer cells and hepatocytes. Decreased 
ferroportin subsequently leads to decreased iron export and iron sequestration in the 
hepatocytes and macrophages, which exacerbates NAFLD/NASH pathogenesis. 
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